rheumatoid AND arthritis )
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"OBJECTIVES: Biologic therapy such as Etanercept, which is a tumor necrosis factor alpha (TNF-Î±) inhibitor, has been extensively used as election therapy in rheumatoid arthritis. The purpose of this case presentation was to inform about the possibility that lichen planus lesions could potentially become complicated by secondary infections in patients treated with Etanercept. Furthermore, we aimed at analyzing if the complication of the cutaneous lesion was coincidental or it was due to the immunosuppressive systemic therapy, and whether the infected lesion would respond to antibiotic therapy. CASE SUMMARY: The patient was a 59-year-old woman with rheumatoid arthritis and that have had lichen planus lesions for approximately 25 years. Only recently, she had been received immunosuppressive therapy (Etanercept and Methotrexate). Further on, the lichen planus flared up with a secondary infection determined by a Methicillin-sensitive Staphylococcus aureus. Uncommon myocardial complications were also characteristic of this case. RESULTS: While a case report described already the appearance of lichen planus following Etanercept therapy (Battistella M et al., 2008), the possibility that the lesion could become secondary complicated following this therapy was never reported before, according to our knowledge. Additionally, we describe in this case the interplay between Etanercept therapy and hypertrophic cardiomyopathy. CONCLUSIONS: Our case is not a lichen planus induced by Etanercept, but it is aggravated and secondary infected with Methicillin-sensitive Staphylococcus during the therapy. The additional cardiac complication (hypertrophic cardiomyopathy) may represent solely an evolutive sign of rheumatoid arthritis and therefore not influenced by Etanercept.","fulltextAvailable":false,"journal":"Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis, Rheumatoid","uri":{"id":"D001172","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Lichen Planus","uri":{"id":"D008010","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Tumor Necrosis Factor-alpha","uri":{"id":"D014409","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Tumor Necrosis Factors","uri":{"id":"D048069","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Coinfection","uri":{"id":"D060085","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Biological Therapy","uri":{"id":"D001691","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cardiomyopathy, Hypertrophic","uri":{"id":"D002312","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Staphylococcus aureus","uri":{"id":"D013211","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anti-Bacterial Agents","uri":{"id":"D000900","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis","uri":{"id":"D001168","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Data Collection","uri":{"id":"D003625","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Methotrexate","uri":{"id":"D008727","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cardiomyopathies","uri":{"id":"D009202","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Necrosis","uri":{"id":"D009336","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasms","uri":{"id":"D009369","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Staphylococcus","uri":{"id":"D013210","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Women","uri":{"id":"D014930","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Knowledge","uri":{"id":"D019359","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Complicity","uri":{"id":"D028661","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Research Report","uri":{"id":"D058028","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Echocardiography","uri":{"id":"D004452","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Female","uri":{"id":"D005260","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Middle Aged","uri":{"id":"D008875","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis, Rheumatoid","uri":{"id":"D001172","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Biological Therapy","uri":{"id":"D001691","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Lichen Planus","uri":{"id":"D008010","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Arthritis, Rheumatoid","Biological Therapy","Echocardiography","Female","Humans","Lichen Planus","Middle Aged"]},"pmid":"24322035","title":"Lichen planus secondary complications associated with the use of biologic therapy for rheumatoid arthritis.","year":"2013"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"We are describing a case of 55-year-old obese female with significant history of uncontrolled rheumatoid arthritis, who recently had decreased her immune-suppression medications. She presented with extensive acral gangrene involving multiple fingers and toes. Clinical picture and laboratory findings were suggestive of vasculitis; however, skin biopsy established diagnosis of calciphylaxis, in settings of normal kidney function. Patient was treated with sodium thiosulfate with gradual improvement in her skin lesions.","fulltextAvailable":false,"journal":"Avicenna journal of medicine","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis, Rheumatoid","uri":{"id":"D001172","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis","uri":{"id":"D001168","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Biopsy","uri":{"id":"D001706","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Diagnosis","uri":{"id":"D003933","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Female","uri":{"id":"D005260","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"History","uri":{"id":"D006664","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Kidney","uri":{"id":"D007668","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Laboratories","uri":{"id":"D007753","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Obesity","uri":{"id":"D009765","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Sodium","uri":{"id":"D012964","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medicalization","uri":{"id":"D062528","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Calciphylaxis","uri":{"id":"D002115","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Gangrene","uri":{"id":"D005734","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Thiosulfates","uri":{"id":"D013885","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Vasculitis","uri":{"id":"D014657","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"24327971","title":"Acral gangrene as a presentation of non-uremic calciphylaxis.","year":"2013"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"Previous studies have described an increased risk of developing an additional connective tissue disease (CTD) when one such ailment is present. We examine here the likelihood that individuals with systemic lupus erythematosus (SLE) screen positive for one or more of the following five autoimmune CTDs: SjÃ¶gren's syndrome, scleroderma, rheumatoid arthritis, dermatomyositis/polymyositis, and mixed connective tissue disorder. Five hundred SLE-diagnosed subjects were asked to complete a CTD screening questionnaire (CSQ). The results were analyzed according to the set of diagnostic criteria given by the American College of Rheumatology to identify probable cases of each CTD. Significant standardized prevalence ratios and comorbidities indicate an increased risk for the other autoimmune CTDs. In all, 96% of the subjects screened positive for at least one additional CTD, and 13% screened positive for at least two additional CTDs. We see that the SLE-diagnosed population may benefit from further attention regarding the presence of additional CTDs, which may further inform treatment strategies. We also see the application of the CSQ as a potentially important tool for clinical practice, and we describe the present study's limitations along with possible ways that these can be addressed.","fulltextAvailable":false,"journal":"Journal of primary care & community health","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis, Rheumatoid","uri":{"id":"D001172","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Connective Tissue","uri":{"id":"D003238","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Connective Tissue Diseases","uri":{"id":"D003240","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Lupus Erythematosus, Systemic","uri":{"id":"D008180","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis","uri":{"id":"D001168","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Probability","uri":{"id":"D011336","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Questionnaires","uri":{"id":"D011795","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Syndrome","uri":{"id":"D013577","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Tissues","uri":{"id":"D014024","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Autoimmunity","uri":{"id":"D015551","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Comorbidity","uri":{"id":"D015897","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prevalence","uri":{"id":"D015995","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Dermatomyositis","uri":{"id":"D003882","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pennsylvania","uri":{"id":"D010414","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Rheumatology","uri":{"id":"D012219","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Polymyositis","uri":{"id":"D017285","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Adult","uri":{"id":"D000328","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Aged","uri":{"id":"D000368","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Female","uri":{"id":"D005260","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Male","uri":{"id":"D008297","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Middle Aged","uri":{"id":"D008875","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Questionnaires","uri":{"id":"D011795","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Comorbidity","uri":{"id":"D015897","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prevalence","uri":{"id":"D015995","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Odds Ratio","uri":{"id":"D016017","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis, Rheumatoid","uri":{"id":"D001172","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Connective Tissue Diseases","uri":{"id":"D003240","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Dermatomyositis","uri":{"id":"D003882","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Lupus Erythematosus, Systemic","uri":{"id":"D008180","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pennsylvania","uri":{"id":"D010414","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Sjogren's Syndrome","uri":{"id":"D012859","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Adult","Aged","Arthritis, Rheumatoid","Comorbidity","Connective Tissue Diseases","Dermatomyositis","Female","Humans","Lupus Erythematosus, Systemic","Male","Middle Aged","Odds Ratio","Pennsylvania","Prevalence","Questionnaires","Sjogren's Syndrome"]},"pmid":"24327597","title":"Implementation of the Connective Tissue Screening Questionnaire in northeast Pennsylvania to identify comorbidities of connective tissue diseases in subjects with systemic lupus erythematosus.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"BACKGROUND AND OBJECTIVE: MicroRNA (miR)-499 rs3746444 polymorphisms may participate in the pathogenesis of autoimmune diseases, but the results remain conflicting. We further investigated this association using a meta-analysis. METHODS: We conducted a retrieval of studies and obtained the eligible studies if they met inclusion criteria. Two researchers independently extracted the data from original articles. The genotype frequencies were analysed using Stata software. RESULTS: We finally archived six eligible studies that included 1,118 cases and 1,673 controls. After pooling the data, the results indicated that homozygote TT had an overall association with autoimmune diseases (TC + CC vs. TT: odds ratio [OR] 1.31, 95% CI 1.11-1.55, p = 0.001). The allele C, genotype TC and CC, may be associated with rheumatoid arthritis (RA) risks in Mediterranean populations (C vs. T: OR 2. 00, 95% CI 1.37-2.91, p < 0.001; TC vs. CC + TT: OR 1.76, 95% CI 1.27-2.44; p = 0.001; CC vs. TC + TT: OR 2.31, 95% CI 1.24-4.27, p = 0.008; CC vs. TT: OR 2.92, 95% CI 1.59-5.37, p = 0.001; TC vs. TT: OR 1.98, 95% CI 1.42-2.77). The genotype TT may decrease the risk of RA in Mediterranean populations (TC + CC vs. TT: OR 2.15, 95% CI 1.57-2.94, p < 0.001) rather than in East Asians. CONCLUSIONS: This study suggested that miR-499 polymorphisms were associated with a significantly increased risk of RA in Mediterranean populations.","fulltextAvailable":false,"journal":"Molecular diagnosis & therapy","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis, Rheumatoid","uri":{"id":"D001172","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Odds Ratio","uri":{"id":"D016017","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Autoimmune Diseases","uri":{"id":"D001327","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Alleles","uri":{"id":"D000483","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis","uri":{"id":"D001168","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Genotype","uri":{"id":"D005838","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Software","uri":{"id":"D012984","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Autoimmunity","uri":{"id":"D015551","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"MicroRNAs","uri":{"id":"D035683","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Asian Continental Ancestry Group","uri":{"id":"D044466","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Archives","uri":{"id":"D001109","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Homozygote","uri":{"id":"D006720","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Genotype","uri":{"id":"D005838","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Genetic Variation","uri":{"id":"D014644","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Genetic Predisposition to Disease","uri":{"id":"D020022","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Polymorphism, Single Nucleotide","uri":{"id":"D020641","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"MicroRNAs","uri":{"id":"D035683","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Genetic Association Studies","uri":{"id":"D056726","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Autoimmune Diseases","uri":{"id":"D001327","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Mediterranean Region","uri":{"id":"D019083","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Autoimmune Diseases","Genetic Association Studies","Genetic Predisposition to Disease","Genetic Variation","Genotype","Humans","Mediterranean Region","MicroRNAs","Polymorphism, Single Nucleotide"]},"pmid":"24327058","title":"MicroRNA-499 rs3746444 polymorphism and autoimmune diseases risk: a meta-analysis.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"IL-15 has a pivotal role in life and death of natural killer (NK) and CD8 memory T cells. IL-15 signals through a heterotrimeric receptor involving the common gamma chain (Î³c) shared with IL-2, IL-4, IL-7, IL-9, and IL-21, IL-2/IL-15 receptor Î² (IL-15RÎ²) shared with IL-2 and a private IL-15RÎ± subunit. IFN- or CD40 ligand-stimulated dendritic cells coordinately express IL-15 and IL-15RÎ±. Cell surface IL-15RÎ± presents IL-15 in trans to cells that express IL-2/IL-15RÎ² and Î³c. IL-15 is being used to treat patients with metastatic malignancy. However, IL-15 is an inflammatory cytokine involved in immunological memory including that to self, thereby playing a role in autoimmune diseases. These insights provide the scientific basis for clinical strategies directed toward diminishing IL-15 action. Dysregulated IL-15 expression was demonstrated in patients with rheumatoid arthritis, inflammatory bowel disease, psoriasis, celiac disease, and alopecia areata. The monoclonal antibody Hu-Mik-Î²-1 targets the cytokine receptor subunit IL-2/IL-15RÎ² (CD122), blocks IL-15 transpresentation, and is being used in clinical trials in patients with autoimmune diseases. In parallel, clinical trials have been initiated involving the Jak2/3 (Janus kinase-2/3) inhibitor tofacitinib and Jak1/2 inhibitor ruxolitinib to block IL-15 signaling.","fulltextAvailable":false,"journal":"The journal of investigative dermatology. Symposium proceedings / the Society for Investigative Dermatology, Inc. [and] European Society for Dermatological Research","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Celiac Disease","uri":{"id":"D002446","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Receptors, Interleukin-2","uri":{"id":"D015375","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis, Rheumatoid","uri":{"id":"D001172","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"T-Lymphocytes","uri":{"id":"D013601","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Inflammatory Bowel Diseases","uri":{"id":"D015212","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Alopecia Areata","uri":{"id":"D000506","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Antibodies, Monoclonal","uri":{"id":"D000911","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Autoimmune Diseases","uri":{"id":"D001327","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Celiac Disease","uri":{"id":"D002446","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Dendritic Cells","uri":{"id":"D003713","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Immunologic Memory","uri":{"id":"D007156","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Receptors, Cytokine","uri":{"id":"D018121","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Receptors, Interleukin-15","uri":{"id":"D053647","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Antibodies","uri":{"id":"D000906","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis","uri":{"id":"D001168","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Biology","uri":{"id":"D001695","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Dendrites","uri":{"id":"D003712","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Autoimmunity","uri":{"id":"D015551","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cytokines","uri":{"id":"D016207","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Nature","uri":{"id":"D019368","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Life","uri":{"id":"D019369","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Alopecia","uri":{"id":"D000505","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Interleukin-2","uri":{"id":"D007376","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Psoriasis","uri":{"id":"D011565","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Interleukin-4","uri":{"id":"D015847","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Interleukin-7","uri":{"id":"D015851","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Interleukin-9","uri":{"id":"D016906","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Interleukin-15","uri":{"id":"D019409","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Animals","uri":{"id":"D000818","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Antibodies, Monoclonal","uri":{"id":"D000911","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasms","uri":{"id":"D009369","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Piperidines","uri":{"id":"D010880","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Signal Transduction","uri":{"id":"D015398","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Leukemia-Lymphoma, Adult T-Cell","uri":{"id":"D015459","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Interleukin-15","uri":{"id":"D019409","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Alopecia Areata","uri":{"id":"D000506","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Autoimmune Diseases","uri":{"id":"D001327","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pyrimidines","uri":{"id":"D011743","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pyrroles","uri":{"id":"D011758","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Protein Kinase Inhibitors","uri":{"id":"D047428","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Receptors, Interleukin-15","uri":{"id":"D053647","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Alopecia Areata","Animals","Antibodies, Monoclonal","Autoimmune Diseases","Humans","Interleukin-15","Leukemia-Lymphoma, Adult T-Cell","Neoplasms","Piperidines","Protein Kinase Inhibitors","Pyrimidines","Pyrroles","Receptors, Interleukin-15","Signal Transduction"]},"pmid":"24326545","title":"The biology of IL-15: implications for cancer therapy and the treatment of autoimmune disorders.","year":"2013"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"OBJECTIVE: The objective of this paper is to evaluate the prevalence and characterize the main epidemiological, clinical and immunological features of annular erythema (AE) in non-Asian patients with primary SjÃ¶gren's syndrome (SS). METHODS: We carried out a retrospective study searching for AE in 377 Spanish patients with primary SS fulfilling the 2002 American-European criteria. In addition, we searched PubMed (1994-2012) using the MeSH terms \"annular erythema\" and \"primary SjÃ¶gren's syndrome\" for additional cases. All cases with AE reported in patients with SS associated with systemic lupus erythematosus were excluded. RESULTS: In our Spanish cohort, we found 35 (9%) patients diagnosed with AE. All were white females, with a mean age of 47 years at diagnosis of AE. AE preceded diagnosis of SS in 27 (77%) patients. Cutaneous AE lesions involved principally the face and upper extremities. All patients reported photosensitivity, with cutaneous flares being reported during the warmest months in 93% of patients. Immunological markers consisted of anti-Ro/La antibodies in 31 (89%) patients. In the literature search, we identified eight additional non-Asian patients with primary SS diagnosed with AE. In comparison with 52 Asian patients, the 43 non-Asian patients with AE related to primary SS were more frequently women (100% vs 78%, p=0.008), and cutaneous lesions were less frequently reported in the face (55% vs 81%, p=0.045) and more frequently in the neck (40% vs 14%, p=0.041). Immunologically, non-Asian patients had a lower frequency of anti-Ro antibodies and a higher frequency of negative Ro/La antibodies, although the differences were not statistically significant. CONCLUSION: AE is not an exclusive cutaneous feature of Asian patients with primary SS. In addition to the characteristic cutaneous expression, AE has a very specific clinical and immunological profile: often presenting before the fulfillment of SS criteria, overwhelmingly associated with anti-Ro antibodies but weakly associated with other immunological markers and the main systemic SS-related features.","fulltextAvailable":false,"journal":"Lupus","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Retrospective Studies","uri":{"id":"D012189","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Biological Markers","uri":{"id":"D015415","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Lupus Erythematosus, Systemic","uri":{"id":"D008180","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Sjogren's Syndrome","uri":{"id":"D012859","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Upper Extremity","uri":{"id":"D034941","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Antibodies","uri":{"id":"D000906","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Diagnosis","uri":{"id":"D003933","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Erythema","uri":{"id":"D004890","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Evaluation Studies as Topic","uri":{"id":"D005069","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Extremities","uri":{"id":"D005121","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Female","uri":{"id":"D005260","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Literature","uri":{"id":"D008091","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Syndrome","uri":{"id":"D013577","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Women","uri":{"id":"D014930","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prevalence","uri":{"id":"D015995","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"PubMed","uri":{"id":"D039781","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"European Continental Ancestry Group","uri":{"id":"D044465","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Asian Continental Ancestry Group","uri":{"id":"D044466","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Research Report","uri":{"id":"D058028","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Photosensitivity Disorders","uri":{"id":"D010787","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Photosensitizing Agents","uri":{"id":"D017319","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Adult","uri":{"id":"D000328","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Female","uri":{"id":"D005260","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Male","uri":{"id":"D008297","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Middle Aged","uri":{"id":"D008875","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Retrospective Studies","uri":{"id":"D012189","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Spain","uri":{"id":"D013030","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cohort Studies","uri":{"id":"D015331","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Asian Continental Ancestry Group","uri":{"id":"D044466","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Antibodies, Antinuclear","uri":{"id":"D000974","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Erythema","uri":{"id":"D004890","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Lupus Erythematosus, Cutaneous","uri":{"id":"D008178","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Sjogren's Syndrome","uri":{"id":"D012859","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Skin Diseases, Genetic","uri":{"id":"D012873","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"European Continental Ancestry Group","uri":{"id":"D044465","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Adult","Antibodies, Antinuclear","Asian Continental Ancestry Group","Cohort Studies","Erythema","European Continental Ancestry Group","Female","Humans","Lupus Erythematosus, Cutaneous","Male","Middle Aged","Retrospective Studies","Sjogren's Syndrome","Skin Diseases, Genetic","Spain"]},"pmid":"24326481","title":"Annular erythema in primary Sjogren's syndrome: description of 43 non-Asian cases.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"OBJECTIVES: Update on rheumatic diseases and their intersection with dermatology. RESULTS: This continuing medical education conference included more than 25 presentations and interactive sessions from leading experts in managing rheumatic diseases, comorbid conditions and related dermatologic diseases. Multiple areas were discussed, including: treating newly diagnosed rheumatoid arthritis; comparing Biologics in rheumatoid arthritis; examining changed approaches to treating SLE, psoriasis, psoriatic arthritis, ankylosing spondylitis, gout and vasculitis. Also visited were new understandings regarding chronic pain and osteoporosis. CONCLUSIONS: Multiple presentations and interactive sessions from leading experts in the management of rheumatic diseases emphasized the interconnection between rheumatology and dermatology. Practical management approaches to both specialties and their sequelae were discussed. Additional content from the conference is available at www.globalacademycme.com and through Rheumatology News at www.rheumatologynews.com.","fulltextAvailable":false,"journal":"Seminars in arthritis and rheumatism","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Education, Continuing","uri":{"id":"D004496","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Disease Management","uri":{"id":"D019468","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis, Rheumatoid","uri":{"id":"D001172","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Education, Medical","uri":{"id":"D004501","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Education, Medical, Continuing","uri":{"id":"D004502","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Spondylitis, Ankylosing","uri":{"id":"D013167","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Chronic Pain","uri":{"id":"D059350","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Rheumatic Diseases","uri":{"id":"D012216","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis, Psoriatic","uri":{"id":"D015535","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Practice Management","uri":{"id":"D020399","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Ankylosis","uri":{"id":"D000844","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis","uri":{"id":"D001168","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Diagnosis","uri":{"id":"D003933","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Education","uri":{"id":"D004493","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Spondylitis","uri":{"id":"D013166","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Comorbidity","uri":{"id":"D015897","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medicalization","uri":{"id":"D062528","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Dermatology","uri":{"id":"D003880","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Gout","uri":{"id":"D006073","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Osteoporosis","uri":{"id":"D010024","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Psoriasis","uri":{"id":"D011565","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Rheumatic Diseases","uri":{"id":"D012216","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Rheumatology","uri":{"id":"D012219","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Vasculitis","uri":{"id":"D014657","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Rheumatic Diseases","uri":{"id":"D012216","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Antirheumatic Agents","uri":{"id":"D018501","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Antirheumatic Agents","Humans","Rheumatic Diseases"]},"pmid":"24326035","title":"Proceedings of the 5th annual perspectives in rheumatic diseases.","year":"2013"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"OBJECTIVE: To determine a concentration-effect curve of adalimumab in rheumatoid arthritis (RA) patients taking into account the effect of methotrexate (MTX) on concentration and effect and to identify a therapeutic range for adalimumab concentrations. METHODS: In a prospective observational cohort study, 221 consecutive patients with RA were treated with 40 mg adalimumab subcutaneously every other week. The relationship between adalimumab trough level and clinical efficacy after 28 weeks of follow-up was determined in a concentration-effect curve. A receiver-operator characteristics (ROC) curve established a therapeutic cut-off concentration. The effect of MTX on adalimumab trough levels was shown by dividing patients that are and are not concomitantly using MTX in the concentration-effect curve and a concentration table. RESULTS: Clinical efficacy improved with increasing adalimumab concentration and reached a maximum (mean disease activity score in 28 joints improvement of 2) with levels between 5-8 Î¼g/mL. Levels exceeding 8 Î¼g/mL were illustrated to have no additional beneficial effect on disease activity. The ROC curve showed an area under the curve of 0.695 (95% CI 0.626 to 0.764) for European League Against Rheumatism response and adalimumab levels: good responders versus non-responders and moderate responders. A cut-off of 5 Î¼g/mL had a sensitivity of 91% and a specificity of 43%. Adalimumab levels are influenced by concomitant MTX use: patients on adalimumab monotherapy had a median adalimumab level of 4.1 Î¼g/mL (IQR 1.3-7.7), whereas patients concomitantly taking MTX had a median level of 7.4 Î¼g/mL (IQR 5.3-10.6, p<0.001). CONCLUSIONS: Adalimumab trough levels in a range of 5-8 Î¼g/mL are sufficient to reach adequate clinical response. These levels are influenced substantially by concomitant MTX use.","fulltextAvailable":false,"journal":"Annals of the rheumatic diseases","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Area Under Curve","uri":{"id":"D019540","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis, Rheumatoid","uri":{"id":"D001172","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"ROC Curve","uri":{"id":"D012372","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cohort Studies","uri":{"id":"D015331","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis","uri":{"id":"D001168","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Data Collection","uri":{"id":"D003625","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Methotrexate","uri":{"id":"D008727","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Sensitivity and Specificity","uri":{"id":"D012680","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Therapeutics","uri":{"id":"D013812","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Rheumatic Diseases","uri":{"id":"D012216","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"ROC Curve","uri":{"id":"D012372","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"24326008","title":"Key findings towards optimising adalimumab treatment: the concentration-effect curve.","year":"2013"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"Cytokines receptors exist in membrane bound and soluble form. A soluble form of the human IL-6R is generated by limited proteolysis and alternative splicing. The complex of IL-6 and soluble IL-6R stimulates target cells not stimulated by IL-6 alone, since they do not express the membrane bound IL-6R. We have named this process trans-signaling. Soluble gp130 is the natural inhibitor of IL-6/soluble IL-6R complex responses. Recombinant soluble gp130 protein is a molecular tool to discriminate between gp130 responses via membrane bound and soluble IL-6R responses. Neutralizing monoclonal antibodies for global blockade of IL-6 signaling and the sgp130Fc protein for selective blockade of IL-6 trans-signaling have been used in several animal models of human diseases. Using the sgp130Fc protein or sgp130Fc transgenic mice we demonstrate in models of inflammatory bowel disease, peritonitis, rheumatoid arthritis, atherosclerosis pancreatitis, colon cancer, ovarian cancer and pancreatic cancer, that IL-6 trans-signaling via the soluble IL-6R is the crucial step in the development and the progression of the disease. Therefore, sgp130Fc is a novel therapeutic agent for the treatment of chronic inflammatory diseases and cancer and it undergoes phase I clinical trials as an anti-inflammatory drug since June 2013.","fulltextAvailable":false,"journal":"Seminars in immunology","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Chronic Disease","uri":{"id":"D002908","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pancreatic Neoplasms","uri":{"id":"D010190","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Antibodies, Neutralizing","uri":{"id":"D057134","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis, Rheumatoid","uri":{"id":"D001172","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Colonic Neoplasms","uri":{"id":"D003110","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Ovarian Neoplasms","uri":{"id":"D010051","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pancreatic Neoplasms","uri":{"id":"D010190","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Inflammatory Bowel Diseases","uri":{"id":"D015212","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Models, Animal","uri":{"id":"D023421","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Antibodies, Monoclonal","uri":{"id":"D000911","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Mice, Transgenic","uri":{"id":"D008822","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Clinical Trials, Phase I as Topic","uri":{"id":"D017321","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Alternative Splicing","uri":{"id":"D017398","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Receptors, Cytokine","uri":{"id":"D018121","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cytokine Receptor gp130","uri":{"id":"D050822","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Animals","uri":{"id":"D000818","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anti-Inflammatory Agents","uri":{"id":"D000893","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Antibodies","uri":{"id":"D000906","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis","uri":{"id":"D001168","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Biology","uri":{"id":"D001695","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Discrimination (Psychology)","uri":{"id":"D004192","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmaceutical Preparations","uri":{"id":"D004364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Membranes","uri":{"id":"D008566","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Names","uri":{"id":"D009275","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pancreatitis","uri":{"id":"D010195","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Peritonitis","uri":{"id":"D010538","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Proteins","uri":{"id":"D011506","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Therapeutics","uri":{"id":"D013812","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cytokines","uri":{"id":"D016207","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Nature","uri":{"id":"D019368","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Internationality","uri":{"id":"D038622","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Atherosclerosis","uri":{"id":"D050197","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Mice","uri":{"id":"D051379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Interleukin-6","uri":{"id":"D015850","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Transgenes","uri":{"id":"D019076","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Proteolysis","uri":{"id":"D059748","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Animals","uri":{"id":"D000818","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Inflammation","uri":{"id":"D007249","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasms","uri":{"id":"D009369","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Recombinant Fusion Proteins","uri":{"id":"D011993","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Signal Transduction","uri":{"id":"D015398","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Interleukin-6","uri":{"id":"D015850","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Inflammation Mediators","uri":{"id":"D018836","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Receptors, Interleukin-6","uri":{"id":"D019947","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Animals","Humans","Inflammation","Inflammation Mediators","Interleukin-6","Neoplasms","Receptors, Interleukin-6","Recombinant Fusion Proteins","Signal Transduction"]},"pmid":"24325804","title":"Interleukin-6: from basic biology to selective blockade of pro-inflammatory activities.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"Abatacept, a selective T-cell costimulation modulator, has become a valuable treatment option for those with moderately to severely active rheumatoid arthritis. Given new clinical evidence, for the first time guidelines from the American College of Rheumatology and Canadian Rheumatology Association are promoting the consideration of abatacept as the first biologic added to initial traditional disease-modifying antirheumatic drugs once an inadequate response to disease-modifying antirheumatic drug monotherapy has been established, putting abatacept at the same line of treatment options as TNF-Î± inhibitors or rituximab. Since the advent of the subcutaneous formulation of abatacept, positive results from its clinical trials have further increased its appeal. In light of these changes, a review of the literature was conducted on the cost-effectiveness of abatacept for moderate-to-severe rheumatoid arthritis. Here we discuss current evidence, gaps in the literature and abatacept's future outlook.","fulltextAvailable":false,"journal":"Expert review of pharmacoeconomics & outcomes research","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis, Rheumatoid","uri":{"id":"D001172","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Antirheumatic Agents","uri":{"id":"D018501","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis","uri":{"id":"D001168","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmaceutical Preparations","uri":{"id":"D004364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Forecasting","uri":{"id":"D005544","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Literature","uri":{"id":"D008091","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"T-Lymphocytes","uri":{"id":"D013601","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Rheumatology","uri":{"id":"D012219","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cost-Benefit Analysis","uri":{"id":"D003362","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Severity of Illness Index","uri":{"id":"D012720","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Antirheumatic Agents","uri":{"id":"D018501","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis, Rheumatoid","uri":{"id":"D001172","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Clinical Trials as Topic","uri":{"id":"D002986","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Immunosuppressive Agents","uri":{"id":"D007166","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Practice Guidelines as Topic","uri":{"id":"D017410","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Immunoconjugates","uri":{"id":"D018796","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Antirheumatic Agents","Arthritis, Rheumatoid","Clinical Trials as Topic","Cost-Benefit Analysis","Humans","Immunoconjugates","Immunosuppressive Agents","Practice Guidelines as Topic","Severity of Illness Index"]},"pmid":"24325566","title":"Cost-effectiveness of abatacept for moderate-to-severe rheumatoid arthritis.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"OBJECTIVE: To determine the association between acute-phase-reactants (APR) and interleukin-6 (IL-6) in patient with dermatomysitis (DM). METHODS: The levels of C-reactive protein (CRP), serum amyloid A protein(SAA) and serum ferritin (SF) in peripheral blood of 31 adult DM patients were determined by chemiluminescence immunoassay, and compared with those of 23 patients with systemic lupus erythematosus (SLE), 22 patients with rheumatoid arthritis (RA), and 18 patients with Sjagren syndrome (SS). The correlations between the levels of those APR and IL-6 were examined. We also measured dermatomyositis disease activity using myositis disease activity assessment tool (MDAAT), and examined its association with APR levels. RESULTS: DM patients had significantly lower level of CRP [(17. 08 +/- 17. 18) mg/L] than those patients with RA [(85. 95 +/-60.62) mg/L, P<0. 000 1], SLE [(51. 34+/-52. 98) mg/L, P=0. 006] and SS [(47. 00+/-47. 24) mg/L, P= 0.018]. DM patients had significantly lower level of SAA [(92. 04 +/- 98. 93) mg/L] than those patients with RA [(311.30 +/- 292. 45) mg/L, P= 0. 002] and SS [(284. 31 +/- 325. 30) mg/L, P= 0. 025]. DM patients had significantly higher level of SF [(510. 10 +/- 610. 73) ng/mL] than those patients with SS [(220. 33 +/- 164. 07) ng/ mL, P=0. 02], as well as those with RA and SLE albeit without statistical significance. All of the three APRs were positive correlated with IL-6 level. No significant associations between APR and systemic or global disease activities were found, although CRP was associated with constitutional disease activity and SF was associated with pulmonary disease activity. CONCLUSION: DM patients have lower levels of elevated APR than the other three common connective tissue diseases, which is associated with IL-6 but not with global disease activity.","fulltextAvailable":false,"journal":"Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Amyloidogenic Proteins","uri":{"id":"D058227","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Serum Amyloid A Protein","uri":{"id":"D000685","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Blood Proteins","uri":{"id":"D001798","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Serum Amyloid A Protein","uri":{"id":"D000685","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis, Rheumatoid","uri":{"id":"D001172","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Lung Diseases","uri":{"id":"D008171","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"C-Reactive Protein","uri":{"id":"D002097","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Connective Tissue","uri":{"id":"D003238","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Connective Tissue Diseases","uri":{"id":"D003240","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Lupus Erythematosus, Systemic","uri":{"id":"D008180","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Adult","uri":{"id":"D000328","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis","uri":{"id":"D001168","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Constitution and Bylaws","uri":{"id":"D003249","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Immunoassay","uri":{"id":"D007118","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Proteins","uri":{"id":"D011506","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Syndrome","uri":{"id":"D013577","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Tissues","uri":{"id":"D014024","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Internationality","uri":{"id":"D038622","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Serum","uri":{"id":"D044967","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Luminescence","uri":{"id":"D049449","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Dermatomyositis","uri":{"id":"D003882","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Ferritins","uri":{"id":"D005293","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Myositis","uri":{"id":"D009220","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Staphylococcal Protein A","uri":{"id":"D013205","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Interleukin-6","uri":{"id":"D015850","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Acute-Phase Proteins","uri":{"id":"D000209","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Adult","uri":{"id":"D000328","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Aged","uri":{"id":"D000368","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Female","uri":{"id":"D005260","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Male","uri":{"id":"D008297","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Middle Aged","uri":{"id":"D008875","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Severity of Illness Index","uri":{"id":"D012720","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Interleukin-6","uri":{"id":"D015850","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Serum Amyloid A Protein","uri":{"id":"D000685","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"C-Reactive Protein","uri":{"id":"D002097","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Dermatomyositis","uri":{"id":"D003882","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Ferritins","uri":{"id":"D005293","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Acute-Phase Proteins","Adult","Aged","C-Reactive Protein","Dermatomyositis","Female","Ferritins","Humans","Interleukin-6","Male","Middle Aged","Serum Amyloid A Protein","Severity of Illness Index"]},"pmid":"24325119","title":"[Levels of acute-phase-reactants in patient with dermatomysitis and its correlations with IL-6 and dermatomyositis disease activity].","year":"2013"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"Background. TNF-Î± inhibitors have shown to be effective in reducing disease activity and improving the quality of life. Due to the high costs associated with acquisition of this treatment, this study was undertaken to evaluate the ICER of TNF-Î± antagonists (etanercept, adalimumab, and infliximab) in improving the quality of life. Methods. The HAQ and SF-36 were administered at phases 1, 2, and 3, in order to assess the improvement in the QOL. Suppression of disease activity was assessed through the DAS-28. Results. Statistically significant improvements (P < 0.05) were noted for the SF-36 and HAQ after 3 months and for the DAS-28 after 6 months of TNF-Î± inhibitor therapy. The mean ICER per 10% improvement in the HAQ, DAS-28, and SF-6D were â¬1976.5, â¬2086.5, and â¬2316.4, respectively, following 6 months of TNF-Î± intervention. Most favorable ICERs were reported from a patient who had to undergo surgical intervention whilst on DMARD therapy. Conclusion. Significant improvement was observed in patients' quality of life, after a short timeframe of 6 months. Such data is useful information in the light of convincing policy makers, in terms of providing access to the medications to individual patients on national health service schemes.","fulltextAvailable":false,"journal":"International journal of inflammation","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Quality Improvement","uri":{"id":"D058996","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis, Rheumatoid","uri":{"id":"D001172","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cost-Benefit Analysis","uri":{"id":"D003362","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Health Services","uri":{"id":"D006296","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"National Health Programs","uri":{"id":"D009313","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Quality of Life","uri":{"id":"D011788","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Administrative Personnel","uri":{"id":"D000288","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis","uri":{"id":"D001168","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Evaluation Studies as Topic","uri":{"id":"D005069","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Life","uri":{"id":"D019369","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Research Report","uri":{"id":"D058028","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medicalization","uri":{"id":"D062528","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Antirheumatic Agents","uri":{"id":"D018501","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"24324915","title":"Cost Effectiveness of TNF-Î± Inhibitors in Rheumatoid Arthritis.","year":"2013"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"Rheumatoid arthritis (RA) is considered as a connective tissue disease while ankylosing spondylitis (AS) is a prototype of spondyloarthritis. These diseases are seen concomitantly only very rarely. Also, rituximab has proven efficacy in the treatment of RA while its role in the treatment of AS is unclear. In this presentation, the concomitant presence of RA and AS in a 43-year-old male patient as well as the efficacy and safety of rituximab is discussed. Rituximab was given due to lack of response to treatment with anti-TNF-alpha. Evaluations made at the 6th and 12th months of treatment showed complete response for RA and partial response for AS.","fulltextAvailable":false,"journal":"Case reports in rheumatology","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis, Rheumatoid","uri":{"id":"D001172","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Spondylitis, Ankylosing","uri":{"id":"D013167","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Connective Tissue","uri":{"id":"D003238","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Connective Tissue Diseases","uri":{"id":"D003240","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Ankylosis","uri":{"id":"D000844","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis","uri":{"id":"D001168","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Evaluation Studies as Topic","uri":{"id":"D005069","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Male","uri":{"id":"D008297","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Safety","uri":{"id":"D012449","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Spondylitis","uri":{"id":"D013166","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Tissues","uri":{"id":"D014024","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"24324911","title":"The efficacy and safety of rituximab in a patient with rheumatoid spondylitis.","year":"2013"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"INTRODUCTION: This study aimed to investigate the efficacy of abatacept for arthritis in patients with rhupus, an overlap syndrome between rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). METHODS: Patients who fulfilled both the 2010 ACR/EULAR criteria for RA classification and the 1997 ACR revised criteria for classification of SLE and received abatacept treatment for arthritis were retrospectively studied. RESULTS: Six rhupus patients who fulfilled the inclusion criteria above were identified. All patients had active arthritis despite receiving antirheumatic drugs including methotrexate when abatacept was initiated. Clinical Disease Activity Index (CDAI) significantly decreased between baseline and 12 weeks (P = 0.028) and remained low through 24 weeks. All patients achieved either a good or moderate response according to the EULAR response criteria at 24 weeks. Health Assessment Questionnaire-Disability Index (HAQ-DI) also significantly decreased between baseline and 24 weeks (P = 0.043). In addition, the levels of immunoglobulin G and anti-DNA antibody significantly decreased between baseline and 24 weeks (P = 0.028 and P = 0.043, resp.). CONCLUSIONS: Treatment with abatacept is likely to be efficacious in patients with rhupus whose arthritis is refractory to methotrexate. In addition, abatacept may have a moderate effect on abnormal antibody production in rhupus patients.","fulltextAvailable":false,"journal":"Clinical & developmental immunology","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Ambulatory Care Facilities","uri":{"id":"D000554","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Antibody Formation","uri":{"id":"D000917","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis, Rheumatoid","uri":{"id":"D001172","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Retrospective Studies","uri":{"id":"D012189","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Antibodies, Antinuclear","uri":{"id":"D000974","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Immunoglobulin G","uri":{"id":"D007074","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Lupus Erythematosus, Systemic","uri":{"id":"D008180","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Antirheumatic Agents","uri":{"id":"D018501","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Abstracting and Indexing as Topic","uri":{"id":"D000043","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Antibodies","uri":{"id":"D000906","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis","uri":{"id":"D001168","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Classification","uri":{"id":"D002965","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmaceutical Preparations","uri":{"id":"D004364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Immunoglobulins","uri":{"id":"D007136","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Methotrexate","uri":{"id":"D008727","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Syndrome","uri":{"id":"D013577","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Adult","uri":{"id":"D000328","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Aged","uri":{"id":"D000368","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Female","uri":{"id":"D005260","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Middle Aged","uri":{"id":"D008875","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Retrospective Studies","uri":{"id":"D012189","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Treatment Outcome","uri":{"id":"D016896","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Antirheumatic Agents","uri":{"id":"D018501","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis","uri":{"id":"D001168","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis, Rheumatoid","uri":{"id":"D001172","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Immunosuppressive Agents","uri":{"id":"D007166","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Lupus Erythematosus, Systemic","uri":{"id":"D008180","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Immunoconjugates","uri":{"id":"D018796","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Adult","Aged","Antirheumatic Agents","Arthritis","Arthritis, Rheumatoid","Female","Humans","Immunoconjugates","Immunosuppressive Agents","Lupus Erythematosus, Systemic","Middle Aged","Retrospective Studies","Treatment Outcome"]},"pmid":"24324510","title":"Efficacy of abatacept for arthritis in patients with an overlap syndrome between rheumatoid arthritis and systemic lupus erythematosus.","year":"2013"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"BACKGROUND: Systemic inflammation plays an important role in the increased cardiac risk observed in rheumatoid arthritis (RA). Effective control of inflammation and disease activity may be of benefit in reducing cardiovascular risk in RA patients. OBJECTIVE: Our study was conducted in patients with active RA to investigate the effects of 24-week abatacept treatment on aortic stiffness measured by pulse wave velocity (PWV). RESULTS: The study included 21 patients, of whom 17 were females, with a mean age of 65.2Â±13.7 years. Ten patients had positive rheumatoid factors, 16 positive anti-citrullinated protein antibodies, and 19 presented an erosive form of RA. Sixteen patients were nonresponders to anti-tumor necrosis factor-alpha treatments. After 6 months of abatacept treatment, there was a significant increase in PWV levels (9.8Â±2.9 versus 8.5Â±3.9 m/second; P=0.02). A nonsignificant increase in total cholesterol and low-density lipoprotein cholesterol was observed. There was also a significant increase in high-density lipoprotein cholesterol levels, which led to a nonsignificant decrease in atherogenic index. The improvement in disease activity was significant, and there was a decrease of systemic inflammatory parameters, but without reaching statistical significancy. Changes in PWV were significantly correlated with changes in Disease Activity Score on 28 joints based on erythrocyte sedimentation rate (r=0.46; P=0.035) and in high-density lipoprotein cholesterol (r=-0.38; P=0.046). No correlation was observed with changes in C-reactive protein and in other parameters of lipid profile or in steroid dose. CONCLUSION: The worsening of aortic stiffness found after 6 months of abatacept therapy might be due to an insufficient decrease in systemic inflammation.","fulltextAvailable":false,"journal":"Biologics : targets & therapy","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis, Rheumatoid","uri":{"id":"D001172","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Lipoproteins, LDL","uri":{"id":"D008077","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Vascular Stiffness","uri":{"id":"D059289","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Blood Sedimentation","uri":{"id":"D001799","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"C-Reactive Protein","uri":{"id":"D002097","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Lipoproteins, HDL","uri":{"id":"D008075","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Rheumatoid Factor","uri":{"id":"D012217","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pulse Wave Analysis","uri":{"id":"D063177","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Abstracting and Indexing as Topic","uri":{"id":"D000043","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Antibodies","uri":{"id":"D000906","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis","uri":{"id":"D001168","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cholesterol","uri":{"id":"D002784","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Data Collection","uri":{"id":"D003625","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Erythrocytes","uri":{"id":"D004912","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Female","uri":{"id":"D005260","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Inflammation","uri":{"id":"D007249","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Lipids","uri":{"id":"D008055","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Lipoproteins","uri":{"id":"D008074","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Necrosis","uri":{"id":"D009336","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Proteins","uri":{"id":"D011506","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pulse","uri":{"id":"D011674","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"24324327","title":"Effects of 6 months of abatacept treatment on aortic stiffness in patients with rheumatoid arthritis.","year":"2013"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"Rheumatoid factors are antibodies directed against the Fc region of immunoglobulin G. First detected in patients with rheumatoid arthritis 70 years ago, they can also be found in patients with other autoimmune and nonautoimmune conditions, as well as in healthy subjects. Rheumatoid factors form part of the workup for the differential diagnosis of arthropathies. In clinical practice, it is recommended to measure anti-cyclic citrullinated peptide antibodies and rheumatoid factors together because anti-cyclic citrullinated peptide antibodies alone are only moderately sensitive, and the combination of the two markers improves diagnostic accuracy, especially in the case of early rheumatoid arthritis. Furthermore, different rheumatoid factor isotypes alone or in combination can be helpful when managing rheumatoid arthritis patients, from the time of diagnosis until deciding on the choice of therapeutic strategy.","fulltextAvailable":false,"journal":"Disease markers","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis, Rheumatoid","uri":{"id":"D001172","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Diagnosis, Differential","uri":{"id":"D003937","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Immunoglobulin G","uri":{"id":"D007074","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Rheumatoid Factor","uri":{"id":"D012217","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Antibodies","uri":{"id":"D000906","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis","uri":{"id":"D001168","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Diagnosis","uri":{"id":"D003933","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Immunoglobulins","uri":{"id":"D007136","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Peptides","uri":{"id":"D010455","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Therapeutics","uri":{"id":"D013812","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Autoimmunity","uri":{"id":"D015551","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Citrulline","uri":{"id":"D002956","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prognosis","uri":{"id":"D011379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Biological Markers","uri":{"id":"D015415","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis, Rheumatoid","uri":{"id":"D001172","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Autoimmune Diseases","uri":{"id":"D001327","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Immunoglobulin G","uri":{"id":"D007074","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Rheumatoid Factor","uri":{"id":"D012217","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Arthritis, Rheumatoid","Autoimmune Diseases","Biological Markers","Humans","Immunoglobulin G","Prognosis","Rheumatoid Factor"]},"pmid":"24324289","title":"Rheumatoid factors: clinical applications.","year":"2013"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"OBJECTIVES: Primary SS is an autoimmune disease characterized by chronic lymphocytic inflammation and ectopic germinal centre (GC) formation within salivary glands. Fractalkine (CX3CL1), associated with the pathogenesis of RA, is the sole member of the CX3C chemokine (CK) family and acts as an adhesion and chemotactic molecule. The objectives of this work are to determine to what extent CX3CL1 and its receptor CX3CR1 expression might be altered in salivary glands obtained from patients and to establish whether these CKs might be involved in SS ectopic lymphoneogenesis. METHODS: We assessed the presence of CX3CL1 protein in sera by ELISA in 21 patients with primary SS, 11 patients with Sicca syndrome (Sicca), 20 RA patients and 10 blood donors. Histological evaluation was performed on sequential sections of salivary gland tissue. Using TaqMan RT-PCR we studied CX3CL1 and CX3CR1 mRNA expression in salivary gland tissues from a molecular point of view. RESULTS: Increased serum levels of CX3CL1 protein were observed in SS patients compared with controls (P < 0.0001) and in RA patients compared with controls (P < 0.0001), but no difference was found between Sicca patients and controls (P = 0.22). We identified histologically the cells expressing CX3CL1 and CX3CR1 in salivary glands of SS patients and we localized the molecule within tertiary lymphoid structures. Finally, the mRNA levels of the CK and its receptor were up-regulated in SS salivary glands. CONCLUSION: We believe that our findings point to the need for future studies on CX3CL1 and CX3CR1 proteins as contributors to the formation of ectopic GCs and possibly as a new tool in the evaluation and diagnosis of SS.","fulltextAvailable":false,"journal":"Rheumatology (Oxford, England)","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Up-Regulation","uri":{"id":"D015854","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Salivary Glands","uri":{"id":"D012469","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Autoimmune Diseases","uri":{"id":"D001327","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Blood Donors","uri":{"id":"D001782","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Sjogren's Syndrome","uri":{"id":"D012859","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Chemokines, CX3C","uri":{"id":"D020523","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Diagnosis","uri":{"id":"D003933","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Enzyme-Linked Immunosorbent Assay","uri":{"id":"D004797","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Evaluation Studies as Topic","uri":{"id":"D005069","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Forecasting","uri":{"id":"D005544","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Inflammation","uri":{"id":"D007249","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Lymphocytes","uri":{"id":"D008214","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Proteins","uri":{"id":"D011506","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"RNA, Messenger","uri":{"id":"D012333","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Syndrome","uri":{"id":"D013577","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Tissue Donors","uri":{"id":"D014019","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Tissues","uri":{"id":"D014024","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Work","uri":{"id":"D014937","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Autoimmunity","uri":{"id":"D015551","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Up-Regulation","uri":{"id":"D015854","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Germination","uri":{"id":"D018525","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Serum","uri":{"id":"D044967","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Chemokines","uri":{"id":"D018925","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Chemokine CX3CL1","uri":{"id":"D054428","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Adult","uri":{"id":"D000328","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Aged","uri":{"id":"D000368","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Female","uri":{"id":"D005260","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Male","uri":{"id":"D008297","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Middle Aged","uri":{"id":"D008875","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"RNA, Messenger","uri":{"id":"D012333","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Case-Control Studies","uri":{"id":"D016022","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Young Adult","uri":{"id":"D055815","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis, Rheumatoid","uri":{"id":"D001172","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Choristoma","uri":{"id":"D002828","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Lymphoid Tissue","uri":{"id":"D008221","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Salivary Gland Diseases","uri":{"id":"D012466","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Salivary Glands, Minor","uri":{"id":"D012470","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Sjogren's Syndrome","uri":{"id":"D012859","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Germinal Center","uri":{"id":"D018858","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Receptors, Chemokine","uri":{"id":"D019707","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Chemokine CX3CL1","uri":{"id":"D054428","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Adult","Aged","Arthritis, Rheumatoid","Case-Control Studies","Chemokine CX3CL1","Choristoma","Female","Germinal Center","Humans","Lymphoid Tissue","Male","Middle Aged","RNA, Messenger","Receptors, Chemokine","Salivary Gland Diseases","Salivary Glands, Minor","Sjogren's Syndrome","Young Adult"]},"pmid":"24324211","title":"CX3CL1 and CX3CR1 expression in tertiary lymphoid structures in salivary gland infiltrates: fractalkine contribution to lymphoid neogenesis in Sjogren's syndrome.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"OBJECTIVE: To estimate the costs related to hospital care, drug use and work loss in prevalent and incident patients with rheumatoid arthritis (RA), and to describe their distribution. METHODS: A cohort of prevalent patients with RA â¥18 years on Jan 1, 2010, was identified from the Swedish National Patient Register (requiring â¥2 visits listing RA) and the Swedish Rheumatology Quality Register, and followed until 31 December 2010. From the same registers, patients with the 1st visit listing RA in 2009, with a 2nd visit within 1 year, were identified to the incident cohort, and were followed for 1 year. Five sex-matched, age-matched, education-matched and county-matched general population comparators were sampled per patient with RA. Costs were retrieved from national registers. RESULTS: The mean annual cost, including productivity losses per patients with RA (n=49 829) aged 18-64 years was â¬23 147 versus â¬8364 (median â¬15 059 vs â¬277) per comparator. In patients with RA â¥65 years, the mean healthcare cost was â¬6438 versus â¬2773 (median â¬2458 vs â¬677) per comparator. 13% of the patients accounted for 50% of the cost.For the incident patients with RA (n=2695), the mean monthly cost increased from a level close to the comparators 1 year before register identification (18-64 years: â¬736 vs â¬644; â¥65 years: â¬192 vs â¬178), peaked the month following the identification date, and decreased to twice the cost of the comparators 1 year after diagnosis (18-64 years: â¬1252 vs â¬628; â¥65 years: â¬487 vs â¬230). CONCLUSIONS: The mean annual cost in patients with established RA, and mean monthly cost in newly diagnosed patients with RA, were 2-3 times higher than in the general population.","fulltextAvailable":false,"journal":"Annals of the rheumatic diseases","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hospital Costs","uri":{"id":"D017721","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis, Rheumatoid","uri":{"id":"D001172","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Health Care Costs","uri":{"id":"D017048","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis","uri":{"id":"D001168","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Delivery of Health Care","uri":{"id":"D003695","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Diagnosis","uri":{"id":"D003933","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmaceutical Preparations","uri":{"id":"D004364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hospitalization","uri":{"id":"D006760","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hospitals","uri":{"id":"D006761","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Work","uri":{"id":"D014937","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Incidence","uri":{"id":"D015994","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prevalence","uri":{"id":"D015995","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Rheumatology","uri":{"id":"D012219","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"24323395","title":"Costs for hospital care, drugs and lost work days in incident and prevalent rheumatoid arthritis: how large, and how are they distributed?","year":"2013"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"The extra-articular complications of rheumatoid arthritis (RA) include ophthalmological manifestations, which can, in some cases, be the first signs of the disease. These inflammatory ophthalmological conditions include episcleritis, scleritis and peripheral ulcerative keratitis (PUK). RA is the leading cause of necrotizing scleritis and of PUK, which are the two most severe ocular conditions associated with the disease. These conditions can rapidly threaten ocular prognosis and are associated with excess mortality in patients with RA owing to their association with systemic vasculitis. Close collaboration between the ophthalmologist and the rheumatologist or internal medicine expert is required for the diagnosis and therapeutic management of these patients. In this Review, we provide an overview of ocular inflammatory diseases in patients with RA with particular focus on the diagnosis and current available therapies (including biologic agents) for these conditions. Furthermore, we propose a decision tree to assist clinicians in their choice of treatment for patients with RA who also have ocular inflammatory disease.","fulltextAvailable":false,"journal":"Nature reviews. Rheumatology","meshAnnotations":{"@type":"java.util.ArrayList"},"meshHeading":{"@type":"java.util.ArrayList","@items":["Adrenal Cortex Hormones","Arthritis, Rheumatoid","Biological Factors","Comorbidity","Corneal Ulcer","Humans","Inflammation","Prognosis","Scleritis"]},"pmid":"24323074","title":"Ocular inflammatory diseases associated with rheumatoid arthritis.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"PURPOSE: Rheumatoid arthritis (RA) is associated with extra-articular features (ExRA) and other co-morbidities. The aim of this study is to quantify their relative contribution to quality of life (QOL) in patients with RA. METHODS: A consecutive series of 114 ambulatory RA patients aged between 40 and 65 years were assessed by a research nurse on a single occasion. Assessment included a patient questionnaire (including EQ-5D), medication review and fasting venous blood sample. Medical records were reviewed by a rheumatologist for co-existing conditions. Multiple linear regression was used to adjust mean differences in EQ-5D in the presence/absence of co-existing conditions for age, sex, university education, arthritis duration, rheumatoid factor, erythrocyte sedimentation rate, current disease-modifying drug therapy, previous hand joint erosions and joint surgery. RESULTS: Mean age was 54 years (82% female) and median arthritis duration 10 years. Unadjusted EQ-5D was -0.09 (95% CI -0.18 to -0.01) lower in patients with any co-existing condition. EQ-5D scores were inversely correlated with the overall number of co-existing conditions (Spearman's Ï -0.31, p = 0.001), number of co-morbidities (Ï -0.22, p = 0.02) and number of ExRA features (Ï -0.22, p = 0.02). There was a linear trend of lower EQ-5D with increasing number of co-existing conditions (p = 0.003). EQ-5D was -0.18 (95% CI -0.33 to -0.02) lower in the presence of more than two co-existing conditions compared to none. Co-morbidity and ExRA features were associated with comparable adjusted reductions (-0.05 vs. -0.06) in EQ-5D scores. CONCLUSION: A wide range of co-existing conditions are associated with poorer QOL in patients with RA.","fulltextAvailable":false,"journal":"Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis, Rheumatoid","uri":{"id":"D001172","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis, Rheumatoid","uri":{"id":"D001172","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Drug Therapy","uri":{"id":"D004358","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medical Records","uri":{"id":"D008499","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Quality of Life","uri":{"id":"D011788","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Blood Sedimentation","uri":{"id":"D001799","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Rheumatoid Factor","uri":{"id":"D012217","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Nursing Research","uri":{"id":"D015399","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Linear Models","uri":{"id":"D016014","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hand Joints","uri":{"id":"D050823","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis","uri":{"id":"D001168","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmaceutical Preparations","uri":{"id":"D004364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Education","uri":{"id":"D004493","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Erythrocytes","uri":{"id":"D004912","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Fasting","uri":{"id":"D005215","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Female","uri":{"id":"D005260","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Nurses","uri":{"id":"D009726","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Nursing","uri":{"id":"D009729","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Questionnaires","uri":{"id":"D011795","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"General Surgery","uri":{"id":"D013502","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Universities","uri":{"id":"D014495","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Comorbidity","uri":{"id":"D015897","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Life","uri":{"id":"D019369","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medicalization","uri":{"id":"D062528","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"24322906","title":"Relationship of EQ-5D quality of life with the presence of co-morbidity and extra-articular features in patients with rheumatoid arthritis.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"Mucosa-associated lymphoid tissue (MALT) lymphoma is a rare type of lymphoma that arises in small CD20-positive lymphocytes. We encountered a case of thymic MALT lymphoma treated with surgical intervention during long-term follow-up for SjÃ¶gren's syndrome and idiopathic thrombocytopenic purpura (ITP). Although symptomatic remission of SjÃ¶gren's syndrome and ITP had already been achieved, the levels of anti-SSA and anti-SSB antibodies remained high. Chronic stimulation by these antibodies may contribute to the development of MALT lymphoma. A careful follow-up may be indicated for this case with a complex immunological background.","fulltextAvailable":false,"journal":"Kyobu geka. The Japanese journal of thoracic surgery","meshAnnotations":{"@type":"java.util.ArrayList"},"meshHeading":{"@type":"java.util.ArrayList","@items":["Female","Follow-Up Studies","Humans","Lymphoma, B-Cell, Marginal Zone","Middle Aged","Purpura, Thrombocytopenic, Idiopathic","Sjogren's Syndrome","Thymus Neoplasms"]},"pmid":"24322322","title":"[Thymic mucosa-associated lymphoid tissue (MALT) lymphoma developing during long-term follow-up for SjÃ¶gren's syndrome and idiopathic thrombocytopenic purpura;report of a case].","year":"2013"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"Rheumatoid arthritis is a complex multifactorial disease, whose pathogenesis has not been fully elucidated. Biologic agents have revolutionized RA treatment, but a significant percentage of patients does not obtain an adequate response to the therapy. Most of the biologic agents do better if combined with conventional immunosuppressive DMARDs and they show a similar efficacy profile: most of the responders achieve the minimum desirable level of response (ACR20) and only few patients obtain a worthwhile clinical improvement (ACR70 or better). We need to identify new strategies of treatment, able to comply the non satisfied needs of RA patients. Taking inspiration from other medical fields, we could hypothesize a combined regimen in which biologic agents are administered simultaneously at a low or ultra-low dosage, targeting several pathogenetic mechanisms but avoiding important side effects. Alternatively it should be useful to identify rapid succession regimens in which biologic drugs are taken according to an established sequence. Research in this field is obviously not encouraged by pharmaceutical industries, but our efforts should be driven in this direction. According to these observations, adequate clinical trials should be designed to search for appropriate drugs associations and dosages.","fulltextAvailable":false,"journal":"Medical hypotheses","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis, Rheumatoid","uri":{"id":"D001172","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Drug Industry","uri":{"id":"D004345","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Biological Factors","uri":{"id":"D001685","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis","uri":{"id":"D001168","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Data Collection","uri":{"id":"D003625","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmaceutical Preparations","uri":{"id":"D004364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Industry","uri":{"id":"D007221","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medicalization","uri":{"id":"D062528","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Dose-Response Relationship, Drug","uri":{"id":"D004305","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Drug Therapy, Combination","uri":{"id":"D004359","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Models, Biological","uri":{"id":"D008954","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Treatment Outcome","uri":{"id":"D016896","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Antirheumatic Agents","uri":{"id":"D018501","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis, Rheumatoid","uri":{"id":"D001172","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Biological Factors","uri":{"id":"D001685","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Antirheumatic Agents","Arthritis, Rheumatoid","Biological Factors","Dose-Response Relationship, Drug","Drug Therapy, Combination","Humans","Models, Biological","Treatment Outcome"]},"pmid":"24321737","title":"Biologic agents for rheumatoid arthritis: can we hypothesize new strategies of treatment?","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"OBJECTIVES: Recent genome-wide association studies disclosed that several single nucleotide polymorphisms (SNPs), including tumour necrosis factor (TNF) receptor-associated factor 1 (TRAF1) (+16860A/G), are associated with the pathophysiology of rheumatoid arthritis (RA). We assessed the usefulness of TRAF1 genotyping as a genetic predictor of the response to anti-TNF treatment in Japanese RA patients. METHODS: TRAF1 (+16860A/G) was genotyped using the TaqMan SNP genotyping assay in 101 Japanese RA patients treated with anti-TNF drugs for >24 weeks. We retrospectively analysed the association between SNP and the clinical response to treatment. TRAF1 mRNA and protein expression was also evaluated in CD4+, CD8+, CD14+, or CD19+ cells from 25 healthy subjects using quantitative polymerase chain reaction and intracellular staining flow cytometry, respectively. RESULTS: No statistical difference in DAS28-ESR at baseline was observed between the patient groups with the AA, AG, or GG genotype. The GG genotype was more frequent in non-responders than in good or moderate responders [odds ratio (OR) 7.4, 95% confidence interval (CI) 1.5-37.5]. The non-responders possessed the G allele more frequently than the good or moderate responders (OR 3.5, 95% CI 1.4-9.0). TRAF1 protein expression increased significantly in CD14+ monocytes from healthy subjects with the GG genotype compared with that in subjects with the AA or AG genotype. CONCLUSIONS: TRAF1 (+16860A/G) may be useful for predicting the clinical response to anti-TNF treatment and may contribute to resistance to treatment in RA patients with the GG genotype by increasing the TRAF1 expression in circulating inflammatory cells.","fulltextAvailable":false,"journal":"Clinical and experimental rheumatology","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis, Rheumatoid","uri":{"id":"D001172","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Flow Cytometry","uri":{"id":"D005434","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Confidence Intervals","uri":{"id":"D016001","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Odds Ratio","uri":{"id":"D016017","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Polymerase Chain Reaction","uri":{"id":"D016133","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Polymorphism, Single Nucleotide","uri":{"id":"D020641","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Tumor Necrosis Factor Receptor-Associated Peptides and Proteins","uri":{"id":"D047988","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"TNF Receptor-Associated Factor 1","uri":{"id":"D047990","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Genome-Wide Association Study","uri":{"id":"D055106","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Alleles","uri":{"id":"D000483","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis","uri":{"id":"D001168","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Data Collection","uri":{"id":"D003625","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmaceutical Preparations","uri":{"id":"D004364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Evaluation Studies as Topic","uri":{"id":"D005069","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Genotype","uri":{"id":"D005838","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Monocytes","uri":{"id":"D009000","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Necrosis","uri":{"id":"D009336","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Nucleotides","uri":{"id":"D009711","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Proteins","uri":{"id":"D011506","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"RNA, Messenger","uri":{"id":"D012333","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Polymorphism, Single Nucleotide","uri":{"id":"D020641","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Asian Continental Ancestry Group","uri":{"id":"D044466","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"TNF Receptor-Associated Factor 1","uri":{"id":"D047990","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Adult","uri":{"id":"D000328","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Aged","uri":{"id":"D000368","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Female","uri":{"id":"D005260","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Japan","uri":{"id":"D007564","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Male","uri":{"id":"D008297","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Middle Aged","uri":{"id":"D008875","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Predictive Value of Tests","uri":{"id":"D011237","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Retrospective Studies","uri":{"id":"D012189","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Tumor Necrosis Factor-alpha","uri":{"id":"D014409","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Treatment Outcome","uri":{"id":"D016896","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Antirheumatic Agents","uri":{"id":"D018501","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Polymorphism, Single Nucleotide","uri":{"id":"D020641","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Asian Continental Ancestry Group","uri":{"id":"D044466","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Antibodies, Monoclonal, Humanized","uri":{"id":"D061067","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis, Rheumatoid","uri":{"id":"D001172","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmacogenetics","uri":{"id":"D010597","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"TNF Receptor-Associated Factor 1","uri":{"id":"D047990","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Genotyping Techniques","uri":{"id":"D060005","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Adult","Aged","Antibodies, Monoclonal, Humanized","Antirheumatic Agents","Arthritis, Rheumatoid","Asian Continental Ancestry Group","Female","Genotyping Techniques","Humans","Japan","Male","Middle Aged","Pharmacogenetics","Polymorphism, Single Nucleotide","Predictive Value of Tests","Retrospective Studies","TNF Receptor-Associated Factor 1","Treatment Outcome","Tumor Necrosis Factor-alpha"]},"pmid":"24321457","title":"A single nucleotide polymorphism of TRAF1 predicts the clinical response to anti-TNF treatment in Japanese patients with rheumatoid arthritis.","year":"2014 Mar-Apr"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"OBJECTIVES: To measure catastrophizing scores in patients on biotherapy for spondyloarthritis (SpA) or rheumatoid arthritis (RA). METHODS: The first 140 outpatients or day-hospital patients seen at a teaching hospital rheumatology department for biotherapy administration completed the validated French version of the Pain Catastrophizing Scale (PCS, total score ranging from 0 to 52); a questionnaire on perceived support and past, current, and future disease activity; and a questionnaire on perceived understanding of their disease by family and co-workers. RESULTS: PCS scores were significantly higher in the 54 SpA patients than in the 86 RA patients (20.8 Â± 12.1 versus 17.0 Â± 13.6; P = 0.08), as a result of a higher helplessness subscore (10.0 Â± 6.2 versus 7.8 Â± 6.2; P = 0.046). The PCS score was â¥30 in 14/54 (26%) SpA patients and in 19/86 (22%) RA patients; physicians identified catastrophizing in only 17 of these 33 patients. PCS scores showed moderate correlations with the AS-DAS and DAS-28 and slightly stronger correlations with the overall pain score (Pearson, +0.431; P = 0.0001). SpA patients reported significantly worse understanding by their co-workers than did RA patients (33.9 Â± 33.4 versus 53.9 Â± 36.3; P = 0.007). CONCLUSION: One-fourth of patients with SpA or RA had very high pain catastrophizing scores despite biotherapy. Pain catastrophizing was missed by the physicians in half the cases and was relatively independent from other follow-up parameters. Pain catastrophizing can jeopardize treatment outcomes and deserves specific management.","fulltextAvailable":false,"journal":"Joint, bone, spine : revue du rhumatisme","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hospital Departments","uri":{"id":"D006748","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis, Rheumatoid","uri":{"id":"D001172","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Treatment Outcome","uri":{"id":"D016896","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hospitals, Teaching","uri":{"id":"D006784","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Catastrophization","uri":{"id":"D058443","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis","uri":{"id":"D001168","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Forecasting","uri":{"id":"D005544","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hospitalization","uri":{"id":"D006760","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hospitals","uri":{"id":"D006761","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Outpatients","uri":{"id":"D010045","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Physicians","uri":{"id":"D010820","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Questionnaires","uri":{"id":"D011795","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Research Report","uri":{"id":"D058028","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Biological Therapy","uri":{"id":"D001691","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Rheumatology","uri":{"id":"D012219","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Teaching","uri":{"id":"D013663","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Spondylarthritis","uri":{"id":"D025241","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Catastrophization","uri":{"id":"D058443","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Adult","uri":{"id":"D000328","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Aged","uri":{"id":"D000368","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Female","uri":{"id":"D005260","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Male","uri":{"id":"D008297","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Middle Aged","uri":{"id":"D008875","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pain Measurement","uri":{"id":"D010147","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Questionnaires","uri":{"id":"D011795","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Antirheumatic Agents","uri":{"id":"D018501","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Catastrophization","uri":{"id":"D058443","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis, Rheumatoid","uri":{"id":"D001172","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Biological Therapy","uri":{"id":"D001691","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Spondylarthritis","uri":{"id":"D025241","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Adult","Aged","Antirheumatic Agents","Arthritis, Rheumatoid","Biological Therapy","Catastrophization","Female","Humans","Male","Middle Aged","Pain Measurement","Questionnaires","Spondylarthritis"]},"pmid":"24321439","title":"High pain catastrophizing scores in one-fourth of patients on biotherapy for spondylarthritis or rheumatoid arthritis.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"Dietary supplementation has traditionally consisted of adding vitamins and/or minerals to correct or prevent a nutritional deficiency. When supplementing the diet with other inflammatory mediators, such as essential fatty acids, there is an adjunctive benefit to the standard therapies used in the control of chronic inflammatory diseases such as Crohn's disease or rheumatoid arthritis. This review focuses on the strategies utilized for therapeutic modulation of the inflammatory cascade through dietary supplementation with specific biomolecules. Examples of how these biomolecules affect local and systemic immune responses to chronic inflammation are examined. In particular, an overview of the literature identifying the potential to modify the host response to chronic periodontitis is provided.","fulltextAvailable":false,"journal":"Periodontology 2000","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Chronic Disease","uri":{"id":"D002908","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis, Rheumatoid","uri":{"id":"D001172","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Crohn Disease","uri":{"id":"D003424","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Fatty Acids","uri":{"id":"D005227","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Immune System","uri":{"id":"D007107","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Fatty Acids, Essential","uri":{"id":"D005228","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Dietary Supplements","uri":{"id":"D019587","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Malnutrition","uri":{"id":"D044342","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Chronic Periodontitis","uri":{"id":"D055113","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis","uri":{"id":"D001168","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Immunity","uri":{"id":"D007109","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Immunization","uri":{"id":"D007114","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Inflammation","uri":{"id":"D007249","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Literature","uri":{"id":"D008091","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Minerals","uri":{"id":"D008903","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Periodontics","uri":{"id":"D010517","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Periodontitis","uri":{"id":"D010518","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Therapeutics","uri":{"id":"D013812","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Vitamins","uri":{"id":"D014815","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"24320963","title":"Dietary modulation of the inflammatory cascade.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"Tobacco smoking is the most important preventable risk factor for periodontitis; however, the underlying biological mechanisms responsible for the detrimental effects of smoking on periodontal health remain largely unclear. It is also well established that smoking has a negative impact on several inflammatory diseases, including rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease. The aim of this paper was to review smoking-related changes in local and systemic host responses with a focus on cellular and molecular effects that could explain a hyperinflammatory response leading to periodontal destruction. Biological mechanisms that may be common to periodontal disease and other chronic inflammatory diseases were also explored, together with gene-smoking interactions. An epidemiologic perspective on the burden of smoking on periodontal health and the potential for smoking cessation is also presented. Tobacco smoking seems to induce changes ranging from decreased leukocyte chemotaxis to decreased production of immunoglobulins. Smoking also seems to cause a stronger inflammatory reaction with an increased release of potentially tissue-destructive substances (e.g. reactive oxygen species, collagenase, serine proteases and proinflammatory cytokines). These findings support a hypothesis that periodontitis is a hyperinflammatory condition rather than a hypo-inflammatory condition.","fulltextAvailable":false,"journal":"Periodontology 2000","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Chronic Disease","uri":{"id":"D002908","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis, Rheumatoid","uri":{"id":"D001172","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Chronic Disease","uri":{"id":"D002908","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Multiple Sclerosis","uri":{"id":"D009103","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Risk Factors","uri":{"id":"D012307","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Inflammatory Bowel Diseases","uri":{"id":"D015212","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Smoking Cessation","uri":{"id":"D016540","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Reactive Oxygen Species","uri":{"id":"D017382","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Serine Proteases","uri":{"id":"D057057","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Chemotaxis, Leukocyte","uri":{"id":"D002634","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Periodontal Diseases","uri":{"id":"D010510","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Smoking","uri":{"id":"D012907","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis","uri":{"id":"D001168","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Immunoglobulins","uri":{"id":"D007136","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Inflammation","uri":{"id":"D007249","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Leukocytes","uri":{"id":"D007962","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Oxygen","uri":{"id":"D010100","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Oxygenators","uri":{"id":"D010106","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Peptide Hydrolases","uri":{"id":"D010447","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Periodontics","uri":{"id":"D010517","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Periodontitis","uri":{"id":"D010518","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Sclerosis","uri":{"id":"D012598","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cytokines","uri":{"id":"D016207","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Chemotaxis","uri":{"id":"D002633","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Serine","uri":{"id":"D012694","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Collagenases","uri":{"id":"D017364","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"24320959","title":"Smoking and inflammation: evidence for a synergistic role in chronic disease.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"OBJECTIVE: To examine associations of depressive feelings with disease-related variables and explore the moderating effect of social support on depressive feelings in individuals with early rheumatoid arthritis (RA) prospectively over 4 years. METHOD: Data were collected annually over 4 years. The sample consisted of 124 individuals with diagnosed RA (85.5% women; mean age 47.9 years; mean disease duration 22.2 months). The strength of cross-sectional and prospective associations of sociodemographic, disease-related variables and the direct and moderating effects of social support on depression were tested using correlations, multilevel models, and hierarchical linear regressions. RESULTS: The study showed that emotional support moderated the influence of functional disability on depressive feelings in individuals with RA. This was not detected for instrumental support. Further prospective associations between functional status, marital status, and depressive feelings were also found. Overall, the strongest association was found between initial depressive feelings and depressive feelings over time. CONCLUSIONS: Initial depression seemed to be a risk factor in explaining later depressive feelings, but emotional support might be prospectively beneficial, especially for individuals with higher levels of disability. Early detection of individuals at risk for depression and providing interventions aimed at the specific functions of social support might help to decrease mental health problems.","fulltextAvailable":false,"journal":"Rehabilitation psychology","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis, Rheumatoid","uri":{"id":"D001172","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Mental Health","uri":{"id":"D008603","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prospective Studies","uri":{"id":"D011446","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Risk Factors","uri":{"id":"D012307","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Social Support","uri":{"id":"D012944","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Linear Models","uri":{"id":"D016014","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Marital Status","uri":{"id":"D017533","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis","uri":{"id":"D001168","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Depression","uri":{"id":"D003863","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Diagnosis","uri":{"id":"D003933","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Emotions","uri":{"id":"D004644","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Socialism","uri":{"id":"D012950","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Socialization","uri":{"id":"D012951","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Women","uri":{"id":"D014930","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Theory of Mind","uri":{"id":"D056345","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"24320944","title":"Social support as a moderator of functional disability's effect on depressive feelings in early rheumatoid arthritis: a four-year prospective study.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"OBJECTIVE: To compare the incidence and risk factors of serious adverse events (SAEs) in rheumatoid arthritis (RA) patients treated with etanercept (ETN) or adalimumab (ADA) between Korean and Japanese registries. METHODS: We recruited 416 RA patients [505.2 patient-years (PYs)] who started ETN or ADA from Korean registry and 537 RA patients (762.0 PY) from Japanese registry. The patient background, incidence rate (IR) of SAE in 2 years, and risk factors for SAEs were compared. RESULTS: Korean patients were younger and used more nonbiologic DMARDs, higher doses of methotrexate, and lower doses of prednisolone (PSL). The IR of SAEs (/100 PY) was higher in the Japanese registry compared to the Korean [13.65 vs. 6.73]. In both registries, infection was the most frequently reported SAE. The only significant risk factor for SAEs in Korean registry was age by decade [1.45]. In Japanese registry, age by decade [1.54], previous use of nonbiologic DMARDs â¥ 4 [1.93], and concomitant use of oral PSL â¥ 5 mg/day [2.20] were identified as risk factors for SAEs. CONCLUSIONS: The IR of SAE in Japan, especially infection, was higher than that of Korea, which was attributed to the difference of demographic and clinical characteristics of RA patients and treatment profiles.","fulltextAvailable":false,"journal":"Modern rheumatology / the Japan Rheumatism Association","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis, Rheumatoid","uri":{"id":"D001172","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Risk Factors","uri":{"id":"D012307","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis","uri":{"id":"D001168","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Demography","uri":{"id":"D003710","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Korea","uri":{"id":"D007723","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Methotrexate","uri":{"id":"D008727","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prednisolone","uri":{"id":"D011239","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Registries","uri":{"id":"D012042","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Incidence","uri":{"id":"D015994","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Asian Continental Ancestry Group","uri":{"id":"D044466","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Research Report","uri":{"id":"D058028","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Japan","uri":{"id":"D007564","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"24320747","title":"A comparison of incidence and risk factors for serious adverse events in rheumatoid arthritis patients with etanercept or adalimumab in Korea and Japan.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"OBJECTIVE: The aim of this study was to investigate the characteristics of power Doppler (PD) subclinical synovitis in patients with RA who achieve clinical remission free from physical synovitis. METHODS: Twenty-nine RA patients were consecutively enrolled. All of the patients had achieved clinical remission [simplified disease activity index (SDAI) 3.3] for at least 6 months at the musculoskeletal ultrasound (MSKUS) examination. Additionally, none of the patients exhibited tender joints at 68 sites or swollen joints at 66 sites. MSKUS of bilateral wrist and finger joints, including the first to fifth MCP joints, the first IP joint and the second to fifth PIP joints, was performed and the findings obtained by grey scale (GS) and PD were graded on a semi-quantitative scale from 0 to 3. RESULTS: The median disease duration upon the introduction of DMARDs was 3 months and that at MSKUS examination was 21 months. The percentages of patients with PD synovitis in at least one joint were PD grade 1, 58.6%; PD grade 2, 31.0% and PD grade 3, 6.9%. The use of biological agents was low in patients with PD synovitis grade 2 (P < 0.05). The presence of US bone erosion was high by patient (P < 0.05) and by joint (P < 0.0001) with PD synovitis as compared with those without PD synovitis. However, no correlations were found between PD synovitis measures and serum biomarkers, including angiogenesis factors. CONCLUSION: PD subclinical synovitis correlates with several clinical characteristics, whereas conventional serum biomarkers are not useful for indicating the presence of subclinical PD synovitis.","fulltextAvailable":false,"journal":"Rheumatology (Oxford, England)","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis, Rheumatoid","uri":{"id":"D001172","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Angiogenesis Inducing Agents","uri":{"id":"D043925","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Biological Factors","uri":{"id":"D001685","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Finger Joint","uri":{"id":"D005384","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Abstracting and Indexing as Topic","uri":{"id":"D000043","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis","uri":{"id":"D001168","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Physics","uri":{"id":"D010825","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Wrist","uri":{"id":"D014953","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Biological Markers","uri":{"id":"D015415","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Personal Autonomy","uri":{"id":"D026684","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Serum","uri":{"id":"D044967","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Synovitis","uri":{"id":"D013585","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Adult","uri":{"id":"D000328","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Aged","uri":{"id":"D000368","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Aged, 80 and over","uri":{"id":"D000369","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Female","uri":{"id":"D005260","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Male","uri":{"id":"D008297","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Middle Aged","uri":{"id":"D008875","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Biological Markers","uri":{"id":"D015415","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Comorbidity","uri":{"id":"D015897","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Incidence","uri":{"id":"D015994","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Vascular Endothelial Growth Factor A","uri":{"id":"D042461","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis, Rheumatoid","uri":{"id":"D001172","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Bone Resorption","uri":{"id":"D001862","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Synovitis","uri":{"id":"D013585","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Ultrasonography, Doppler","uri":{"id":"D018608","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Matrix Metalloproteinase 3","uri":{"id":"D019278","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Angiopoietin-2","uri":{"id":"D042702","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"RANK Ligand","uri":{"id":"D053245","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Adult","Aged","Aged, 80 and over","Angiopoietin-2","Arthritis, Rheumatoid","Biological Markers","Bone Resorption","Comorbidity","Female","Humans","Incidence","Male","Matrix Metalloproteinase 3","Middle Aged","RANK Ligand","Synovitis","Ultrasonography, Doppler","Vascular Endothelial Growth Factor A"]},"pmid":"24319104","title":"Ultrasonographic examination of rheumatoid arthritis patients who are free of physical synovitis: power Doppler subclinical synovitis is associated with bone erosion.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"QUESTIONS UNDER STUDY: Clinical trials do not necessarily reflect the results obtained in daily clinical practice. By conducting a non-interventional, observational study with biologics in rheumatoid arthritis (RA) patients in Switzerland, we aimed to generate real-world data on reasons for treatment initiation and discontinuation, physicians' expectations for treatment, co-medication, and various treatment outcome parameters. METHODS: Sixty-nine patients with a confirmed diagnosis of RA were included in this non-interventional observational study. Participating physicians used standardised questionnaires to collect data on the use of biologics at three visits over one year. Due to the small sample size of patients receiving biologics other than abatacept, only patients treated with abatacept were considered for analysis. RESULTS: The population receiving intravenously administered abatacept consisted of 56 patients. Of these, 25% received abatacept as a first-line biologic therapy. The retention rate over one year was high (75%) and similar to what has been previously observed in randomised clinical trials. Overall, abatacept was found to be effective in patients irrespective of their baseline disease activity or levels in C-reactive protein and erythrocyte sedimentation rate. Moreover, the use of glucocorticoids was found to be reduced under therapy. There was a tendency for better treatment outcomes and physicians' satisfaction with abatacept the earlier the drug was used in the sequence of biologic therapies. CONCLUSIONS: The present study suggests that abatacept is an effective and well tolerated treatment in RA patients in routine clinical practice, irrespective of disease parameter at baseline.","fulltextAvailable":false,"journal":"Swiss medical weekly","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Abstracting and Indexing as Topic","uri":{"id":"D000043","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Infant","uri":{"id":"D007223","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Science","uri":{"id":"D012586","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pliability","uri":{"id":"D018583","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Generalization (Psychology)","uri":{"id":"D005793","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Play and Playthings","uri":{"id":"D010988","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Multilingualism","uri":{"id":"D019303","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Adult","Aged","Antirheumatic Agents","Arthritis, Rheumatoid","Cohort Studies","Drug Therapy, Combination","Female","Glucocorticoids","Humans","Immunoconjugates","Isoxazoles","Male","Methotrexate","Middle Aged","Prospective Studies","Switzerland","Treatment Outcome"]},"pmid":"24318979","title":"RAISE - rheumatoid arthritis independent Swiss treatment expectations and outcome: results for the abatacept subpopulation.","year":"2013"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"PURPOSE: Septic arthritis can be disabling and life-threatening, requiring prompt diagnosis and treatment. The infectious agent is not always identified in these patients. We revaluate septic arthritis cases discharged from our department, describing the affected population, causative microorganisms and antibiotic therapy used, and characterised differences between patients with and without isolated pathogenic agents. METHODS: Sixty-eight septic arthritis patients were included in this study. Diagnosis was based on clinical findings, and/or the presence of joint purulent material, and/or bacterial pathogen isolation from joint fluid/synovial membrane/blood cultures and response to antibiotics. Data analysis was performed using SPSS 20. RESULTS: Patients had a mean age of 61.1 Â± 18.8 years, without sex predominance. 26.5 % had an infection â¤ 15 days before septic arthritis diagnosis. Besides previous infection, 57.4 % had â¥ 1 risk factors for septic arthritis, most commonly pharmacological immunosuppression (20.6 %), diabetes mellitus type 2 (19.1 %) and rheumatoid arthritis (17.6 %). The knee was the most often affected (54.3 %). Only 39.7 % presented fever from clinical onset until hospital admission (mean 13.4 Â± 18.9 days). Leucocytosis was present in 45.6 % of patients, elevated erythrocyte sedimentation rate (ESR) in 75 % and elevated C-reactive protein (CRP) in 97.1 %. 5.9 % had articular damage attributable to septic arthritis. An infectious agent was isolated in 41.2 % of patients, with Staphylococcus aureus being the most frequent. 38.7 % of synovial fluid and 23.5 % of synovial membrane cultures were positive. Patients with an identified infectious agent have no significant differences other than more days of hospitalisation (p = 0.003) and in-hospital antibiotic treatment (p = 0.017). CONCLUSION: Synovial fluid and synovial membrane cultures more often identified pathogens compared to blood or urine cultures. Patients with and without an identified infectious agent have similar demographic, clinical, laboratory and radiographic characteristics.","fulltextAvailable":false,"journal":"Infection","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Synovial Fluid","uri":{"id":"D013582","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis, Rheumatoid","uri":{"id":"D001172","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Diabetes Mellitus","uri":{"id":"D003920","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Diabetes Mellitus, Type 2","uri":{"id":"D003924","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Risk Factors","uri":{"id":"D012307","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Statistics as Topic","uri":{"id":"D013223","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis, Infectious","uri":{"id":"D001170","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Blood Sedimentation","uri":{"id":"D001799","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"C-Reactive Protein","uri":{"id":"D002097","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Staphylococcus aureus","uri":{"id":"D013211","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Synovial Fluid","uri":{"id":"D013582","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Synovial Membrane","uri":{"id":"D013583","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anti-Bacterial Agents","uri":{"id":"D000900","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis","uri":{"id":"D001168","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Culture","uri":{"id":"D003469","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Demography","uri":{"id":"D003710","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Diagnosis","uri":{"id":"D003933","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Erythrocytes","uri":{"id":"D004912","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hospitalization","uri":{"id":"D006760","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hospitals","uri":{"id":"D006761","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Laboratories","uri":{"id":"D007753","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Membranes","uri":{"id":"D008566","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Proteins","uri":{"id":"D011506","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Staphylococcus","uri":{"id":"D013210","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Urination","uri":{"id":"D014554","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Urine","uri":{"id":"D014556","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Virulence","uri":{"id":"D014774","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Immunosuppression","uri":{"id":"D007165","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"24318567","title":"Septic arthritis: patients with or without isolated infectious agents have similar characteristics.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"The use of anti-TNF-Î± has been associated with several changes in lipid profile, although some study results are conflicting. The knowledge of this fact is of great importance when one observes at the association between rheumatic diseases and accelerated atherogenesis. The aim of this analysis was search for changes in lipid profile in anti TNF-Î± users in the population of Southern Brazil and its association with duration of use, indications, patient gender and type of anti-TNF. For this purpose, we studied the profiles of total cholesterol (TC), HDL cholesterol (HDLc), LDL cholesterol (LDLc), atherogenic index (ATI) and triglycerides (TGs) of 58 patients (42 with rheumatoid arthritis and 16 with spondyloarthritis) before and after using this drug for a median of 16.0 months. There were no changes in the levels of TC, HDLc, LDLc and ATI (P = NS). However, there was a significant increase in TG levels (P = 0.03). The median difference between first and second TG measurements was 16 mg/dL and this increase was not associated with gender, time of use, use indication or type of anti TNF-Î± (P = NS). It was concluded that the use of anti TNF-Î± is associated with increased values of TG.","fulltextAvailable":false,"journal":"Revista brasileira de reumatologia","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cholesterol, HDL","uri":{"id":"D008076","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cholesterol, LDL","uri":{"id":"D008078","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis, Rheumatoid","uri":{"id":"D001172","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cholesterol, LDL","uri":{"id":"D008078","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cholesterol, HDL","uri":{"id":"D008076","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Rheumatic Diseases","uri":{"id":"D012216","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Abstracting and Indexing as Topic","uri":{"id":"D000043","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Acceleration","uri":{"id":"D000054","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis","uri":{"id":"D001168","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cholesterol","uri":{"id":"D002784","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmaceutical Preparations","uri":{"id":"D004364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Lipids","uri":{"id":"D008055","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Triglycerides","uri":{"id":"D014280","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Knowledge","uri":{"id":"D019359","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Atherosclerosis","uri":{"id":"D050197","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Brazil","uri":{"id":"D001938","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Rheumatic Diseases","uri":{"id":"D012216","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"24316903","title":"Lipid profile and anti-TNF-Î± use.","year":"2013 Sep-Oct"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"Since the discovery of the role of tumor necrosis factor in the physiopathological process of rheumatoid arthritis, five drugs that block this cytokine have been used as therapeutic options. To evaluate the efficacy and safety of adalimumab in the treatment of rheumatoid arthritis we performed a systematic review and meta-analysis of randomized controlled trials. A search of relevant studies in Medline (through PubMed) and LILACS in June 2011 was carried out. Study selection, data collection and analysis were performed in pairs and independently by two reviewers and by a third reviewer in cases of disagreement. The meta-analysis was performed using the software Review ManagerÂ® 5.1 using the random effects model. Eleven articles related to adalimumab were included and considered nine studies with 3461 patients. Ten studies showed low risk of bias regarding the blinding of participants and personnel and blinding of outcome assessment. Patients who received the combination treatment of adalimumab and methotrexate showed better efficacy results and lower radiographic progression when compared to placebo + methotrexate in 24-104 weeks. Patients who received adalimumab as monotherapy showed better efficacy outcomes when compared to placebo in 24 and 26 weeks. The results of the meta-analyses of adverse events were not statistically significant, except for reactions at the injection site, which favored the control group. Adalimumab efficacy was demonstrated in monotherapy and when associated to a DMARD, but the evidence for combined use is more robust.","fulltextAvailable":false,"journal":"Revista brasileira de reumatologia","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Therapeutic Uses","uri":{"id":"D045506","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis, Rheumatoid","uri":{"id":"D001172","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Data Collection","uri":{"id":"D003625","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Tumor Necrosis Factor-alpha","uri":{"id":"D014409","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Outcome Assessment (Health Care)","uri":{"id":"D017063","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Control Groups","uri":{"id":"D035061","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Tumor Necrosis Factors","uri":{"id":"D048069","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis","uri":{"id":"D001168","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Classification","uri":{"id":"D002965","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmaceutical Preparations","uri":{"id":"D004364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Evaluation Studies as Topic","uri":{"id":"D005069","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Methotrexate","uri":{"id":"D008727","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Necrosis","uri":{"id":"D009336","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasms","uri":{"id":"D009369","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Safety","uri":{"id":"D012449","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Software","uri":{"id":"D012984","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Therapeutics","uri":{"id":"D013812","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Bias (Epidemiology)","uri":{"id":"D015982","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cytokines","uri":{"id":"D016207","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"PubMed","uri":{"id":"D039781","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Antirheumatic Agents","uri":{"id":"D018501","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"24316899","title":"Adalimumab in rheumatoid arthritis treatment: a systematic review and meta-analysis of randomized clinical trials.","year":"2013 Sep-Oct"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"INTRODUCTION: The 2012 Consensus of the Brazilian Society of Rheumatology (SBR) for the treatment of Rheumatoid Arthritis (RA) recommends that patients should regularly perform physical exercises. There have been no studies in Brazil on physical activity among patients with early RA. OBJECTIVE: To investigate the physical activity practice among patients with early RA and the possible association between physical activity, disease activity and functional disability. METHODS: Cross-sectional study of patients from the Brasilia cohort of early RA. Demographic data (sex, age and level of schooling), physical activity practice, Disease Activity Score 28 (DAS 28), functional disability (Health Assessment Questionnaire - HAQ), as well as data on smoking status, alcohol consumption, comorbidities and RA treatment were analyzed. RESULTS: A total of 72 patients were evaluated, 90.27% females, mean age 50.2 Â± 13.3 years, mean DAS 28: 3.66 and HAQ: 0.69. Of them, 43.05% were regularly active, with walking being the most often practiced exercise (80.64%). The mean duration of exercise was 48.22 Â± 27.18 min, with a frequency of 3.7 Â± 1.64 times per week. There was no association between physical activity and gender, age, educational level, disease activity, functional disability, alcoholism or smoking, presence of comorbidities and treatment with drugs that alter the course of disease. CONCLUSION: Given the importance of regular physical activity practice, it is necessary to recommend it to patients, especially resistance physical activities, which are not frequent among the patients in our study.","fulltextAvailable":false,"journal":"Revista brasileira de reumatologia","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Activator Appliances","uri":{"id":"D000202","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Activator Appliances","uri":{"id":"D000202","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis, Rheumatoid","uri":{"id":"D001172","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cross-Sectional Studies","uri":{"id":"D003430","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Motor Activity","uri":{"id":"D009043","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Alcohol Drinking","uri":{"id":"D000428","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Exercise","uri":{"id":"D015444","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis","uri":{"id":"D001168","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Demography","uri":{"id":"D003710","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmaceutical Preparations","uri":{"id":"D004364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Education","uri":{"id":"D004493","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Evaluation Studies as Topic","uri":{"id":"D005069","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Female","uri":{"id":"D005260","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Physics","uri":{"id":"D010825","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Questionnaires","uri":{"id":"D011795","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Schools","uri":{"id":"D012574","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Societies","uri":{"id":"D012952","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Exercise","uri":{"id":"D015444","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Comorbidity","uri":{"id":"D015897","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Consensus","uri":{"id":"D032921","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Alcoholism","uri":{"id":"D000437","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Brazil","uri":{"id":"D001938","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Rheumatology","uri":{"id":"D012219","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"24316895","title":"Physical activity among patients from the BrasÃ­lia cohort of early rheumatoid arthritis.","year":"2013 Sep-Oct"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"INTRODUCTION: The involvement of the cervical spine is a common feature of rheumatoid arthritis (RA). OBJECTIVE: To study the prevalence of radiographic changes of the cervical spine in patients with RA and their association with clinical and serological profiles of the disease. METHODS: We analysed lateral (neutral position, hyperextension, hyperflexion) and transoral views of cervical spine radiographs from 80 individuals with RA to investigate the presence of atlanto-axial subluxation (AAS), basilar invagination (BI), and subaxial instability (SAI). Demographic, clinical (nodules, interstitial pneumonitis, secondary SjÃ¶gren's syndrome, medications etc.), and serologic (rheumatoid factor--RF, cyclic citrullinated peptide antibody--anti-CCP, and antinuclear factor--ANF) data were obtained from the clinical records. RESULTS: Cervical spine misalignments were identified in 26/80 (32.5%) participants; AAS occurred in 12/80 (15%) participants, BI in 6/80 (7.5%), and SAI in 13/80 (32.5%). Odontoid erosions were identified in 16/80 (20.0%) participants. Cervical spine misalignment exhibited associations with age at onset and disease duration (P = 0.03 and 0.02, respectively). No associations were identified between the cervical spine changes and the participants' ethnicity or gender, presence of nodules, interstitial pneumonitis, secondary SjÃ¶gren's syndrome, RF, ANF, or anti-CCP. The participants with cervical spine misalignment exhibited higher frequencies of odontoid erosion (P = 0.03). CONCLUSIONS: Cervical spine misalignment was a common radiographic finding and occurred more frequently in participants with earlier onset and longer length of RA.","fulltextAvailable":false,"journal":"Revista brasileira de reumatologia","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cross-Sectional Studies","uri":{"id":"D003430","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Peptides, Cyclic","uri":{"id":"D010456","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis, Rheumatoid","uri":{"id":"D001172","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Lung Diseases, Interstitial","uri":{"id":"D017563","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Age of Onset","uri":{"id":"D017668","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Antibodies, Antinuclear","uri":{"id":"D000974","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Rheumatoid Factor","uri":{"id":"D012217","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Antibodies","uri":{"id":"D000906","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis","uri":{"id":"D001168","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Demography","uri":{"id":"D003710","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Peptides","uri":{"id":"D010455","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Periodicity","uri":{"id":"D010507","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pneumonia","uri":{"id":"D011014","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Syndrome","uri":{"id":"D013577","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prevalence","uri":{"id":"D015995","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medicalization","uri":{"id":"D062528","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Citrulline","uri":{"id":"D002956","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Atrial Natriuretic Factor","uri":{"id":"D009320","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"24316894","title":"Radiographic changes of cervical spine in rheumatoid arthritis.","year":"2013 Sep-Oct"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"We previously reported that somatic mutations in the p53 gene accumulated at a higher frequency in AID(activation induced cytidine deaminase)(+) RA-FLS, which may result in the malfunction of p53, causing the tumor-like properties of RA-FLS. Among the p53 mutations identified from 3 sources of AID(+) RA-FLS, we focused on the p53R248Q mutation because it was reported to enhance the invasiveness of lung cancer cells and to have dominant-negative activity for pro-apoptotic molecules. We obtained cDNA encoding the p53R248Q mutant and introduced it into the MH7A RA-FLS cell line. P53R248Q dramatically suppressed the expression of the pro-apoptotic molecule p53AIP1 even under oxidative stress, which normally upregulates p53AIP1, leading to apoptosis. Moreover, overexpression of p53AIP1 increased apoptosis, whereas p53AIP1 knockdown rescued the cells from apoptosis. Together, these studies indicate the critical role of p53AIP1 under DNA damaging stresses for cell fate determination in RA-FLS containing the p53R248Q mutation.","fulltextAvailable":false,"journal":"Clinical immunology (Orlando, Fla.)","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cell Line","uri":{"id":"D002460","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"DNA Damage","uri":{"id":"D004249","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Lung Neoplasms","uri":{"id":"D008175","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Oxidative Stress","uri":{"id":"D018384","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cytidine Deaminase","uri":{"id":"D003564","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Genes, p53","uri":{"id":"D016158","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"DNA","uri":{"id":"D004247","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Genes","uri":{"id":"D005796","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Lung","uri":{"id":"D008168","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Mutation","uri":{"id":"D009154","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Oxides","uri":{"id":"D010087","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Proteins","uri":{"id":"D011506","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Up-Regulation","uri":{"id":"D015854","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Apoptosis","uri":{"id":"D017209","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"DNA, Complementary","uri":{"id":"D018076","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Research Report","uri":{"id":"D058028","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cytidine","uri":{"id":"D003562","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Insemination, Artificial, Heterologous","uri":{"id":"D007316","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Fibroblasts","uri":{"id":"D005347","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hydrogen Peroxide","uri":{"id":"D006861","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Mutation","uri":{"id":"D009154","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Phosphorylation","uri":{"id":"D010766","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Tumor Suppressor Protein p53","uri":{"id":"D016159","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Oxidants","uri":{"id":"D016877","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Apoptosis","uri":{"id":"D017209","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Oxidative Stress","uri":{"id":"D018384","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Gene Knockdown Techniques","uri":{"id":"D055785","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis, Rheumatoid","uri":{"id":"D001172","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cell Line","uri":{"id":"D002460","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Synovial Membrane","uri":{"id":"D013583","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"RNA, Small Interfering","uri":{"id":"D034741","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Apoptosis Regulatory Proteins","uri":{"id":"D051017","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Apoptosis","Apoptosis Regulatory Proteins","Arthritis, Rheumatoid","Cell Line","Fibroblasts","Gene Knockdown Techniques","Humans","Hydrogen Peroxide","Mutation","Oxidants","Oxidative Stress","Phosphorylation","RNA, Small Interfering","Synovial Membrane","Tumor Suppressor Protein p53"]},"pmid":"24316591","title":"Anti-apoptotic roles for the mutant p53R248Q through suppression of p53-regulated apoptosis-inducing protein 1 in the RA-derived fibroblast-like synoviocyte cell line MH7A.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"Bone-resorbing osteoclasts play an essential role in normal bone homeostasis, as well as in various bone disorders such as osteoporosis and rheumatoid arthritis. Previously we showed that the Tec family of tyrosine kinases is essential for the differentiation of osteoclasts and the inhibition of Btk is a promising strategy for the prevention of the bone loss in osteoclast-associated bone disorders. Here we demonstrate that an orally available Btk inhibitor, ibrutinib (PCI-32765), suppresses osteoclastic bone resorption by inhibiting both osteoclast differentiation and function. Ibrutinib downregulated the expression of NFATc1, the key transcription factor for osteoclastogenesis, and disrupted the formation of the actin ring in mature osteoclasts. In addition, genome-wide screening revealed that Btk regulates the expression of the genes involved in osteoclast differentiation and function in both an NFATc1-dependent and -independent manner. Finally, we showed that ibrutinib administration ameliorated the bone loss that developed in a RANKL-induced osteoporosis mouse model. Thus, this study suggests ibrutinib to be a promising therapeutic agent for osteoclast-associated bone diseases.","fulltextAvailable":false,"journal":"Bone","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Estrogens","uri":{"id":"D004967","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Motor Activity","uri":{"id":"D009043","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Serum Albumin","uri":{"id":"D012709","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Serum Albumin, Bovine","uri":{"id":"D012710","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Rats, Sprague-Dawley","uri":{"id":"D017207","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Microscopy, Confocal","uri":{"id":"D018613","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Extracellular Fluid","uri":{"id":"D045604","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Albumins","uri":{"id":"D000418","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Estrogens","uri":{"id":"D004967","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Female","uri":{"id":"D005260","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Microscopy","uri":{"id":"D008853","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Physics","uri":{"id":"D010825","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Tibia","uri":{"id":"D013977","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Serum","uri":{"id":"D044967","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Nanostructures","uri":{"id":"D049329","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anesthetics","uri":{"id":"D000777","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Epiphyses","uri":{"id":"D004838","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Injections","uri":{"id":"D007267","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Osteocytes","uri":{"id":"D010011","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Osteoporosis","uri":{"id":"D010024","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Ovariectomy","uri":{"id":"D010052","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Convection","uri":{"id":"D018481","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Animals","uri":{"id":"D000818","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cattle","uri":{"id":"D002417","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Female","uri":{"id":"D005260","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Stress, Mechanical","uri":{"id":"D013314","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Rats, Sprague-Dawley","uri":{"id":"D017207","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Rats","uri":{"id":"D051381","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Biological Transport","uri":{"id":"D001692","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Osteocytes","uri":{"id":"D010011","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Ovariectomy","uri":{"id":"D010052","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Tibia","uri":{"id":"D013977","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Weight-Bearing","uri":{"id":"D016474","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Administration, Oral","Animals","Bone Resorption","Cell Differentiation","Disease Models, Animal","Female","Gene Expression Regulation","Mice","Mice, Inbred C57BL","Osteoblasts","Osteoclasts","Osteoporosis","Protein Kinase Inhibitors","Protein-Tyrosine Kinases","Pyrazoles","Pyrimidines","RANK Ligand"]},"pmid":"24316417","title":"The orally available Btk inhibitor ibrutinib (PCI-32765) protects against osteoclast-mediated bone loss.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"Dendritic cells (DC) are highly-specialized, bone marrow-derived antigen-presenting cells that induce or regulate innate and adaptive immunity. Regulatory or \"tolerogenic\" DC play a crucial role in maintaining self tolerance in the healthy steady-state. These regulatory innate immune cells subvert naÃ¯ve or memory T cell responses by various mechanisms. Regulatory DC (DCreg) also exhibit the ability to induce or restore T cell tolerance in many animal models of autoimmune disease or transplant rejection. There is also evidence that adoptive transfer of DCreg can regulate T cell responses in non-human primates and humans. Important insights gained from in vitro studies and animal models have led recently to the development of clinical grade human DCreg, with potential to treat autoimmune disease or enhance transplant survival while reducing patient dependency on immunosuppressive drugs. Phase I trials have been conducted in type-1 diabetes and rheumatoid arthritis, with results that emphasize the feasibility and safety of DCreg therapy. This mini-review will outline how observations made using animal models have been translated into human use, and discuss the challenges faced in further developing this form of regulatory immune cell therapy in the fields of autoimmunity and transplantation.","fulltextAvailable":false,"journal":"Immunology letters","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis, Rheumatoid","uri":{"id":"D001172","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"T-Lymphocytes","uri":{"id":"D013601","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Models, Animal","uri":{"id":"D023421","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cell- and Tissue-Based Therapy","uri":{"id":"D064987","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Antigen-Presenting Cells","uri":{"id":"D000938","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Autoimmune Diseases","uri":{"id":"D001327","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Dendritic Cells","uri":{"id":"D003713","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Graft Rejection","uri":{"id":"D006084","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Immunity, Innate","uri":{"id":"D007113","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Self Tolerance","uri":{"id":"D017634","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Adoptive Transfer","uri":{"id":"D019264","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Adaptive Immunity","uri":{"id":"D056704","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Animals","uri":{"id":"D000818","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis","uri":{"id":"D001168","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Dendrites","uri":{"id":"D003712","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmaceutical Preparations","uri":{"id":"D004364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Immunity","uri":{"id":"D007109","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Immunization","uri":{"id":"D007114","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Primates","uri":{"id":"D011323","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Rodentia","uri":{"id":"D012377","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Safety","uri":{"id":"D012449","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Survival","uri":{"id":"D013534","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Autoimmunity","uri":{"id":"D015551","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"24316407","title":"Regulatory dendritic cell therapy: from rodents to clinical application.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"Complement is viewed as a critical serum-operative component of innate immunity, with processing of its key component, C3, into activation fragments C3a and C3b confined to the extracellular space. We report here that C3 activation also occurred intracellularly. We found that the T cell-expressed protease cathepsin L (CTSL) processed C3 into biologically active C3a and C3b. Resting T cells contained stores of endosomal and lysosomal C3 and CTSL and substantial amounts of CTSL-generated C3a. While \"tonic\" intracellular C3a generation was required for homeostatic T cell survival, shuttling of this intracellular C3-activation-system to the cell surface upon T cell stimulation induced autocrine proinflammatory cytokine production. Furthermore, T cells from patients with autoimmune arthritis demonstrated hyperactive intracellular complement activation and interferon-Î³ production and CTSL inhibition corrected this deregulated phenotype. Importantly, intracellular C3a was observed in all examined cell populations, suggesting that intracellular complement activation might be of broad physiological significance.","fulltextAvailable":false,"journal":"Immunity","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Complement C3-C5 Convertases","uri":{"id":"D050577","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cell Survival","uri":{"id":"D002470","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"T-Lymphocytes","uri":{"id":"D013601","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Complement Activation","uri":{"id":"D003167","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Extracellular Space","uri":{"id":"D005110","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Immunity, Innate","uri":{"id":"D007113","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Complement C3-C5 Convertases","uri":{"id":"D050577","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cathepsin L","uri":{"id":"D056668","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis","uri":{"id":"D001168","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Homeostasis","uri":{"id":"D006706","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Immunity","uri":{"id":"D007109","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Immunization","uri":{"id":"D007114","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Peptide Hydrolases","uri":{"id":"D010447","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Phenotype","uri":{"id":"D010641","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Endosomes","uri":{"id":"D011992","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Rest","uri":{"id":"D012146","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Survival","uri":{"id":"D013534","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Autoimmunity","uri":{"id":"D015551","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cytokines","uri":{"id":"D016207","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Research Report","uri":{"id":"D058028","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cathepsins","uri":{"id":"D002403","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Lysosomes","uri":{"id":"D008247","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Adult","uri":{"id":"D000328","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cell Differentiation","uri":{"id":"D002454","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cell Survival","uri":{"id":"D002470","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Child","uri":{"id":"D002648","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Gene Expression Regulation","uri":{"id":"D005786","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Homeostasis","uri":{"id":"D006706","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis, Rheumatoid","uri":{"id":"D001172","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cell Line","uri":{"id":"D002460","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Complement Activation","uri":{"id":"D003167","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Complement C3","uri":{"id":"D003176","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Complement C3b","uri":{"id":"D003179","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"CD4-Positive T-Lymphocytes","uri":{"id":"D015496","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Complement C3a","uri":{"id":"D015926","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"B-Lymphocyte Subsets","uri":{"id":"D016175","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cathepsin L","uri":{"id":"D056668","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Adult","Arthritis, Rheumatoid","B-Lymphocyte Subsets","CD4-Positive T-Lymphocytes","Cathepsin L","Cell Differentiation","Cell Line","Cell Survival","Child","Complement Activation","Complement C3","Complement C3a","Complement C3b","Gene Expression Regulation","Homeostasis","Humans"]},"pmid":"24315997","title":"Intracellular complement activation sustains T cell homeostasis and mediates effector differentiation.","year":"2013"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"OBJECTIVES: Rheumatoid arthritis (RA) is a chronic inflammatory disease. Transforming growth factor-Î²1 (TGF-Î²1) may be a promising candidate gene for susceptibility and severity in RA. We aimed to determine whether TGF-Î²1 polymorphism is associated with susceptibility to RA and progression of joint destruction, as well as to identify the interaction between TGF-Î²1 polymorphism and biochemical risk factor. METHODS: A total of 160 RA patients and 168 healthy unrelated controls were tested for the TGF-Î²1 (869C/T) polymorphism using polymerase chain reaction. RESULTS: The TGF-Î²1 T allele was associated with susceptibility to RA. Within the RA group, TGF-Î²1 T allele carriers had a significant increased risk to develop osteoporosis (OR=4.4, 95% CI=-2. 4-8.1, P<0.001), as well as more likely to develop bone erosion (OR=1.7, 95% CI=0. 99-2.7, P=0. 034). Better prediction was achieved when the TGF-Î²1 TT genotype was used in combination with either elevated, rheumatoid factor (RF) or C-reactive protein (CRP) (OR=6.8, 3.7 respectively). Also, they increased the risk to develop bone erosion in patients with rheumatoid arthritis (OR=3.3, 9.8, P=0.017, 0.001 respectively). CONCLUSION: Our results suggest that TGF-Î²1 TT genotype may determine the development of osteoporosis and bone erosion in RA. Also, our results points to a synergism between TGF-Î²1 TT genotype and elevated serum RF or elevated CRP that lead to the development of osteoporosis and bone erosion in patients with rheumatoid arthritis.","fulltextAvailable":false,"journal":"Gene","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Chronic Disease","uri":{"id":"D002908","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis, Rheumatoid","uri":{"id":"D001172","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Risk Factors","uri":{"id":"D012307","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Polymerase Chain Reaction","uri":{"id":"D016133","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Disease Progression","uri":{"id":"D018450","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"C-Reactive Protein","uri":{"id":"D002097","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Rheumatoid Factor","uri":{"id":"D012217","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Alleles","uri":{"id":"D000483","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis","uri":{"id":"D001168","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Genes","uri":{"id":"D005796","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Genotype","uri":{"id":"D005838","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Proteins","uri":{"id":"D011506","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Serum","uri":{"id":"D044967","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Osteoporosis","uri":{"id":"D010024","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Genotype","uri":{"id":"D005838","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Middle Aged","uri":{"id":"D008875","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Risk Factors","uri":{"id":"D012307","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Disease Progression","uri":{"id":"D018450","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Genetic Predisposition to Disease","uri":{"id":"D020022","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Polymorphism, Single Nucleotide","uri":{"id":"D020641","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Transforming Growth Factor beta1","uri":{"id":"D053773","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Alleles","uri":{"id":"D000483","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis, Rheumatoid","uri":{"id":"D001172","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"C-Reactive Protein","uri":{"id":"D002097","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Osteoporosis","uri":{"id":"D010024","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Alleles","Arthritis, Rheumatoid","C-Reactive Protein","Disease Progression","Genetic Predisposition to Disease","Genotype","Humans","Middle Aged","Osteoporosis","Polymorphism, Single Nucleotide","Risk Factors","Transforming Growth Factor beta1"]},"pmid":"24315820","title":"Interaction between TGF-Î²1 (869C/T) polymorphism and biochemical risk factor for prediction of disease progression in rheumatoid arthritis.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"BACKGROUND: This is an update on a previously documented cohort of patients who underwent shoulder arthroplasty for rheumatoid arthritis, with a minimum 5-year clinical follow-up. METHODS: The survivorship of 303 consecutive shoulder arthroplasties (108 hemiarthroplasties, 195 total shoulder arthroplasties) for rheumatoid arthritis at one institution was assessed. There were 255 arthroplasties in the clinical analysis and 188 in the radiographic analysis. RESULTS: Kaplan-Meier survivorship free of revision at 5 years and 10 years was 96.1% and 92.9% for total shoulder arthroplasty (TSA) and 89.2% and 87.9% for hemiarthroplasty (HA). The most common indications were glenoid loosening (5%) and infection (2%) for TSA revision and glenoid arthrosis (7%) for HA revision. Pain relief was greater with TSA than with HA. In patients with an intact rotator cuff, in comparing TSA with HA, those with a TSA had greater improvements in pain scores (-2.7 vs. -1.8 on a 5-point scale) and degrees of elevation (45 versus 24) (P = .08). Approximately 30% of humeral components and 73% of glenoid components had periprosthetic lucencies. There was a shift in position of the glenoid in 33% of TSAs, and 36% were \"at risk.\" Eighty-one percent of HAs had moderate or severe glenoid erosion. DISCUSSION/CONCLUSION: Both HA and TSA provide pain relief and improved motion in patients with rheumatoid arthritis. In patients with an intact rotator cuff, pain relief and range of motion are more improved with TSA compared with HA. There is a high rate of component lucency, but component revision is uncommon. LEVEL OF EVIDENCE: Level IV, case series, treatment study.","fulltextAvailable":false,"journal":"Journal of shoulder and elbow surgery / American Shoulder and Elbow Surgeons ... [et al.]","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis, Rheumatoid","uri":{"id":"D001172","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Range of Motion, Articular","uri":{"id":"D016059","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis","uri":{"id":"D001168","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthroplasty","uri":{"id":"D001178","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Rotation","uri":{"id":"D012399","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Rotator Cuff","uri":{"id":"D017006","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Personal Autonomy","uri":{"id":"D026684","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Survival Rate","uri":{"id":"D015996","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hemiarthroplasty","uri":{"id":"D062785","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Adolescent","uri":{"id":"D000293","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Adult","uri":{"id":"D000328","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Aged","uri":{"id":"D000368","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Aged, 80 and over","uri":{"id":"D000369","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Female","uri":{"id":"D005260","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Follow-Up Studies","uri":{"id":"D005500","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Male","uri":{"id":"D008297","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Middle Aged","uri":{"id":"D008875","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Retrospective Studies","uri":{"id":"D012189","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Range of Motion, Articular","uri":{"id":"D016059","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Treatment Outcome","uri":{"id":"D016896","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Young Adult","uri":{"id":"D055815","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis, Rheumatoid","uri":{"id":"D001172","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Shoulder Joint","uri":{"id":"D012785","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Rotator Cuff","uri":{"id":"D017006","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthroplasty, Replacement","uri":{"id":"D019643","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Adolescent","Adult","Aged","Aged, 80 and over","Arthritis, Rheumatoid","Arthroplasty, Replacement","Female","Follow-Up Studies","Humans","Male","Middle Aged","Range of Motion, Articular","Retrospective Studies","Rotator Cuff","Shoulder Joint","Treatment Outcome","Young Adult"]},"pmid":"24315477","title":"Shoulder arthroplasty for rheumatoid arthritis: 303 consecutive cases with minimum 5-year follow-up.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"With the establishment of the new American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) 2010 criteria for rheumatoid arthritis (RA) to diagnose patients earlier and with the introduction of early and aggressive treatment, the current aim is remission resulting in less functional disability, halting of radiographic damage, less pain, less fatigue and no loss of employment. These outcomes can be related to the World Health Organization International Classification of Functioning, Disability and Health (the WHO ICF framework). This framework includes the component body functions, body structures, activities and participation related to the disease. These components are related to each other in a bidirectional way and can be influenced by contextual factors including environmental and personal factors. This framework can be used to describe trends in RA outcomes and the impact of contextual factors on these outcomes. Despite aggressive treatment strategies, patients with RA still experience loss of function, pain and fatigue, and a relatively high proportion of patients have to take sick leave or become work disabled within the first few years of the disease. There is evidence that more stringent definitions of remission lead to greater improvement of outcomes and that the aim should be sustained remission and not just remission. There is, however, a need for a better understanding of the relation between contextual factors and activity and participation outcomes to better guide therapy decisions by rheumatologists and provide information to patients, families and policymakers about the impact of RA on their lives and to the society. The overall aim of this overview is to highlight the important contextual factors and consequences that relate to outcomes typically measured in RA studies and to demonstrate the additional benefits that can be achieved with remission and sustained remission.","fulltextAvailable":false,"journal":"Best practice & research. Clinical rheumatology","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Outcome Assessment (Health Care)","uri":{"id":"D017063","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis, Rheumatoid","uri":{"id":"D001172","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"World Health","uri":{"id":"D014943","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"World Health Organization","uri":{"id":"D014944","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Sick Leave","uri":{"id":"D018582","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"International Classification of Functioning, Disability and Health","uri":{"id":"D064702","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis","uri":{"id":"D001168","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Classification","uri":{"id":"D002965","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Diagnosis","uri":{"id":"D003933","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Fatigue","uri":{"id":"D005221","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Societies","uri":{"id":"D012952","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Work","uri":{"id":"D014937","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"World Health Organization","uri":{"id":"D014944","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Living Wills","uri":{"id":"D016224","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Rheumatic Diseases","uri":{"id":"D012216","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Rheumatology","uri":{"id":"D012219","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Disability Evaluation","uri":{"id":"D004185","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Antirheumatic Agents","uri":{"id":"D018501","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis, Rheumatoid","uri":{"id":"D001172","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"World Health Organization","uri":{"id":"D014944","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Outcome Assessment (Health Care)","uri":{"id":"D017063","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"International Classification of Functioning, Disability and Health","uri":{"id":"D064702","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Antirheumatic Agents","Arthritis, Rheumatoid","Disability Evaluation","Humans","International Classification of Functioning, Disability and Health","Outcome Assessment (Health Care)","World Health Organization"]},"pmid":"24315054","title":"Outcomes of early rheumatoid arthritis--the WHO ICF framework.","year":"2013"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"The use of biological disease-modifying antirheumatic drugs (bDMARDs) has changed the face of rheumatoid arthritis (RA). Achieving remission, normal function and prevention of joint damage are now possible for many patients with RA. In clinical practice, however, particularly with cost considerations, bDMARDs are usually prescribed after failure of one or more conventional synthetic DMARDs. With evidence that early treatment has a greater impact than later on, the question regarding initial bDMARD therapy and their potential role within a window of opportunity to influence disease outcomes remain. The increasing emphasis on early diagnosis and research into the preclinical phase of the disease also heralds the question, 'Can bDMARDs prevent the development of RA?' The aim of this review is to review randomised controlled trials with bDMARDs as initial therapy in early RA and to discuss their role in early disease.","fulltextAvailable":false,"journal":"Best practice & research. Clinical rheumatology","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Secondary Prevention","uri":{"id":"D055502","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis, Rheumatoid","uri":{"id":"D001172","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Early Diagnosis","uri":{"id":"D042241","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Antirheumatic Agents","uri":{"id":"D018501","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis","uri":{"id":"D001168","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Diagnosis","uri":{"id":"D003933","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmaceutical Preparations","uri":{"id":"D004364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Randomized Controlled Trials as Topic","uri":{"id":"D016032","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Antirheumatic Agents","uri":{"id":"D018501","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis, Rheumatoid","uri":{"id":"D001172","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Antirheumatic Agents","Arthritis, Rheumatoid","Humans","Randomized Controlled Trials as Topic"]},"pmid":"24315053","title":"Is there a place for initial treatment with biological DMARDs in the early phase of RA?","year":"2013"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"Treatment of early rheumatoid arthritis has to be started very early, when the diagnosis is made, preferentially before 6 months of symptoms. Combination therapy with conventional disease-modifying anti-rheumatic drugs (DMARDs) with low-dose, oral glucocorticoids in the induction phase from the start gives the best results. The patient should be monitored systematically, at start between 1 and 3 months, and the patient should have access to additional visits if a flare or arthritis or adverse event occurs. The treatment should aim to remission (no tender and swollen joints, no signs of inflammatory activity), which can be reached by 60-80% of the patients. Intra-articular glucocorticoid injections as part of the treatment strategy increase the suppression of arthritis and retard joint destruction. Biological drugs are reserved for patients who have consistent active disease and who do not respond to conventional combinations.","fulltextAvailable":false,"journal":"Best practice & research. Clinical rheumatology","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Injections, Intra-Articular","uri":{"id":"D007270","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis, Rheumatoid","uri":{"id":"D001172","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Antirheumatic Agents","uri":{"id":"D018501","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis","uri":{"id":"D001168","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Classification","uri":{"id":"D002965","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Data Collection","uri":{"id":"D003625","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Diagnosis","uri":{"id":"D003933","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmaceutical Preparations","uri":{"id":"D004364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glucocorticoids","uri":{"id":"D005938","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Drug Therapy, Combination","uri":{"id":"D004359","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Antirheumatic Agents","uri":{"id":"D018501","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis, Rheumatoid","uri":{"id":"D001172","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glucocorticoids","uri":{"id":"D005938","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Injections, Intra-Articular","uri":{"id":"D007270","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Antirheumatic Agents","Arthritis, Rheumatoid","Drug Therapy, Combination","Glucocorticoids","Humans","Injections, Intra-Articular"]},"pmid":"24315052","title":"What is the best treatment strategy for early RA?","year":"2013"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"Imaging in early rheumatoid arthritis (RA) has undergone extraordinary change in recent years and new techniques are now available to help the clinician diagnose and manage patients much more effectively than previously. While established modalities such as plain radiography (X-Ray) remain important, especially for detection of erosions and determining the progression of joint damage, there are many instances where ultrasound (US), magnetic resonance imaging (MRI) and computed tomography (CT) scanning provide added information. MRI and US are now used regularly by clinicians to help diagnose RA in the pre-radiographic stage as they offer improved visualisation of joint erosions. They also have the potential to provide prognostic information as MRI bone oedema/osteitis is linked to the later development of erosions and power Doppler ultrasound (PDUS) joint positivity is also a predictor of joint damage. Nuclear imaging techniques such as single photon emission computed tomography (SPECT) and positron emission tomography (PET) are also highly sensitive for detecting joint change in early RA and pre-RA but not yet used clinically mainly because of accessibility and radiation exposure. MRI, US, scintigraphy, SPECT and PET have all been shown to detect sub-clinical joint inflammation in patients in clinical remission, a state that is now the goal of most treat-to-target management strategies. Thus, imaging may be used to direct therapeutic decision making and MRI is also now being used in clinical trials to determine the impact of disease-suppressing therapy on the course of synovitis and osteitis. As is the case for all tests, it would be unwise to rely completely on any one imaging result, as false positives and negatives can occur for all modalities. Thus, the clinician needs to choose the most relevant and reliable imaging test, while also striving to minimise patient discomfort, radiation burden and economic impact.","fulltextAvailable":false,"journal":"Best practice & research. Clinical rheumatology","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis, Rheumatoid","uri":{"id":"D001172","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Magnetic Resonance Imaging","uri":{"id":"D008279","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Magnetic Resonance Spectroscopy","uri":{"id":"D009682","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Decision Making","uri":{"id":"D003657","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Tomography, Emission-Computed","uri":{"id":"D014055","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Tomography, Emission-Computed, Single-Photon","uri":{"id":"D015899","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Positron-Emission Tomography","uri":{"id":"D049268","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis","uri":{"id":"D001168","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Computers","uri":{"id":"D003201","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Diagnosis","uri":{"id":"D003933","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Electrons","uri":{"id":"D004583","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Inflammation","uri":{"id":"D007249","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Radiation","uri":{"id":"D011827","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Radiography","uri":{"id":"D011859","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Therapeutics","uri":{"id":"D013812","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Tomography","uri":{"id":"D014054","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"X-Rays","uri":{"id":"D014965","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Photons","uri":{"id":"D017785","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Optics and Photonics","uri":{"id":"D055095","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Osteitis","uri":{"id":"D010000","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Radionuclide Imaging","uri":{"id":"D011877","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Synovitis","uri":{"id":"D013585","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Tomography, Emission-Computed, Single-Photon","uri":{"id":"D015899","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prognosis","uri":{"id":"D011379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Disease Progression","uri":{"id":"D018450","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis, Rheumatoid","uri":{"id":"D001172","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Diagnostic Imaging","uri":{"id":"D003952","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Joints","uri":{"id":"D007596","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Arthritis, Rheumatoid","Diagnostic Imaging","Disease Progression","Humans","Joints","Prognosis"]},"pmid":"24315051","title":"Imaging in early rheumatoid arthritis.","year":"2013"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"There is accumulating evidence demonstrating that early treatment leads to better outcomes in rheumatoid arthritis. In order to be treated early, patients thus need to be identified at the earliest possible stage. This means identifying patients with rheumatoid arthritis at their earliest clinical signs but it could also mean screening for healthy individuals at high risk of developing rheumatoid arthritis. The different tools available to screen for these individuals are reviewed here and their relevance is discussed.","fulltextAvailable":false,"journal":"Best practice & research. Clinical rheumatology","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis, Rheumatoid","uri":{"id":"D001172","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis","uri":{"id":"D001168","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Risk Factors","uri":{"id":"D012307","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Early Diagnosis","uri":{"id":"D042241","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis, Rheumatoid","uri":{"id":"D001172","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Arthritis, Rheumatoid","Early Diagnosis","Humans","Risk Factors"]},"pmid":"24315050","title":"To screen or not to screen: how to find and identify very early arthritis.","year":"2013"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"The discovery of elevations of rheumatoid arthritis (RA)-related biomarkers prior to the onset of clinically apparent RA raises hopes that individuals who are at risk of future RA can be identified in a preclinical phase of disease that is defined as abnormalities of RA-related immune activity prior to the clinically apparent onset of joint disease. Additionally, there is a growing understanding of the immunologic processes that are occurring in preclinical RA, as well as a growing understanding of risk factors that may be mechanistically related to RA development. Furthermore, there are data supporting that treatment of early RA can lead to drug-free remission. Taken as a whole, these findings suggest that it may be possible to use biomarkers and other factors to accurately identify the likelihood and timing of onset of future RA, and then intervene with immunomodulatory therapies and/or risk factor modification to prevent the future onset of RA in at-risk individuals. Importantly, several clinical prevention trials for RA have already been tried, and one is underway. However, while our growing understanding of the mechanisms and natural history of RA development may be leading us to the implementation of prevention strategies for RA, there are still several challenges to be met. These include developing sufficiently accurate methods of predicting those at high risk of future RA so that clinical trials can be developed based on accurate rates of development of arthritis and subjects can be adequately informed of their risk of disease, identifying the appropriate interventions and biologic targets for optimal prevention, and addressing the psychosocial and economic aspects that are crucial to developing broadly applicable prevention measures for RA. These issues notwithstanding, prevention of RA may be within reach in the near future.","fulltextAvailable":false,"journal":"Best practice & research. Clinical rheumatology","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis, Rheumatoid","uri":{"id":"D001172","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Immunity, Active","uri":{"id":"D007110","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Risk Factors","uri":{"id":"D012307","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Vaccination","uri":{"id":"D014611","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Joint Diseases","uri":{"id":"D007592","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Natural History","uri":{"id":"D019021","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Immunomodulation","uri":{"id":"D056747","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis","uri":{"id":"D001168","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Forecasting","uri":{"id":"D005544","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"History","uri":{"id":"D006664","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Immunity","uri":{"id":"D007109","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Immunization","uri":{"id":"D007114","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Biological Markers","uri":{"id":"D015415","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Nature","uri":{"id":"D019368","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hope","uri":{"id":"D065026","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Biological Markers","uri":{"id":"D015415","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Risk Assessment","uri":{"id":"D018570","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis, Rheumatoid","uri":{"id":"D001172","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Arthritis, Rheumatoid","Biological Markers","Humans","Risk Assessment"]},"pmid":"24315049","title":"Can rheumatoid arthritis be prevented?","year":"2013"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"New classification criteria for rheumatoid arthritis (RA) were presented by the American College of Rheumatology (ACR) and the European League Against Rheumatism (EULAR) in 2010, aiming for early identification of patients at risk of developing persistent and erosive arthritis. Since their publication, the criteria have been extensively validated against several reference standards, but there is still debate regarding how the criteria should be implemented in studies and clinical care. We present an overview of the published validation studies and discuss the strengths and limitations of the classification criteria, as well as whether the criteria are ready for diagnostic purposes in clinical practice.","fulltextAvailable":false,"journal":"Best practice & research. Clinical rheumatology","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis, Rheumatoid","uri":{"id":"D001172","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Reference Standards","uri":{"id":"D012015","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis","uri":{"id":"D001168","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Classification","uri":{"id":"D002965","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Diagnosis","uri":{"id":"D003933","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Publications","uri":{"id":"D011642","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Publishing","uri":{"id":"D011643","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Rheumatic Diseases","uri":{"id":"D012216","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Rheumatology","uri":{"id":"D012219","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Rheumatology","uri":{"id":"D012219","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Societies, Medical","uri":{"id":"D012955","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Antirheumatic Agents","uri":{"id":"D018501","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Early Diagnosis","uri":{"id":"D042241","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis, Rheumatoid","uri":{"id":"D001172","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Practice Guidelines as Topic","uri":{"id":"D017410","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Antirheumatic Agents","Arthritis, Rheumatoid","Early Diagnosis","Humans","Practice Guidelines as Topic","Rheumatology","Societies, Medical"]},"pmid":"24315048","title":"Early rheumatoid arthritis: the performance of the 2010 ACR/EULAR criteria for diagnosing RA.","year":"2013"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"INTRODUCTION: Adipokines such as adiponectin, leptin, and visfatin/nicotinamide phosphoribosyltransferase (NAMPT) have recently emerged as pro-inflammatory mediators involved in the pathophysiology of rheumatoid arthritis (RA). We aimed to determine whether serum adipokine levels independently predicted early radiographic disease progression in early RA. METHODS: In total, 791 patients were included from the prospective Etude et Suivi des POlyarthrites IndiffÃ©renciÃ©es RÃ©centes (ESPOIR) cohort who met the American College of Rheumatology-European League Against Rheumatism criteria for RA (nâ=â632) or had undifferentiated arthritis (UA) (nâ=â159). Enzyme-linked immunosorbent assay (ELISA) was used to assess baseline serum levels of adiponectin, leptin, and visfatin/NAMPT. In the RA group, we tested the association of serum adipokine levels and (a) baseline radiographic damage and (b) radiographic disease progression, defined as a change >0 or â¥ 5 in total Sharp-van der Heijde Score (âSHS) between inclusion and 1 year (âSHS â¥1 or rapid radiographic progression: âSHS â¥5), adjusting for confounders (age, sex, body-mass index, insulin resistance, C-reactive protein level, Disease Activity Score in 28 joints, Health Assessment Questionnaire score, autoantibody status, steroid use, and radiographic evidence of RA damage at inclusion). RESULTS: Adiponectin level was independently associated with baseline total SHS (adjusted Î²â=â0.12; Pâ=â0.006). It was also associated with âSHS â¥1 (adjusted odds ratio (aOR)â=â1.84 (1.25 to 2.72)) involving erosive as well as narrowing disease progression (aORâ=â1.73 (1.17 to 2.55) and 1.93 (1.04 to 3.57), respectively). Serum adiponectin level predicted âSHS â¥5 (aORâ=â2.0 (1.14 to 3.52)). Serum leptin level was independently associated only with âSHS >0 (aORâ=â1.59 (1.05 to 2.42)). Conversely, serum visfatin/NAMPT level and radiographic disease progression were unrelated. Considering the receiver-operated characteristic curves, the best adiponectin cut-offs were 4.14 Î¼g/ml for âSHS â¥1 and 6.04 Î¼g/ml for âSHS â¥5, with a good specificity (58% and 75% for âSHS â¥1 and âSHS â¥5, respectively) and high negative predictive values (75% and 92% for âSHS â¥1 or âSHS â¥5, respectively). CONCLUSION: Serum adiponectin level is a simple useful biomarker associated with early radiographic disease progression in early RA, independent of RA-confounding factors and metabolic status.","fulltextAvailable":false,"journal":"Arthritis research & therapy","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis, Rheumatoid","uri":{"id":"D001172","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Insulin Resistance","uri":{"id":"D007333","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Odds Ratio","uri":{"id":"D016017","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Disease Progression","uri":{"id":"D018450","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"C-Reactive Protein","uri":{"id":"D002097","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Enzyme-Linked Immunosorbent Assay","uri":{"id":"D004797","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Abstracting and Indexing as Topic","uri":{"id":"D000043","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis","uri":{"id":"D001168","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Enzyme-Linked Immunosorbent Assay","uri":{"id":"D004797","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Insulin","uri":{"id":"D007328","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Metabolism","uri":{"id":"D008660","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Proteins","uri":{"id":"D011506","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Questionnaires","uri":{"id":"D011795","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Sensitivity and Specificity","uri":{"id":"D012680","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Biological Markers","uri":{"id":"D015415","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Leptin","uri":{"id":"D020738","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Serum","uri":{"id":"D044967","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Insulins","uri":{"id":"D061385","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Autoantibodies","uri":{"id":"D001323","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Immunosorbents","uri":{"id":"D007164","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Niacinamide","uri":{"id":"D009536","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Rheumatic Diseases","uri":{"id":"D012216","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Adiponectin","uri":{"id":"D052242","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Adipokines","uri":{"id":"D054392","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Nicotinamide Phosphoribosyltransferase","uri":{"id":"D054409","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Enzyme-Linked Immunosorbent Assay","uri":{"id":"D004797","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Female","uri":{"id":"D005260","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Male","uri":{"id":"D008297","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Middle Aged","uri":{"id":"D008875","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cohort Studies","uri":{"id":"D015331","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Biological Markers","uri":{"id":"D015415","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Disease Progression","uri":{"id":"D018450","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis, Rheumatoid","uri":{"id":"D001172","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Adiponectin","uri":{"id":"D052242","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Adiponectin","Arthritis, Rheumatoid","Biological Markers","Cohort Studies","Disease Progression","Enzyme-Linked Immunosorbent Assay","Female","Humans","Male","Middle Aged"]},"pmid":"24314299","title":"Serum level of adiponectin is a surrogate independent biomarker of radiographic disease progression in early rheumatoid arthritis: results from the ESPOIR cohort.","year":"2013"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"INTRODUCTION: The FMS-related tyrosine kinase 3 ligand (Flt3L)/CD135 axis plays a fundamental role in proliferation and differentiation of dendritic cells (DCs). As DCs play an important role in rheumatoid arthritis (RA) immunopathology we studied in detail the Flt3L/CD135 axis in RA patients. METHODS: The levels of Flt3L in (paired) serum and synovial fluid (SF) were quantified by enzyme-link immunosorbent assay (ELISA). Expression of Flt3L and CD135 in paired peripheral blood mononuclear cells (PBMCs) and synovial fluid mononuclear cells (SFMCs) was quantified by fluorescence-activated cell sorting (FACS). The expression of Flt3L, CD135 and TNF-Converting Enzyme (TACE) in synovial tissues (STs) and in vitro polarized macrophages and monocyte-derived DCs (Mo-DCs) was assessed by quantitative PCR (qPCR). CD135 ST expression was evaluated by immunohistochemistry and TACE ST expression was assessed by immunofluorescence. Flt3L serum levels were assessed in RA patients treated with oral prednisolone or adalimumab. RESULTS: Flt3L levels in RA serum, SF and ST were significantly elevated compared to gout patients and healthy individuals (HI). RA SF monocytes, natural killer cells and DCs expressed high levels of Flt3L and CD135 compared to HI. RA ST CD68+ and CD163+ macrophages, CD55+ fibroblast-like synoviocytes (FLS), CD31+ endothelial cells or infiltrating monocytes and CD19+ B cells co-expressed TACE. IFN-Î³-differentiated macrophages expressed higher levels of Flt3L compared to other polarized macrophages. Importantly, Flt3L serum levels were reduced by effective therapy. CONCLUSIONS: The Flt3L/CD135 axis is active in RA patients and is responsive to both prednisolone and adalimumab treatment. Conceivably, this ligand receptor pair represents a novel therapeutic target.","fulltextAvailable":false,"journal":"Arthritis research & therapy","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Blood Cells","uri":{"id":"D001773","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Macrophages","uri":{"id":"D008264","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis, Rheumatoid","uri":{"id":"D001172","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Flow Cytometry","uri":{"id":"D005434","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Killer Cells, Natural","uri":{"id":"D007694","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Endothelial Cells","uri":{"id":"D042783","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Dendritic Cells","uri":{"id":"D003713","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Enzyme-Linked Immunosorbent Assay","uri":{"id":"D004797","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Protein-Tyrosine Kinases","uri":{"id":"D011505","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Synovial Fluid","uri":{"id":"D013582","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis","uri":{"id":"D001168","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Axis","uri":{"id":"D001368","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"B-Lymphocytes","uri":{"id":"D001402","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Dendrites","uri":{"id":"D003712","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Enzyme-Linked Immunosorbent Assay","uri":{"id":"D004797","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Enzymes","uri":{"id":"D004798","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Evaluation Studies as Topic","uri":{"id":"D005069","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Fluorescent Antibody Technique","uri":{"id":"D005455","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Immunohistochemistry","uri":{"id":"D007150","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Ligands","uri":{"id":"D008024","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Macrophages","uri":{"id":"D008264","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Monocytes","uri":{"id":"D009000","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Phosphotransferases","uri":{"id":"D010770","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prednisolone","uri":{"id":"D011239","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Therapeutics","uri":{"id":"D013812","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Tissues","uri":{"id":"D014024","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Tyrosine","uri":{"id":"D014443","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Polymerase Chain Reaction","uri":{"id":"D016133","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Nature","uri":{"id":"D019368","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Serum","uri":{"id":"D044967","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Gout","uri":{"id":"D006073","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Immunosorbents","uri":{"id":"D007164","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Aged","uri":{"id":"D000368","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Enzyme-Linked Immunosorbent Assay","uri":{"id":"D004797","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Female","uri":{"id":"D005260","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Flow Cytometry","uri":{"id":"D005434","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Immunohistochemistry","uri":{"id":"D007150","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Male","uri":{"id":"D008297","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Membrane Proteins","uri":{"id":"D008565","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Middle Aged","uri":{"id":"D008875","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Reverse Transcriptase Polymerase Chain Reaction","uri":{"id":"D020133","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis, Rheumatoid","uri":{"id":"D001172","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Leukocytes, Mononuclear","uri":{"id":"D007963","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Synovial Fluid","uri":{"id":"D013582","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Synovial Membrane","uri":{"id":"D013583","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"fms-Like Tyrosine Kinase 3","uri":{"id":"D051941","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Aged","Arthritis, Rheumatoid","Enzyme-Linked Immunosorbent Assay","Female","Flow Cytometry","Humans","Immunohistochemistry","Leukocytes, Mononuclear","Male","Membrane Proteins","Middle Aged","Reverse Transcriptase Polymerase Chain Reaction","Synovial Fluid","Synovial Membrane","fms-Like Tyrosine Kinase 3"]},"pmid":"24314260","title":"FMS-related tyrosine kinase 3 ligand (Flt3L)/CD135 axis in rheumatoid arthritis.","year":"2013"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"INTRODUCTION: Cyclophilin A (CypA) is implicated in rheumatoid arthritis (RA) pathogenesis. We studied whether a novel anti-CypA single domain antibody (sdAb) treatment would modulate the severity of the disease in two different animal models of RA. METHODS: A novel sdAb, named sdAbA1, was screened from an immunized camel sdAb library and found to have a high binding affinity (KDâ=â6.9âÃâ10-9 M) for CypA. The SCID-HuRAg model and the collagen-induced arthritis (CIA) in mice were used to evaluate the effects of sdAbA1 treatment on inflammation and joint destruction. For in vitro analysis, monocytes/macrophages were purified from synovial fluid and peripheral blood of patients with RA and were tested for the effect of anti-CypA sdAb on metalloproteinase (MMP) production. Human monocyte cell line THP-1 cells were selected and western blot analyses were performed to examine the potential signaling pathways. RESULTS: In the CIA model of RA, the sdAbA1 treatment resulted in a significant decrease in clinical symptoms as well as of joint damage (P <0.05). In the SCID-HuRAg model, treatment with anti-CypA antibody sdAbA1 significantly reduced cartilage erosion, inflammatory cell numbers and MMP-9 production in the implanted tissues (P <0.05). It also significantly reduced the levels of human inflammatory cytokines IL-6 and IL-8 in mouse serum (P <0.05). No toxic effects were observed in the two animal models. In vitro results showed that sdAbA1 could counteract CypA-dependent MMP-9 secretion and IL-8 production by interfering with the ERK-NF-ÎºB pathway. CONCLUSIONS: Blockade of CypA significantly inhibited synovitis and cartilage/bone erosion in the two tested animal models of RA. Our findings provide evidence that sdAbA1 may be a potential therapeutic agent for RA.","fulltextAvailable":false,"journal":"Arthritis research & therapy","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cell Line","uri":{"id":"D002460","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis, Rheumatoid","uri":{"id":"D001172","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cell Count","uri":{"id":"D002452","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cell Line","uri":{"id":"D002460","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Models, Animal","uri":{"id":"D023421","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Antibody Specificity","uri":{"id":"D000918","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis, Experimental","uri":{"id":"D001169","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Synovial Fluid","uri":{"id":"D013582","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Blotting, Western","uri":{"id":"D015153","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cyclophilin A","uri":{"id":"D021984","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Single-Domain Antibodies","uri":{"id":"D061905","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Animals","uri":{"id":"D000818","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Antibodies","uri":{"id":"D000906","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis","uri":{"id":"D001168","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cartilage","uri":{"id":"D002356","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Evaluation Studies as Topic","uri":{"id":"D005069","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Immunity","uri":{"id":"D007109","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Immunization","uri":{"id":"D007114","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Inflammation","uri":{"id":"D007249","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Libraries","uri":{"id":"D007990","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Macrophages","uri":{"id":"D008264","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Monocytes","uri":{"id":"D009000","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Names","uri":{"id":"D009275","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Therapeutics","uri":{"id":"D013812","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Tissues","uri":{"id":"D014024","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cytokines","uri":{"id":"D016207","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Serum","uri":{"id":"D044967","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Mice","uri":{"id":"D051379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Camels","uri":{"id":"D002162","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Synovitis","uri":{"id":"D013585","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Interleukin-6","uri":{"id":"D015850","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Interleukin-8","uri":{"id":"D016209","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cyclophilins","uri":{"id":"D021983","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Metalloproteases","uri":{"id":"D045726","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Animals","uri":{"id":"D000818","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Disease Models, Animal","uri":{"id":"D004195","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Blotting, Western","uri":{"id":"D015153","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Signal Transduction","uri":{"id":"D015398","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Mice, SCID","uri":{"id":"D016513","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Mice, Inbred NOD","uri":{"id":"D016688","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Mice","uri":{"id":"D051379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Ankle Joint","uri":{"id":"D000843","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis, Experimental","uri":{"id":"D001169","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis, Rheumatoid","uri":{"id":"D001172","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cell Line","uri":{"id":"D002460","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Mice, Inbred DBA","uri":{"id":"D008811","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Monocytes","uri":{"id":"D009000","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Synovitis","uri":{"id":"D013585","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Surface Plasmon Resonance","uri":{"id":"D020349","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cyclophilin A","uri":{"id":"D021984","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Single-Domain Antibodies","uri":{"id":"D061905","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Animals","Ankle Joint","Arthritis, Experimental","Arthritis, Rheumatoid","Blotting, Western","Cell Line","Cyclophilin A","Disease Models, Animal","Humans","Mice","Mice, Inbred DBA","Mice, Inbred NOD","Mice, SCID","Monocytes","Signal Transduction","Single-Domain Antibodies","Surface Plasmon Resonance","Synovitis"]},"pmid":"24314202","title":"Inhibition of synovitis and joint destruction by a new single domain antibody specific for cyclophilin A in two different mouse models of rheumatoid arthritis.","year":"2013"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"OBJECTIVE: To investigate the clinical features of neuromyelitis optica (NMO) and NMO spectrum disorders (NMOSD) with primary SjÃ¶gren's syndrome (pSS). METHODS: Eleven inpatients diagnosed as NMO secondary to pSS in Peking Union Medical College Hospital were retrospectively analyzed. RESULTS: Eleven patients of pSS with NMO were enrolled in this study, including 10 females and 1 male. The mean age was (35 Â± 15) years old. The course of disease ranged from one month to 16 years, with a median of 10 months. The interval between optic nerve and spinal cord involvement was 3 months to 2 years.Eight patients had NMOSD as initial presentations of pSS. Eight patients had history of optic neuropathy. The most frequently involved spinal segment was cervical cord (10 cases) shown by magnetic resonance.Serum NMO-IgG antibodies were tested in 7 patients and 6 of them were positive. CONCLUSION: NMOSD may present as an important and initial clinical manifestation of pSS, which suggesting the involvement of central nervous system. Autoimmune antibodies, NMO-IgG and imaging were supposed to be done for further evaluation of prognosis and therapy regimens.","fulltextAvailable":false,"journal":"Zhonghua nei ke za zhi","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Spinal Nerves","uri":{"id":"D013127","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Central Nervous System","uri":{"id":"D002490","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Nervous System","uri":{"id":"D009420","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Spinal Cord","uri":{"id":"D013116","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neuromyelitis Optica","uri":{"id":"D009471","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Optic Nerve","uri":{"id":"D009900","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Optic Nerve Diseases","uri":{"id":"D009901","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Antibodies","uri":{"id":"D000906","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Diagnosis","uri":{"id":"D003933","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Evaluation Studies as Topic","uri":{"id":"D005069","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Female","uri":{"id":"D005260","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"History","uri":{"id":"D006664","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hospitalization","uri":{"id":"D006760","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hospitals","uri":{"id":"D006761","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Inpatients","uri":{"id":"D007297","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Male","uri":{"id":"D008297","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prognosis","uri":{"id":"D011379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Syndrome","uri":{"id":"D013577","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Autoimmunity","uri":{"id":"D015551","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medicalization","uri":{"id":"D062528","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Adult","uri":{"id":"D000328","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Aged","uri":{"id":"D000368","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Autoantibodies","uri":{"id":"D001323","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Female","uri":{"id":"D005260","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Male","uri":{"id":"D008297","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Middle Aged","uri":{"id":"D008875","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Retrospective Studies","uri":{"id":"D012189","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Young Adult","uri":{"id":"D055815","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neuromyelitis Optica","uri":{"id":"D009471","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Sjogren's Syndrome","uri":{"id":"D012859","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Adult","Aged","Autoantibodies","Female","Humans","Male","Middle Aged","Neuromyelitis Optica","Retrospective Studies","Sjogren's Syndrome","Young Adult"]},"pmid":"24314164","title":"[The clinical characteristics of primary SjÃ¶gren syndrome with neuromyelitis optica].","year":"2013"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"Galectins constitute an evolutionary conserved family that bind to Î²-galactosides. Increasing evidence shows that galectins are involved in many fundamental biological processes such as cellular communication, inflammation, differentiation and apoptosis. Changes in galectin-3 (Gal-3) expression are commonly seen in cancer and pre-cancerous conditions, and Gal-3 may be involved in the regulation of diverse cancer cell activities that contribute to tumourigenesis, cancer progression and metastasis. In addition, Gal-3 is a pro-inflammatory regulator in rheumatoid arthritis. Gal-3 has been shown to be involved in many aspects in allergic inflammation, such as eosinophil recruitment, airway remodeling, development of a Th2 phenotype as well as increased expression of inflammatory mediators. In an in vivo model it was shown that bronchoalveolar lavage (BAL) fluid from ovalbumin-challenged mice contained significantly higher levels of Gal-3 compared to control mice. The molecular mechanisms of Gal-3 in human asthma have not been fully elucidated. This review will focus on what is known about the Gal-3 and its role in the pathophysiological mechanisms of asthma to evaluate the potential of Gal-3 as a biomarker and therapeutic target of asthma.","fulltextAvailable":false,"journal":"Respiratory research","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Bronchoalveolar Lavage Fluid","uri":{"id":"D001992","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis, Rheumatoid","uri":{"id":"D001172","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Precancerous Conditions","uri":{"id":"D011230","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Bronchoalveolar Lavage","uri":{"id":"D018893","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Biological Processes","uri":{"id":"D055694","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Airway Remodeling","uri":{"id":"D056151","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anti-Inflammatory Agents","uri":{"id":"D000893","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis","uri":{"id":"D001168","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Asthma","uri":{"id":"D001249","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Communication","uri":{"id":"D003142","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Eosinophils","uri":{"id":"D004804","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Evaluation Studies as Topic","uri":{"id":"D005069","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Inflammation","uri":{"id":"D007249","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasm Metastasis","uri":{"id":"D009362","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Phenotype","uri":{"id":"D010641","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Therapeutics","uri":{"id":"D013812","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Biological Markers","uri":{"id":"D015415","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Apoptosis","uri":{"id":"D017209","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Mice","uri":{"id":"D051379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Therapeutic Irrigation","uri":{"id":"D007507","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Galectins","uri":{"id":"D037161","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Galectin 3","uri":{"id":"D037502","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Animals","uri":{"id":"D000818","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anti-Inflammatory Agents","uri":{"id":"D000893","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Disease Models, Animal","uri":{"id":"D004195","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Biological Markers","uri":{"id":"D015415","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Mice","uri":{"id":"D051379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Asthma","uri":{"id":"D001249","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Bronchoalveolar Lavage Fluid","uri":{"id":"D001992","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Ovalbumin","uri":{"id":"D010047","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Galectin 3","uri":{"id":"D037502","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Animals","Anti-Inflammatory Agents","Asthma","Biological Markers","Bronchoalveolar Lavage Fluid","Disease Models, Animal","Galectin 3","Mice","Ovalbumin"]},"pmid":"24313993","title":"Galectin-3: its role in asthma and potential as an anti-inflammatory target.","year":"2013"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"OBJECTIVES: This 24-week, multicenter, double-blind, randomized, placebo-controlled study (NCT00791999) compared efficacy and safety of certolizumab pegol (CZP) in combination with methotrexate (MTX) vs placebo plus MTX in Japanese rheumatoid arthritis (RA) patients with inadequate response to MTX. METHODS: In total, 316 patients were randomized 1:1:1:1 to subcutaneous CZP 100, 200, or 400 mg (induction dose: 200 mg or 400 mg CZP at Weeks 0, 2, and 4) plus MTX or placebo plus MTX every 2 weeks. Primary endpoint was ACR20 response at Week 12. RESULTS: ACR20 response rates were 62.5%, 76.8%, 77.6%, and 28.6% at Week 12, and 61.1%, 73.2%, 71.8%, and 24.7% at Week 24 for CZP 100, 200, and 400 mg, and placebo groups, respectively, with statistical significance between each CZP group and placebo. Change in Total Sharp Score over 24 weeks was significantly smaller in CZP 200 and 400 mg groups vs placebo. Improvements in health-related quality of life (HRQoL) were observed in all three CZP groups vs placebo. Incidence of adverse events was similar between CZP groups. CONCLUSIONS: CZP plus MTX resulted in rapid, sustained reductions in RA signs and symptoms in Japanese patients with inadequate response to MTX, with significant inhibition of radiographic progression and improved HRQoL.","fulltextAvailable":false,"journal":"Modern rheumatology / the Japan Rheumatism Association","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis, Rheumatoid","uri":{"id":"D001172","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Quality of Life","uri":{"id":"D011788","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Signs and Symptoms","uri":{"id":"D012816","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis","uri":{"id":"D001168","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Methotrexate","uri":{"id":"D008727","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Safety","uri":{"id":"D012449","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Incidence","uri":{"id":"D015994","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Life","uri":{"id":"D019369","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Asian Continental Ancestry Group","uri":{"id":"D044466","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"24313916","title":"Efficacy and safety of certolizumab pegol plus methotrexate in Japanese rheumatoid arthritis patients with an inadequate response to methotrexate: the J-RAPID randomized, placebo-controlled trial.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"OBJECTIVES: To evaluate the association between inflammation, oxidative stress, and circulating progenitor cell (CPC) number and redox equilibrium, vascular lesions and accelerated atherosclerosis in rheumatoid arthritis (RA). METHOD: Circulating CD34+ cells were isolated from 33 RA patients and 33 controls. Reactive oxygen species (ROS) levels and mRNA expression of manganese superoxide dismutase (MnSOD), catalase (CAT), glutathione peroxidase type 1 (GPx-1) antioxidant enzymes, and the gp91phox-containing nicotinamide adenine dinucleotide phosphate (NADPH) oxidase NOX2 were measured in CD34+ cells. C-reactive protein (CRP), fibrinogen, erythrocyte sedimentation rate (ESR), carotid intima-media thickness (cIMT), and arterial stiffness (AS) were also evaluated. We investigated the relationships between inflammatory markers, vascular parameters, cell number, and antioxidant enzymes. RESULTS: CD34+ cell number was lower in RA patients than in controls. In CD34+ cells from RA patients, ROS levels, MnSOD mRNA, and NOX2 mRNA were higher, while mRNA expression of GPx-1 and CAT was significantly lower. The AS, pulse wave velocity (PWV), and augmentation index (AIx) were higher, as was cIMT. CD34+ cell number was inversely correlated with CRP, ROS, PWV, and AIx, and with the CAT/MnSOD and GPx-1/MnSOD ratios. CRP was correlated with MnSOD mRNA, PWV, and AIx but not with CAT and GPx-1 mRNA. CONCLUSIONS: Our data show a link between inflammation, oxidative stress, and the impairment of the antioxidant system of CPCs and their number, and with arterial stiffness in RA subjects. This could suggest a perspective on the accelerated development of vascular damage and atherosclerosis in RA.","fulltextAvailable":false,"journal":"Scandinavian journal of rheumatology","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cell Count","uri":{"id":"D002452","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cell Separation","uri":{"id":"D002469","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis, Rheumatoid","uri":{"id":"D001172","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cell Count","uri":{"id":"D002452","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Stem Cells","uri":{"id":"D013234","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Superoxide Dismutase","uri":{"id":"D013482","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Reactive Oxygen Species","uri":{"id":"D017382","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Oxidative Stress","uri":{"id":"D018384","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Vascular Stiffness","uri":{"id":"D059289","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Blood Sedimentation","uri":{"id":"D001799","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"C-Reactive Protein","uri":{"id":"D002097","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glutathione Peroxidase","uri":{"id":"D005979","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"NAD","uri":{"id":"D009243","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"NADP","uri":{"id":"D009249","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"NADPH Oxidase","uri":{"id":"D019255","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Carotid Intima-Media Thickness","uri":{"id":"D059168","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pulse Wave Analysis","uri":{"id":"D063177","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Abstracting and Indexing as Topic","uri":{"id":"D000043","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Acceleration","uri":{"id":"D000054","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Antioxidants","uri":{"id":"D000975","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arteries","uri":{"id":"D001158","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis","uri":{"id":"D001168","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Enzymes","uri":{"id":"D004798","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Erythrocytes","uri":{"id":"D004912","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Evaluation Studies as Topic","uri":{"id":"D005069","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Inflammation","uri":{"id":"D007249","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"NADP","uri":{"id":"D009249","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Oxidation-Reduction","uri":{"id":"D010084","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Oxides","uri":{"id":"D010087","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Oxidoreductases","uri":{"id":"D010088","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Oxygen","uri":{"id":"D010100","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Oxygenators","uri":{"id":"D010106","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Phosphates","uri":{"id":"D010710","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Proteins","uri":{"id":"D011506","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pulse","uri":{"id":"D011674","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"RNA, Messenger","uri":{"id":"D012333","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Superoxides","uri":{"id":"D013481","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Atherosclerosis","uri":{"id":"D050197","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Adenine","uri":{"id":"D000225","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Catalase","uri":{"id":"D002374","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Fibrinogen","uri":{"id":"D005340","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glutathione","uri":{"id":"D005978","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Manganese","uri":{"id":"D008345","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Peroxidase","uri":{"id":"D009195","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Niacinamide","uri":{"id":"D009536","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Peroxidases","uri":{"id":"D010544","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Superoxide Dismutase","uri":{"id":"D013482","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Aged","uri":{"id":"D000368","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Angiography","uri":{"id":"D000792","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Female","uri":{"id":"D005260","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Inflammation","uri":{"id":"D007249","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Male","uri":{"id":"D008297","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Middle Aged","uri":{"id":"D008875","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Predictive Value of Tests","uri":{"id":"D011237","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prognosis","uri":{"id":"D011379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Severity of Illness Index","uri":{"id":"D012720","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Stem Cells","uri":{"id":"D013234","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Comorbidity","uri":{"id":"D015897","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Multivariate Analysis","uri":{"id":"D015999","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Linear Models","uri":{"id":"D016014","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Case-Control Studies","uri":{"id":"D016022","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Reactive Oxygen Species","uri":{"id":"D017382","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Oxidative Stress","uri":{"id":"D018384","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Disease Progression","uri":{"id":"D018450","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Atherosclerosis","uri":{"id":"D050197","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis, Rheumatoid","uri":{"id":"D001172","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Blood Flow Velocity","uri":{"id":"D001783","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"C-Reactive Protein","uri":{"id":"D002097","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Catalase","uri":{"id":"D002374","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Superoxide Dismutase","uri":{"id":"D013482","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Causality","uri":{"id":"D015984","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Ultrasonography, Doppler","uri":{"id":"D018608","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Inflammation Mediators","uri":{"id":"D018836","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Antigens, CD34","uri":{"id":"D018952","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Carotid Intima-Media Thickness","uri":{"id":"D059168","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Vascular Stiffness","uri":{"id":"D059289","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Aged","Angiography","Antigens, CD34","Arthritis, Rheumatoid","Atherosclerosis","Blood Flow Velocity","C-Reactive Protein","Carotid Intima-Media Thickness","Case-Control Studies","Catalase","Causality","Comorbidity","Disease Progression","Female","Humans","Inflammation","Inflammation Mediators","Linear Models","Male","Middle Aged","Multivariate Analysis","Oxidative Stress","Predictive Value of Tests","Prognosis","Reactive Oxygen Species","Severity of Illness Index","Stem Cells","Superoxide Dismutase","Ultrasonography, Doppler","Vascular Stiffness"]},"pmid":"24313545","title":"Circulating progenitor cells in rheumatoid arthritis: association with inflammation and oxidative stress.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"OBJECTIVES: Etanercept is an effective tumour necrosis factor (TNF)-Î± inhibitor drug with the unique ability to block not only TNF-Î± but also lymphotoxin (LT)-Î±, at least in vitro. We aimed to investigate the in vivo effect of etanercept on synovial expression of TNF-Î± and LT-Î±. METHOD: Synovial biopsies from 12 rheumatoid arthritis (RA) patients started on etanercept and 11 RA patients started on infliximab were obtained at baseline and 8 weeks after treatment initiation. Synovial expression of TNF-Î± and LT-Î± was evaluated by immunohistochemistry followed by computer-assisted image analysis. Differences between paired samples were analysed by the Wilcoxon test and between groups by the Mann-Whitney test. A p-value < 0.05 was considered statistically significant. RESULTS: Six out of the 12 of the patients started on etanercept achieved an American College of Rheumatology (ACR)50 response. Macroscopic evaluation of the joints during arthroscopy revealed a significant decrease of local inflammation mainly in good ACR50 responders. Synovial expression of both LT-Î± and TNF-Î± decreased but the differences did not reach statistical significance at a group level. By contrast, a significant decrease in both LT-Î± and TNF-Î± was observed when only good ACR50 responders were analysed. Despite higher levels of baseline synovial TNF-Î± in the good responders, neither baseline LT-Î± nor TNF-Î± could predict clinical response after 8 weeks. A decreasing trend of the synovial levels of LT-Î± was also observed in good responders to infliximab, but the difference did not reach statistical significance. CONCLUSIONS: Etanercept treatment modulates the synovial expression of both TNF-Î± and LT-Î± in vivo, a mechanism that might partly explain its clinical efficacy in RA.","fulltextAvailable":false,"journal":"Scandinavian journal of rheumatology","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Aftercare","uri":{"id":"D000359","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis, Rheumatoid","uri":{"id":"D001172","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Image Processing, Computer-Assisted","uri":{"id":"D007091","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis","uri":{"id":"D001168","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Biopsy","uri":{"id":"D001706","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Data Collection","uri":{"id":"D003625","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmaceutical Preparations","uri":{"id":"D004364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Evaluation Studies as Topic","uri":{"id":"D005069","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Immunohistochemistry","uri":{"id":"D007150","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Inflammation","uri":{"id":"D007249","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Necrosis","uri":{"id":"D009336","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthroscopy","uri":{"id":"D001182","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Lymphotoxin-alpha","uri":{"id":"D008233","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Rheumatology","uri":{"id":"D012219","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Adult","uri":{"id":"D000328","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Aged","uri":{"id":"D000368","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Antibodies, Monoclonal","uri":{"id":"D000911","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Female","uri":{"id":"D005260","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Image Processing, Computer-Assisted","uri":{"id":"D007091","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Immunohistochemistry","uri":{"id":"D007150","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Male","uri":{"id":"D008297","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Middle Aged","uri":{"id":"D008875","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Tumor Necrosis Factor-alpha","uri":{"id":"D014409","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Treatment Outcome","uri":{"id":"D016896","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Antirheumatic Agents","uri":{"id":"D018501","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis, Rheumatoid","uri":{"id":"D001172","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthroscopy","uri":{"id":"D001182","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Biopsy","uri":{"id":"D001706","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Immunoglobulin G","uri":{"id":"D007074","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Lymphotoxin-alpha","uri":{"id":"D008233","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Synovial Membrane","uri":{"id":"D013583","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Receptors, Tumor Necrosis Factor","uri":{"id":"D018124","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Adult","Aged","Antibodies, Monoclonal","Antirheumatic Agents","Arthritis, Rheumatoid","Arthroscopy","Biopsy","Female","Humans","Image Processing, Computer-Assisted","Immunoglobulin G","Immunohistochemistry","Lymphotoxin-alpha","Male","Middle Aged","Receptors, Tumor Necrosis Factor","Synovial Membrane","Treatment Outcome","Tumor Necrosis Factor-alpha"]},"pmid":"24313444","title":"Etanercept decreases synovial expression of tumour necrosis factor-Î± and lymphotoxin-Î± in rheumatoid arthritis.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"Proinflammatory CD4(+) CD28(null) T cells are frequently found in the circulation of patients with rheumatoid arthritis (RA), but are less common in the rheumatic joint. In the present study, we sought to identify functional differences between CD4(+) CD28(null) T cells from blood and synovial fluid in comparison with conventional CD28-expressing CD4(+) T cells. Forty-four patients with RA, displaying a distinct CD4(+) CD28(null) T cell population in blood, were recruited for this study; the methylation status of the IFNG locus was examined in isolated T cell subsets, and intracellular cytokine production (IFN-Î³, TNF, IL-17) and chemokine receptor expression (CXCR3, CCR6 and CCR7) were assessed by flow cytometry on T cells from the two compartments. Circulating CD4(+) CD28(null) T cells were significantly more hypomethylated in the CNS-1 region of the IFNG locus than conventional CD4(+) CD28(+) T cells and produced higher levels of both IFN-Î³ and TNF after TCR cross-linking. CD4(+) CD28(null) T cells from the site of inflammation expressed significantly more CXCR3 and CCR6 compared to their counterparts in blood. While IL-17A production could hardly be detected in CD4(+) CD28(null) cells from the blood, a significant production was observed in CD4(+) CD28(null) T cells from synovial fluid. CD4(+) CD28(null) T cells were not only found to differ from conventional CD4(+) CD28(+) T cells in the circulation, but we could also demonstrate that synovial CD4(+) CD28(null) T cells showed additional effector functions (IL-17 coproduction) as compared to the same subset in peripheral blood, suggesting an active role for these cells in the perpetuation of inflammation in the subset of patients having a CD28(null) population.","fulltextAvailable":false,"journal":"Scandinavian journal of immunology","meshAnnotations":{"@type":"java.util.ArrayList"},"meshHeading":{"@type":"java.util.ArrayList","@items":["Adolescent","Adult","Aged","Aged, 80 and over","Antigens, CD28","Arthritis, Rheumatoid","CD4-Positive T-Lymphocytes","Cytokines","DNA Methylation","Female","Humans","Interferon-gamma","Male","Middle Aged","Receptors, Chemokine"]},"pmid":"24313359","title":"Peripheral and site-specific CD4(+) CD28(null) T cells from rheumatoid arthritis patients show distinct characteristics.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"PURPOSE: The purpose of this study was the isolation and structure elucidation of chemical compounds from the rhizomes of Eremostachys laciniata (L) Bunge (EL), an Iranian traditional medicinal herb with a thick root and pale purple or white flowers as well as the clinical studies on the therapeutic efficacy and safety of topical application of the EL extract in the management of some inflammatory conditions, e.g., arthritis, rheumatoid arthritis and septic arthritis (Riter's syndrome). METHODS: The structures of the isolated compounds were elucidated unequivocally on the basis of one and two dimensional NMR, UV and HR-FABMS spectroscopic data analyses. A single-blinded randomized clinical trial was carried out with the extract of the rhizomes of E. laciniata (EL) to determine the efficacy and safety of the traditional uses of EL compared to that of piroxicam in treatment of inflammatory diseases, e.g., osteoarthritis, rheumatoid arthritis and Reiter's syndrome. RESULTS: Eleven iridoid glycosides, two phenylethanoids and two phytosterols were isolated and identified for the first time from the rhizomes of EL. After 14 days of treatment with the EL and piroxicam ointments, all groups showed significant improvements compared to the control groups. EL (5%) ointment induced better initial therapeutic response than piroxicam (5%) onitment. CONCLUSION: This clinical trial established that EL was suitable for topical applications as a safe and effective complementary therapy for inflammatory diseases.","fulltextAvailable":false,"journal":"Advanced pharmaceutical bulletin","meshAnnotations":{"@type":"java.util.ArrayList"},"meshHeading":null,"pmid":"24312865","title":"Rhizomes of Eremostachys laciniata: Isolation and Structure Elucidation of Chemical Constituents and a Clinical Trial on Inflammatory Diseases.","year":"2013"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"PURPOSE: This research was aimed to formulate and characterize a microemolsion systems as a topical delivery system of naproxen for relief of symptoms of rheumatoid arthritis, osteoarthritis and treatment of dysmenorrheal. METHODS: ME formulations prepared by mixing of appropriate amount of surfactant including Tween 80 and Span 80, co-surfactant such as propylene glycol (PG) and oil phase including Labrafac PG - transcutol P (10:1 ratio). The prepared microemolsions were evaluated regarding their particle size, zeta potential, conductivity, stability, viscosity, differential scanning calorimetry (DSC), scanning electron microscopy (SEM), refractory index (RI) and pH. RESULTS: The mean droplets size of microemulsion formulation were in the range of 7.03 to 79.8 nm, and its refractory index (RI) and pH were 1.45 and 6.75, respectively. Viscosity range was 253.73- 802.63cps. Drug release profile showed that 26.15% of the drug released in the first 24 hours of experiment. Also, Hexagonal and bicontinuous structures were seen in the SEM photograph of the microemulsions. CONCLUSION: characterization, physicochemical properties and in vitro release were dependent upon the contents of S/C ratio, water and, oil phase percentage in formulations. Also, ME-6 may be preferable for topical naproxen formulation.","fulltextAvailable":false,"journal":"Advanced pharmaceutical bulletin","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis, Rheumatoid","uri":{"id":"D001172","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Microscopy, Electron","uri":{"id":"D008854","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Microscopy, Electron, Scanning","uri":{"id":"D008855","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Calorimetry, Differential Scanning","uri":{"id":"D002152","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Particle Size","uri":{"id":"D010316","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Polysorbates","uri":{"id":"D011136","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Propylene Glycols","uri":{"id":"D011409","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Propylene Glycol","uri":{"id":"D019946","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Abstracting and Indexing as Topic","uri":{"id":"D000043","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis","uri":{"id":"D001168","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Calorimetry","uri":{"id":"D002151","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmaceutical Preparations","uri":{"id":"D004364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Electronics","uri":{"id":"D004581","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Electrons","uri":{"id":"D004583","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Evaluation Studies as Topic","uri":{"id":"D005069","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hydrogen-Ion Concentration","uri":{"id":"D006863","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Microscopy","uri":{"id":"D008853","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Viscosity","uri":{"id":"D014783","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Naproxen","uri":{"id":"D009288","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Osteoarthritis","uri":{"id":"D010003","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Polysorbates","uri":{"id":"D011136","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Surface-Active Agents","uri":{"id":"D013501","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"24312814","title":"Design and characterization of microemulsion systems for naproxen.","year":"2013"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"Despite the important diagnostic value of evaluating antibody responses to individual human pathogens, antibody profiles against multiple infectious agents have not been used to explore health and disease mainly for technical reasons.Â Â We hypothesized that the interplay between infection and chronic disease might be revealed by profiling antibodies against multiple agents. Here, the levels of antibodies against a panel of 13 common infectious agents were evaluated with the quantitative Luciferase Immunoprecipitation Systems (LIPS) in patients from three disease cohorts including those with pathogenic anti-interferon-Î³ autoantibodies (IFN-Î³ AAB), HIV and SjÃ¶gren's syndrome (SjS) to determine if their antibody profiles differed from control subjects.Â  The IFN-Î³ AAB patients compared to controls demonstrated statistically higher levels of antibodies against VZV (p=0.0003), EBV (p=0.002), CMV (p=0.003), and C. albicans (p=0.03), but lower antibody levels against poliovirus (p=0.04). Comparison of HIV patients with blood donor controls revealed that the patients had higher levels of antibodies against CMV (p=0.0008), HSV-2 (p=0.0008), EBV (p=0.001), and C. albicans (p=0.01), but showed decreased levels of antibodies against coxsackievirus B4 (p=0.0008), poliovirus (p=0.0005),Â Â  and HHV-6B (p=0.002). Lastly, SjS patients had higher levels of anti-EBV antibodies (p=0.03), but lower antibody levels against several enteroviruses including a newly identified picornavirus, HCoSV-A (p=0.004), coxsackievirus B4 (p=0.04), and poliovirus (p=0.02). For the IFN-Î³ AAB and HIV cohorts, principal component analysis revealed unique antibody clusters that showed the potential to discriminate patients from controls.Â  The results suggest that antibody profiles against these and likely other common infectious agents may yield insight into the interplay between exposure to infectious agents, dysbiosis, adaptive immunity and disease activity.","fulltextAvailable":false,"journal":"PloS one","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Immune System Diseases","uri":{"id":"D007154","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Antibodies, Monoclonal, Humanized","uri":{"id":"D061067","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Antibody Formation","uri":{"id":"D000917","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Chronic Disease","uri":{"id":"D002908","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Principal Component Analysis","uri":{"id":"D025341","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Blood Donors","uri":{"id":"D001782","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Adaptive Immunity","uri":{"id":"D056704","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Antibodies","uri":{"id":"D000906","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Discrimination (Psychology)","uri":{"id":"D004192","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Evaluation Studies as Topic","uri":{"id":"D005069","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"HIV","uri":{"id":"D006678","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Immunity","uri":{"id":"D007109","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Immunization","uri":{"id":"D007114","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Luciferases","uri":{"id":"D008156","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Syndrome","uri":{"id":"D013577","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Tissue Donors","uri":{"id":"D014019","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Virulence","uri":{"id":"D014774","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cluster Analysis","uri":{"id":"D016000","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Poliovirus","uri":{"id":"D017955","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Herpesvirus 2, Human","uri":{"id":"D018258","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Autoantibodies","uri":{"id":"D001323","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Enterovirus","uri":{"id":"D004770","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Herpesvirus 4, Human","uri":{"id":"D004854","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Picornaviridae","uri":{"id":"D010849","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Herpesvirus 6, Human","uri":{"id":"D015654","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Immunoprecipitation","uri":{"id":"D047468","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Dysbiosis","uri":{"id":"D064806","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Autoantibodies","uri":{"id":"D001323","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Female","uri":{"id":"D005260","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Interferon-gamma","uri":{"id":"D007371","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Male","uri":{"id":"D008297","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"HIV Infections","uri":{"id":"D015658","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Computational Biology","uri":{"id":"D019295","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Antibodies","uri":{"id":"D000906","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Chronic Disease","uri":{"id":"D002908","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Sjogren's Syndrome","uri":{"id":"D012859","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Immunity, Humoral","uri":{"id":"D056724","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Antibodies, Neutralizing","uri":{"id":"D057134","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Antibodies","Antibodies, Neutralizing","Autoantibodies","Chronic Disease","Computational Biology","Female","HIV Infections","Humans","Immunity, Humoral","Interferon-gamma","Male","Sjogren's Syndrome"]},"pmid":"24312567","title":"Altered antibody profiles against common infectious agents in chronic disease.","year":"2013"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"A 77-year-old female, who suffered from rheumatoid arthritis and hypothyroidism, developed severe muscle weakness. Clinical features, blood results and muscle biopsy suggested a possible diagnosis of dermatomyositis. A computed tomography of the chest, abdomen and pelvis showed a solid mass in the left kidney. She underwent a left laparoscopic nephrectomy and histology confirmed conventional (clear cell) renal cell carcinoma. She recovered slowly and almost back to normal life after 6 months. Early appreciation of the typical skin rash may provide a clue to the diagnosis and screening for neoplasm may improve prognosis.","fulltextAvailable":false,"journal":"Urology annals","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Carcinoma, Renal Cell","uri":{"id":"D002292","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Muscle Development","uri":{"id":"D024510","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis, Rheumatoid","uri":{"id":"D001172","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Carcinoma, Renal Cell","uri":{"id":"D002292","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Exanthema","uri":{"id":"D005076","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Muscle Weakness","uri":{"id":"D018908","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Adult","uri":{"id":"D000328","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis","uri":{"id":"D001168","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Biopsy","uri":{"id":"D001706","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Carcinoma","uri":{"id":"D002277","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Computers","uri":{"id":"D003201","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Diagnosis","uri":{"id":"D003933","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Female","uri":{"id":"D005260","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Histology","uri":{"id":"D006653","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Kidney","uri":{"id":"D007668","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Muscles","uri":{"id":"D009132","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasms","uri":{"id":"D009369","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Nephrectomy","uri":{"id":"D009392","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prognosis","uri":{"id":"D011379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Tomography","uri":{"id":"D014054","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Life","uri":{"id":"D019369","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Laparoscopes","uri":{"id":"D020706","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Dermatomyositis","uri":{"id":"D003882","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hypothyroidism","uri":{"id":"D007037","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pelvis","uri":{"id":"D010388","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"24311917","title":"Renal cell carcinoma-associated adult dermatomyositis treated laparoscopic nephrectomy.","year":"2013"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"Rheumatoid arthritis (RA) is a chronic, systemic autoimmune disease with unknown aetiology that causes the immune system to attack the joints (synoviums), leading to chronic inflammation. According to the traditional Chinese medicine (TCM), RA falls into the category of Impediment disease (\"Bi\" syndrome), that is, poor circulation of qi and blood (stasis). Tongue diagnosis is an important method of TCM to detect blood stasis. In this study, 74 RA patients, meeting the pre-set criteria, were recruited via rheumatology outpatient clinic and examined by experienced rheumatology physicians. Two images-one of the tongue and the other, sublingual vessels-of the same patient were taken by a Canon digital camera in a darkroom with uniform lighting conditions. Relevant features of the tongue were extracted by utilising image processing techniques. Every tongue was classified into corresponding patterns based on the features identified. The subjects included 62 females and 12 males with an average age of 49.86 Â± 13.81 years old, an average morbidity period of 4.56 Â± 3.92 years, an average rheumatoid factor (RF) of 225.3 Â± 373.8 IU/mL and an average erythrocyte sedimentation rate of (ESR) 40.9 Â± 31.9 m/hr. According to our study, 86% of the patients with RA have tongues with sublingual vessels with a width of more than 2.7 mm, a length of more than 3/5 from tongue tipto sublingual caruncle, or a count of sublingual vessels more than 2. Moreover, since RA index is highly correlated with blood stasis in TCM, a logistic regression is conducted to predict the probability of presence of RA using RF and ESR as explanatory variables. Also, the logistic regression analysis of RA with respect to the conventional tongue diagnosis criteria was performed. Based on the aforementioned studies, we concluded that tongue diagnosis is helpful in detecting blood stasis of RA.","fulltextAvailable":false,"journal":"African journal of traditional, complementary, and alternative medicines : AJTCAM / African Networks on Ethnomedicines","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medicine, Traditional","uri":{"id":"D008519","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Ambulatory Care Facilities","uri":{"id":"D000554","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis, Rheumatoid","uri":{"id":"D001172","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Immune System","uri":{"id":"D007107","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medicine, Chinese Traditional","uri":{"id":"D008516","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Regression Analysis","uri":{"id":"D012044","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Logistic Models","uri":{"id":"D016015","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Autoimmune Diseases","uri":{"id":"D001327","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Blood Sedimentation","uri":{"id":"D001799","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Rheumatoid Factor","uri":{"id":"D012217","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Abstracting and Indexing as Topic","uri":{"id":"D000043","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis","uri":{"id":"D001168","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Diagnosis","uri":{"id":"D003933","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Erythrocytes","uri":{"id":"D004912","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Female","uri":{"id":"D005260","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Immunity","uri":{"id":"D007109","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Immunization","uri":{"id":"D007114","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Inflammation","uri":{"id":"D007249","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Lighting","uri":{"id":"D008029","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Male","uri":{"id":"D008297","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medicine","uri":{"id":"D008511","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Morbidity","uri":{"id":"D009017","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Organization and Administration","uri":{"id":"D009934","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Outpatients","uri":{"id":"D010045","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Physicians","uri":{"id":"D010820","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Probability","uri":{"id":"D011336","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Syndrome","uri":{"id":"D013577","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Tongue","uri":{"id":"D014059","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Autoimmunity","uri":{"id":"D015551","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Qi","uri":{"id":"D019413","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Asian Continental Ancestry Group","uri":{"id":"D044466","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Rheumatology","uri":{"id":"D012219","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Synovial Membrane","uri":{"id":"D013583","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Adult","uri":{"id":"D000328","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Female","uri":{"id":"D005260","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Male","uri":{"id":"D008297","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Middle Aged","uri":{"id":"D008875","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Logistic Models","uri":{"id":"D016015","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis, Rheumatoid","uri":{"id":"D001172","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Blood Sedimentation","uri":{"id":"D001799","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Diagnosis, Differential","uri":{"id":"D003937","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medicine, Chinese Traditional","uri":{"id":"D008516","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Rheumatoid Factor","uri":{"id":"D012217","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Tongue","uri":{"id":"D014059","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Adult","Arthritis, Rheumatoid","Blood Sedimentation","Diagnosis, Differential","Female","Humans","Logistic Models","Male","Medicine, Chinese Traditional","Middle Aged","Rheumatoid Factor","Tongue"]},"pmid":"24311851","title":"Tongue diagnosis of traditional Chinese medicine for rheumatoid arthritis.","year":"2013"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"This study aimed to assess symptoms of insomnia in elderly residents in the community and its association with rheumatoid arthritis. Descriptive and cross-sectional study, part of a multicentre research project entitled Fragility in Brazilian elderly . A total number of 689 elderly (68.9% female, average age of 72.2 years) were interviewed using a questionnaire on sociodemographic data and clinical conditions. Two tools to identify symptoms of insomnia (the Nottingham Health profile) and to screen cognitive impairment (Mini Mental State Examination) were also applied. For data analysis, we used descriptive statistical techniques and multiple logistic regression, considering a 5% significance level. The association between insomnia symptoms and rheumatoid arthritis was found to be significant in the multivariate analysis; other associated factors were a very poor subjective evaluation of health, being retired, and the presence of depression. Health professionals should investigate carefully the sleep quality in elderly with rheumatoid arthritis, considering its high prevalence in this population.","fulltextAvailable":false,"journal":"Revista da Escola de Enfermagem da U S P","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis, Rheumatoid","uri":{"id":"D001172","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cross-Sectional Studies","uri":{"id":"D003430","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Statistics as Topic","uri":{"id":"D013223","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Multivariate Analysis","uri":{"id":"D015999","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Logistic Models","uri":{"id":"D016015","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Symptom Assessment","uri":{"id":"D063189","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Aged","uri":{"id":"D000368","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis","uri":{"id":"D001168","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Depression","uri":{"id":"D003863","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Evaluation Studies as Topic","uri":{"id":"D005069","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Female","uri":{"id":"D005260","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Sleep Initiation and Maintenance Disorders","uri":{"id":"D007319","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Internship and Residency","uri":{"id":"D007396","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Organization and Administration","uri":{"id":"D009934","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Questionnaires","uri":{"id":"D011795","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Residence Characteristics","uri":{"id":"D012111","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prevalence","uri":{"id":"D015995","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Theory of Mind","uri":{"id":"D056345","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Retirement","uri":{"id":"D012179","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Aged","uri":{"id":"D000368","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cross-Sectional Studies","uri":{"id":"D003430","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Female","uri":{"id":"D005260","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Male","uri":{"id":"D008297","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis, Rheumatoid","uri":{"id":"D001172","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Sleep Initiation and Maintenance Disorders","uri":{"id":"D007319","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Aged","Arthritis, Rheumatoid","Cross-Sectional Studies","Female","Humans","Male","Sleep Initiation and Maintenance Disorders"]},"pmid":"24310684","title":"[Association between insomnia and rheumatoid arthritis in elderly].","year":"2013"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"Rheumatoid arthritis (RA) is a chronic inflammatory disease leading to joint destruction and bone resorption. The proinflammatory cytokine interleukin 17 (IL-17), primarily produced by Th17 cells, has been shown to be involved in all stages of the disease and to be an important contributor of RA chronicity. Three major processes drive the IL-17-mediated chronicity. Several epigenetic events, enhanced in RA patients, lead to the increased production of IL-17 by Th17 cells. IL-17 then induces the production of several inflammatory mediators in the diseased synovium, which are further synergistically enhanced via combinations of IL-17 with other cytokines. IL-17 also promotes the survival of both the synoviocytes and inflammatory cells and promotes the maturation of these immune cells. This leads to an increased number of synoviocytes and inflammatory cells in the synovial fluid and in the synovium leading to the hyperplasia and exacerbated inflammation observed in joints of RA patients. Furthermore, these IL-17-driven events initiate several feedback-loop mechanisms leading to increased expansion of Th17 cells and thereby increased production of IL-17. In this review, we aim to depict a complete picture of the IL-17-driven vicious circle leading to RA chronicity and to pinpoint the key aspects that require further exploration.","fulltextAvailable":false,"journal":"European journal of immunology","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Chronic Disease","uri":{"id":"D002908","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis, Rheumatoid","uri":{"id":"D001172","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Bone Resorption","uri":{"id":"D001862","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Synovial Fluid","uri":{"id":"D013582","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Interleukin-17","uri":{"id":"D020381","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Th17 Cells","uri":{"id":"D058504","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis","uri":{"id":"D001168","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Drive","uri":{"id":"D004328","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hyperplasia","uri":{"id":"D006965","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Immunity","uri":{"id":"D007109","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Immunization","uri":{"id":"D007114","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Inflammation","uri":{"id":"D007249","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Interleukins","uri":{"id":"D007378","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Survival","uri":{"id":"D013534","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cytokines","uri":{"id":"D016207","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Interleukin-17","uri":{"id":"D020381","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Epigenomics","uri":{"id":"D057890","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Synovial Membrane","uri":{"id":"D013583","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Animals","uri":{"id":"D000818","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Inflammation","uri":{"id":"D007249","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis, Rheumatoid","uri":{"id":"D001172","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Interleukin-17","uri":{"id":"D020381","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Th17 Cells","uri":{"id":"D058504","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Animals","Arthritis, Rheumatoid","Humans","Inflammation","Interleukin-17","Th17 Cells"]},"pmid":"24310226","title":"Interleukin 17 contributes to the chronicity of inflammatory diseases such as rheumatoid arthritis.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"This study was conducted to determine the predictors of foot ulceration occurring in patients with rheumatoid arthritis (RA) without diabetes. A multi-centre case control study was undertaken; participants were recruited from eight sites (UK). Cases were adults diagnosed with RA (without diabetes) and the presence of a validated foot ulcer, defined as a full thickness skin defect occurring in isolation on / below the midline of the malleoli and requiring > 14 days to heal. Controls met the same criteria but were ulcer naive. Clinical examination included loss of sensation (10g monofilament); ankle-brachial pressure index (ABPI); forefoot deformity (Platto); plantar pressures (PressureStat); RA disease activity (36 swollen/tender joint counts) and the presence of vasculitis. History taking included past ulceration/foot surgery; current medication and smoking status. Participants completed the Health Assessment Questionnaire (HAQ) and Foot Impact Scale. A total of 83 cases with 112 current ulcers and 190 ulcer naÃ¯ve controls participated. Cases were significantly older (mean age 71Â years; 95Â % confidence interval [CI], 69-73 vs. 62Â years, 60-64) and had longer RA disease duration (mean 22Â years; 19-25 vs. 15, 13-17). Univariate analysis showed that risk of ulceration increases with loss of sensation; abnormality of ABPI and foot deformity. Plantar pressures and joint counts were not significant predictors. HAQ score and history of foot surgery were strongly associated with ulceration (odds ratio [OR]â=â1.704, 95Â % CI 1.274-2.280 and ORâ=â2.256, 95Â % CI 1.294-3.932). Three cases and two controls presented with suspected cutaneous vasculitis. In logistic regression modelling, ABPI (ORâ=â0.04; 95Â % CI, 0.01-0.28) forefoot deformity (ORâ=â1.14; 95Â % CI, 1.08-1.21) and loss of sensation (ORâ=â1.22; 95Â % CI, 1.10-1.36) predicted risk of ulceration. In patients with RA, ABPI, forefoot deformity and loss of sensation predict risk of ulceration but, in contrast with diabetes, raised plantar pressures do not predict risk.","fulltextAvailable":false,"journal":"Clinical rheumatology","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Logistic Models","uri":{"id":"D016015","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Ankle Brachial Index","uri":{"id":"D055109","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis, Rheumatoid","uri":{"id":"D001172","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Confidence Intervals","uri":{"id":"D016001","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Logistic Models","uri":{"id":"D016015","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Odds Ratio","uri":{"id":"D016017","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Case-Control Studies","uri":{"id":"D016022","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Foot Deformities","uri":{"id":"D005530","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Foot Ulcer","uri":{"id":"D016523","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Congenital Abnormalities","uri":{"id":"D000013","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Abstracting and Indexing as Topic","uri":{"id":"D000043","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Adult","uri":{"id":"D000328","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis","uri":{"id":"D001168","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Diagnosis","uri":{"id":"D003933","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"History","uri":{"id":"D006664","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Organization and Administration","uri":{"id":"D009934","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pressure","uri":{"id":"D011312","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Questionnaires","uri":{"id":"D011795","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Sensation","uri":{"id":"D012677","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"General Surgery","uri":{"id":"D013502","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Ulcer","uri":{"id":"D014456","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medicalization","uri":{"id":"D062528","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Vasculitis","uri":{"id":"D014657","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"24310107","title":"The predictors of foot ulceration in patients with rheumatoid arthritis.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"INTRODUCTION: Juvenile chronic arthritis (JCA) is a systemic disease of childhood affecting particularly joints. JCA is a heterogeneous group of inflammatory joint disorders with onset before the age of 16 years and is comprised of 7 subtype groups. The pathogenesis of JCA seen in the cervical spine is synovial inflammation, hyperaemia, and pannus formation at the occipitoatlantoaxial joints resulting in characteristic craniovertebral junction findings. Treatment of craniovertebral junction instability as a result of JCA is a challenge. The best treatment strategy may be difficult because of various radiological and clinical severities. A review of the literature and management considerations is presented. REVIEW: No randomised controlled trial or systematic review on this subject has been published. Only experts' opinions, case reports, and case series have been described. Thirty-four studies have been reviewed in this study. Involvement of the cervical spine in patients with JCA can lead to pain and functional disability. The subtypes that usually affect the cervical spine are the polyarticular type and systemic onset type and rarely the pauciarticular type. The most common cervical spine changes related to JCA are as follows: (1) apophyseal joint ankylosis at C2-C3, (2) atlantoaxial subluxation, (3) atlantoaxial impaction, (4) atlantoaxial rotatory fixation, and (5) growth disturbances of the cervical spine. The incidence of severe subluxations has decreased in the last decade as result of antirheumatoid drugs and biologicals. However, neurological compromise still occurs in JCA patients necessitating surgical treatment. CONCLUSION: Whenever the cervical spine is involved in rheumatoid arthritis patients without neurological deficits, conservative treatment is legitimate. Once patients develop neurological signs and symptoms, surgical treatment should be considered with particular focus to age, severity of the disease, and general health condition. Skilled anaesthesia is crucial and the surgical procedure should only be carried out in centres with experience in craniovertebral junction abnormalities.","fulltextAvailable":false,"journal":"Advances and technical standards in neurosurgery","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis, Juvenile","uri":{"id":"D001171","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis, Rheumatoid","uri":{"id":"D001172","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Expert Testimony","uri":{"id":"D005104","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis, Juvenile","uri":{"id":"D001171","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neurologic Manifestations","uri":{"id":"D009461","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Signs and Symptoms","uri":{"id":"D012816","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Ankylosis","uri":{"id":"D000844","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis","uri":{"id":"D001168","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Classification","uri":{"id":"D002965","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmaceutical Preparations","uri":{"id":"D004364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Inflammation","uri":{"id":"D007249","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Literature","uri":{"id":"D008091","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Methods","uri":{"id":"D008722","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Population Characteristics","uri":{"id":"D011154","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Publishing","uri":{"id":"D011643","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Incidence","uri":{"id":"D015994","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Research Report","uri":{"id":"D058028","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"24309924","title":"Juvenile chronic arthritis and the craniovertebral junction in the paediatric patient: review of the literature and management considerations.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"Rheumatoid arthritis (RA) is a chronic autoimmune disease with high morbidity and mortality. Within the inflammatory milieu, resident fibroblast-like synoviocytes (FLS) in the synovial tissue undergo hyperplasia, which leads to joint destruction. Epidemiologic studies and our previous research suggest that activation of the aryl hydrocarbon receptor (AHR) pathway plays an instrumental role in the inflammatory and destructive RA phenotype. In addition, our recent studies implicate the AHR in the regulation of the expression of several growth factors in established tumor cell lines. Thus, under inflammatory conditions, we hypothesized that the AHR is involved in the constitutive and inducible expression of several growth factors, FLS proliferation and migration, along with protease-dependent invasion in FLS from patients with RA (RA-FLS). Treatment with the AHR antagonist GNF351 inhibits cytokine-induced expression of vascular endothelial growth factor-A (VEGF-A), epiregulin, amphiregulin, and basic fibroblast growth factor mRNA through an AHR-dependent mechanism in both RA-FLS and FLS. Secretion of VEGF-A and epiregulin from RA-FLS was also inhibited upon GNF351 treatment. RA-FLS cell migration, along with cytokine-induced RA-FLS cell proliferation, was significantly attenuated by GNF351 exposure. Treatment of RA-FLS with GNF351 mitigated cytokine-mediated expression of matrix metalloproteinase-2 and -9 mRNA and diminished the RA-FLS invasive phenotype. These findings indicate that inhibition of AHR activity may be a viable therapeutic target in amelioration of disease progression in RA by attenuating growth factor release; FLS proliferation, migration, and invasion; and inflammatory activity.","fulltextAvailable":false,"journal":"The Journal of pharmacology and experimental therapeutics","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Chronic Disease","uri":{"id":"D002908","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis, Rheumatoid","uri":{"id":"D001172","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cell Line","uri":{"id":"D002460","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Epidemiologic Studies","uri":{"id":"D016021","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Receptors, Aryl Hydrocarbon","uri":{"id":"D018336","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Disease Progression","uri":{"id":"D018450","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Intercellular Signaling Peptides and Proteins","uri":{"id":"D036341","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cell Proliferation","uri":{"id":"D049109","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Autoimmune Diseases","uri":{"id":"D001327","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cell Movement","uri":{"id":"D002465","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Fibroblast Growth Factors","uri":{"id":"D005346","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Fibroblast Growth Factor 2","uri":{"id":"D016222","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Matrix Metalloproteinase 2","uri":{"id":"D020778","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Vascular Endothelial Growth Factor A","uri":{"id":"D042461","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cell Line, Tumor","uri":{"id":"D045744","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis","uri":{"id":"D001168","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Emigration and Immigration","uri":{"id":"D004641","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Fibroblasts","uri":{"id":"D005347","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hydrocarbons","uri":{"id":"D006838","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hyperplasia","uri":{"id":"D006965","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Internship and Residency","uri":{"id":"D007396","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Morbidity","uri":{"id":"D009017","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Mortality","uri":{"id":"D009026","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasms","uri":{"id":"D009369","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Phenotype","uri":{"id":"D010641","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"RNA, Messenger","uri":{"id":"D012333","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Therapeutics","uri":{"id":"D013812","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Tissues","uri":{"id":"D014024","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Autoimmunity","uri":{"id":"D015551","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Vascular Endothelial Growth Factor A","uri":{"id":"D042461","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cell Movement","uri":{"id":"D002465","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cells, Cultured","uri":{"id":"D002478","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Indoles","uri":{"id":"D007211","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Down-Regulation","uri":{"id":"D015536","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cytokines","uri":{"id":"D016207","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Antirheumatic Agents","uri":{"id":"D018501","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Intercellular Signaling Peptides and Proteins","uri":{"id":"D036341","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Vascular Endothelial Growth Factor A","uri":{"id":"D042461","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cell Proliferation","uri":{"id":"D049109","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Interleukin-1beta","uri":{"id":"D053583","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis, Rheumatoid","uri":{"id":"D001172","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Epidermal Growth Factor","uri":{"id":"D004815","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glycoproteins","uri":{"id":"D006023","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Promoter Regions, Genetic","uri":{"id":"D011401","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Purines","uri":{"id":"D011687","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Recombinant Proteins","uri":{"id":"D011994","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Synovial Membrane","uri":{"id":"D013583","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Fibroblast Growth Factor 2","uri":{"id":"D016222","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Gelatinases","uri":{"id":"D018093","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Receptors, Aryl Hydrocarbon","uri":{"id":"D018336","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Response Elements","uri":{"id":"D020218","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Gene Silencing","uri":{"id":"D020868","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Basic Helix-Loop-Helix Transcription Factors","uri":{"id":"D051792","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Molecular Targeted Therapy","uri":{"id":"D058990","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Antirheumatic Agents","Arthritis, Rheumatoid","Basic Helix-Loop-Helix Transcription Factors","Cell Movement","Cell Proliferation","Cells, Cultured","Cytokines","Down-Regulation","Epidermal Growth Factor","Fibroblast Growth Factor 2","Gelatinases","Gene Silencing","Glycoproteins","Humans","Indoles","Intercellular Signaling Peptides and Proteins","Interleukin-1beta","Molecular Targeted Therapy","Promoter Regions, Genetic","Purines","Receptors, Aryl Hydrocarbon","Recombinant Proteins","Response Elements","Synovial Membrane","Vascular Endothelial Growth Factor A"]},"pmid":"24309559","title":"Aryl hydrocarbon receptor antagonism attenuates growth factor expression, proliferation, and migration in fibroblast-like synoviocytes from patients with rheumatoid arthritis.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"Glucocorticoids (GC) have potent anti-inflammatory and immunomodulatory effects and are widely used in the management of rheumatoid arthritis in combination with other disease-modifying anti-rheumatoid drugs. Concern about the risk of adverse effects may be to some extent misplaced as low to moderate doses of GC have different mechanisms of action and risk profiles compared with high doses. This review discusses the current understanding about the different modes of action of GC, their strong disease-modifying properties and the efforts at improving the therapeutic ratio of GC through the development of new drugs which promise greater safety such as selective GC receptor agonists, liposomal GC and modified-release (MR) prednisone.","fulltextAvailable":false,"journal":"Expert review of clinical immunology","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis, Rheumatoid","uri":{"id":"D001172","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anti-Inflammatory Agents","uri":{"id":"D000893","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis","uri":{"id":"D001168","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmaceutical Preparations","uri":{"id":"D004364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glucocorticoids","uri":{"id":"D005938","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Safety","uri":{"id":"D012449","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Therapeutics","uri":{"id":"D013812","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Intelligence","uri":{"id":"D007360","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Liposomes","uri":{"id":"D008081","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prednisone","uri":{"id":"D011241","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Delayed-Action Preparations","uri":{"id":"D003692","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis, Rheumatoid","uri":{"id":"D001172","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glucocorticoids","uri":{"id":"D005938","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prednisone","uri":{"id":"D011241","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Arthritis, Rheumatoid","Delayed-Action Preparations","Glucocorticoids","Humans","Prednisone"]},"pmid":"24308837","title":"The intelligent use of systemic glucocorticoids in rheumatoid arthritis.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"Haemophilic arthropathy (HA) is characterized by chronic proliferative synovitis leading to cartilage destruction and shares some pathological features with rheumatoid arthritis (RA). Apoptosis has been implicated in RA pathogenesis, and an agonistic anti-Fas monoclonal antibody (mAb) was found to induce RA fibroblast-like synoviocyte (FLS) apoptosis and suppress synovial hyperplasia in animal models of RA. The aim of this study was to evaluate the effect of anti-Fas mAb on HA-FLS. FLS were isolated from knee synovial biopsies from six HA patients, six RA patients and six healthy subjects. The expression of Fas in synovial biopsies was investigated by immunohistochemistry. FLS were stimulated with anti-Fas mAb at different concentrations, alone or in combination with tumour necrosis factor-Î± (TNF-Î±) and basic fibroblast growth factor (bFGF). Fas expression in FLS was assessed by Western blot. Cell viability was studied with the WST-1 assay. Active caspase-3 levels were measured using ELISA and Western blot. A strong Fas-immunoreactivity was observed in different cells of HA synovium, including FLS, inflammatory cells and endothelial cells. Fas antigen was constitutively overexpressed in cultured HA-FLS. Anti-Fas mAb had a significant cytotoxicity on HA-FLS in a dose-dependent manner, either alone or in combination with TNF-Î± and bFGF. These cytotoxic effects were due to the ability of anti-Fas to induce HA-FLS apoptosis, as shown by the increased active caspase-3 levels. Anti-Fas mAb exhibited a more pronounced pro-apoptotic effect on HA-FLS than RA-FLS. Fas antigen is highly expressed on HA-FLS and its stimulation by anti-Fas mAb may be an effective strategy to induce HA-FLS apoptosis.","fulltextAvailable":false,"journal":"Haemophilia : the official journal of the World Federation of Hemophilia","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Mechanical Processes","uri":{"id":"D055596","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Refuse Disposal","uri":{"id":"D012037","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Biofuels","uri":{"id":"D056804","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Adult","Antibodies, Monoclonal","Antigens, CD95","Apoptosis","Arthritis, Rheumatoid","Caspase 3","Cell Survival","Fibroblasts","Hemarthrosis","Hemophilia A","Humans","Immunoglobulin M","Male","Middle Aged","Synovial Membrane","Young Adult"]},"pmid":"24308756","title":"Agonistic anti-human Fas monoclonal antibody induces fibroblast-like synoviocyte apoptosis in haemophilic arthropathy: potential therapeutic implications.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"The American College of Rheumatology annual meeting opened in San Diego, California, with a poster session in which prominent clinical and preclinical research into experimental and putative novel therapies for rheumatoid arthritis and other inflammatory conditions were discussed. The meeting continued through 2 more days of poster presentations and 4 days of very active oral sessions, in which information was discussed on therapeutics and candidate drugs for managing rheumatological diseases ranging from rheumatoid arthritis, osteoarthritis and systemic lupus erythematosus to many other conditions frequently seen in the rheumatology ward. The following report summarizes a selection of oral and poster presentations that reflect the state of the art of current rheumatology pharmacotherapy and what is arising as novel investigational therapy.","fulltextAvailable":false,"journal":"Drugs of today (Barcelona, Spain : 1998)","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Disease Management","uri":{"id":"D019468","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis, Rheumatoid","uri":{"id":"D001172","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Therapies, Investigational","uri":{"id":"D035703","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Lupus Erythematosus, Systemic","uri":{"id":"D008180","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis","uri":{"id":"D001168","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Drug Therapy","uri":{"id":"D004358","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmaceutical Preparations","uri":{"id":"D004364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Therapeutics","uri":{"id":"D013812","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Research Report","uri":{"id":"D058028","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Art","uri":{"id":"D001154","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"California","uri":{"id":"D002140","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Osteoarthritis","uri":{"id":"D010003","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Rheumatology","uri":{"id":"D012219","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Animals","uri":{"id":"D000818","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Rheumatic Diseases","uri":{"id":"D012216","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Rheumatology","uri":{"id":"D012219","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Clinical Trials as Topic","uri":{"id":"D002986","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Drug Evaluation, Preclinical","uri":{"id":"D004353","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Drug Design","uri":{"id":"D015195","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Animals","Clinical Trials as Topic","Drug Design","Drug Evaluation, Preclinical","Humans","Rheumatic Diseases","Rheumatology"]},"pmid":"24308018","title":"A report from the American College of Rheumatology 2013 Meeting (October 26-30, 2013 - San Diego, California, USA).","year":"2013"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"OBJECTIVE: Chronic inflammatory demyelinating polyneuropathy (CIDP) has been reported in patients with multiple sclerosis (MS). However, there have been limited reports of peripheral neuropathy as a complication of neuromyelitis optica (NMO). In this paper, we showed the characteristics and differences between peripheral neuropathy as a complication of MS and NMO. METHOD: We analyzed a series of 58 MS and 28 NMO patients and evaluated nerve conduction studies (NCS) in 21 MS and 5 NMO patients. RESULTS: Six of the 58 MS and 3 of the 28 NMO patients revealed abnormal NCS findings. Three (5.2%) of the 58 MS patients fulfilled the criteria for CIDP. One (3.6%) of the 28 NMO patients showed peripheral neuropathy at the same time of NMO relapse, although CIDP was not seen in NMO. The other 5 (3 MS and 2 NMO) patients were complicated with neuropathy caused by concomitant diabetes mellitus and SjÃ¶gren's syndrome. CONCLUSION: Frequency of abnormal NCS findings might exhibit no significant difference between MS and NMO, although the cause and pathophysiology of peripheral neuropathy were different in MS and in NMO. There might be a group of NMO who were affected simultaneously in the central and peripheral nervous tissues.","fulltextAvailable":false,"journal":"BioMed research international","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Diabetes Mellitus","uri":{"id":"D003920","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Multiple Sclerosis","uri":{"id":"D009103","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neural Conduction","uri":{"id":"D009431","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neuromyelitis Optica","uri":{"id":"D009471","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Peripheral Nervous System Diseases","uri":{"id":"D010523","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Evaluation Studies as Topic","uri":{"id":"D005069","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Recurrence","uri":{"id":"D012008","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Sclerosis","uri":{"id":"D012598","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Syndrome","uri":{"id":"D013577","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Tissues","uri":{"id":"D014024","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Complicity","uri":{"id":"D028661","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Research Report","uri":{"id":"D058028","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Demyelinating Diseases","uri":{"id":"D003711","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Polyneuropathies","uri":{"id":"D011115","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Polyradiculoneuropathy, Chronic Inflammatory Demyelinating","uri":{"id":"D020277","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Adult","uri":{"id":"D000328","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Female","uri":{"id":"D005260","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Male","uri":{"id":"D008297","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Middle Aged","uri":{"id":"D008875","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Retrospective Studies","uri":{"id":"D012189","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Young Adult","uri":{"id":"D055815","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Diabetic Neuropathies","uri":{"id":"D003929","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Multiple Sclerosis","uri":{"id":"D009103","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neural Conduction","uri":{"id":"D009431","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neuromyelitis Optica","uri":{"id":"D009471","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Peripheral Nervous System Diseases","uri":{"id":"D010523","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Sjogren's Syndrome","uri":{"id":"D012859","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Polyradiculoneuropathy, Chronic Inflammatory Demyelinating","uri":{"id":"D020277","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Adult","Diabetic Neuropathies","Female","Humans","Male","Middle Aged","Multiple Sclerosis","Neural Conduction","Neuromyelitis Optica","Peripheral Nervous System Diseases","Polyradiculoneuropathy, Chronic Inflammatory Demyelinating","Retrospective Studies","Sjogren's Syndrome","Young Adult"]},"pmid":"24308009","title":"Abnormal nerve conduction study findings indicating the existence of peripheral neuropathy in multiple sclerosis and neuromyelitis optica.","year":"2013"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"Objectives. To examine the patterns of low-dose aspirin use in rheumatoid arthritis (RA) patients with high risk for coronary artery disease (CAD). Methods. Cross-sectional study of 36 consecutive RA patients with a Framingham score â¥10% for CAD. Eligible RA patients were provided with a questionnaire on CAD risk factors and use of low-dose aspirin. For aspirin nonusers, the reason for nonuse was requested by both the patient and rheumatologist. Questions for patients included physician's advice, self-preference, history of gastrointestinal bleeding, allergy to aspirin, or concomitant use of other anti-inflammatory medications. Questions for rheumatologists included awareness of the increased CAD risk, attribution, patient preference, history of gastrointestinal bleeding, allergy to aspirin, and medication interactions. Results. Patients participated in the study; 8 patients reported using daily aspirin, while 23 patients did not. The main reason cited by patients for not taking aspirin was that they were not instructed by their primary care physician (PCP) to do so (n = 16), which was also the main reason cited by rheumatologists (n = 9). Conclusion. This study confirmed underutilization of aspirin in RA patients at high risk for CAD, largely due to the perception that this is an issue which should be handled by the PCP.","fulltextAvailable":false,"journal":"ISRN rheumatology","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Coronary Disease","uri":{"id":"D003327","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis, Rheumatoid","uri":{"id":"D001172","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cardiovascular Diseases","uri":{"id":"D002318","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cross-Sectional Studies","uri":{"id":"D003430","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Primary Health Care","uri":{"id":"D011320","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Risk Factors","uri":{"id":"D012307","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patient Preference","uri":{"id":"D057240","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Coronary Artery Disease","uri":{"id":"D003324","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Coronary Vessels","uri":{"id":"D003331","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patient Participation","uri":{"id":"D010358","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Physicians, Primary Care","uri":{"id":"D058007","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anti-Inflammatory Agents","uri":{"id":"D000893","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arteries","uri":{"id":"D001158","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis","uri":{"id":"D001168","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Awareness","uri":{"id":"D001364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hemorrhage","uri":{"id":"D006470","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"History","uri":{"id":"D006664","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hypersensitivity","uri":{"id":"D006967","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Perception","uri":{"id":"D010465","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Physicians","uri":{"id":"D010820","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Questionnaires","uri":{"id":"D011795","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Research Report","uri":{"id":"D058028","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medicalization","uri":{"id":"D062528","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Aspirin","uri":{"id":"D001241","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"24307951","title":"Aspirin use in rheumatoid arthritis patients with increased risk of cardiovascular disease.","year":"2013"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"To avoid immune rejection, allograft recipients require drug-based immunosuppression, which has significant toxicity. An emerging approach is adoptive transfer of immunoregulatory cells. While mature dendritic cells (DCs) present donor antigen to the immune system, triggering rejection, regulatory DCs interact with regulatory T cells to promote immune tolerance. Intravenous injection of immature DCs of either donor or host origin at the time of transplantation have prolonged allograft survival in solid-organ transplant models. DCs can be treated with pharmacological agents before injection, which may attenuate their maturation in vivo. Recent data suggest that injected immunosuppressive DCs may inhibit allograft rejection, not by themselves, but through conventional DCs of the host. Genetically engineered DCs have also been tested. Two clinical trials in type-1 diabetes and rheumatoid arthritis have been carried out, and other trials, including one trial in kidney transplantation, are in progress or are imminent.","fulltextAvailable":false,"journal":"Journal of transplantation","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis, Rheumatoid","uri":{"id":"D001172","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Immune System","uri":{"id":"D007107","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"T-Lymphocytes","uri":{"id":"D013601","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Kidney Transplantation","uri":{"id":"D016030","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Dendritic Cells","uri":{"id":"D003713","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Genetic Engineering","uri":{"id":"D005818","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Immune Tolerance","uri":{"id":"D007108","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Injections, Intravenous","uri":{"id":"D007275","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Adoptive Transfer","uri":{"id":"D019264","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"T-Lymphocytes, Regulatory","uri":{"id":"D050378","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Antigens","uri":{"id":"D000941","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis","uri":{"id":"D001168","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Dendrites","uri":{"id":"D003712","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Immunity","uri":{"id":"D007109","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Immunization","uri":{"id":"D007114","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Kidney","uri":{"id":"D007668","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Survival","uri":{"id":"D013534","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Therapeutics","uri":{"id":"D013812","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Tissue Donors","uri":{"id":"D014019","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Transplantation, Homologous","uri":{"id":"D014184","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Allografts","uri":{"id":"D064591","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Immunosuppression","uri":{"id":"D007165","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Injections","uri":{"id":"D007267","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"24307940","title":"Dendritic cell-based approaches for therapeutic immune regulation in solid-organ transplantation.","year":"2013"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"Tumor necrosis factor-Î± (TNF-Î±) inhibitors are known to increase reactivation of concurrent chronic hepatitis B, but their impact on the hepatitis C virus (HCV) is controversial. Some conditions of immunosuppression, such as liver transplantation, typically cause an increase in the rate of HCV evolution. Inhibition of TNF-Î±, a cytokine involved in the apoptotic signaling pathway of hepatocytes infected by HCV, could potentially increase viral replication. Currently available clinical data appear to contradict this hypothesis. A review of medical literature revealed that a total of 216 patients with HCV were exposed to one or more treatments with TNF-Î± inhibitors, with a median observation time of 1.2 years and 260 cumulative patient-years of exposure. Only three cases of drug withdrawal due to suspected HCV liver disease recrudescence were reported. Treatment with TNF-Î± inhibitors in patients with HCV infection appears to be safe in the short term, but there are insufficient data to assess their long-term safety. Universal screening for HCV before beginning treatment with TNF-Î± inhibitors is currently controversial. The presence of HCV is not a contraindication to therapy with TNF-Î± inhibitors, with the exception of cirrhotic patients. In cases of cirrhosis, the benefit/risk ratio should be evaluated at the individual level. Prior to treatment with TNF-Î± inhibitors, patients with HCV should be referred to a hepatologist to determine the necessity of hepatic disease assessment, using liver biopsy or non-invasive methods, and the potential indication for antiviral therapy. In patients with HCV infection who are treated with TNF-Î± inhibitors, liver function monitoring every three months is advised.","fulltextAvailable":false,"journal":"World journal of gastroenterology : WJG","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hepatitis Viruses","uri":{"id":"D006518","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Risk Assessment","uri":{"id":"D018570","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hepatitis, Chronic","uri":{"id":"D006521","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hepatitis C","uri":{"id":"D006526","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Liver Diseases","uri":{"id":"D008107","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Odds Ratio","uri":{"id":"D016017","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Liver Transplantation","uri":{"id":"D016031","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hepacivirus","uri":{"id":"D016174","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hepatitis C, Chronic","uri":{"id":"D019698","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hepatitis B","uri":{"id":"D006509","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Virus Replication","uri":{"id":"D014779","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hepatitis B, Chronic","uri":{"id":"D019694","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Antiviral Agents","uri":{"id":"D000998","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Biopsy","uri":{"id":"D001706","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmaceutical Preparations","uri":{"id":"D004364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Evaluation Studies as Topic","uri":{"id":"D005069","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Fibrosis","uri":{"id":"D005355","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hepatitis","uri":{"id":"D006505","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Literature","uri":{"id":"D008091","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Necrosis","uri":{"id":"D009336","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasms","uri":{"id":"D009369","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Recurrence","uri":{"id":"D012008","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Safety","uri":{"id":"D012449","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Universities","uri":{"id":"D014495","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Viruses","uri":{"id":"D014780","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cytokines","uri":{"id":"D016207","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hepatocytes","uri":{"id":"D022781","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Research Report","uri":{"id":"D058028","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medicalization","uri":{"id":"D062528","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Immunosuppression","uri":{"id":"D007165","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Animals","uri":{"id":"D000818","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Risk Factors","uri":{"id":"D012307","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Tumor Necrosis Factor-alpha","uri":{"id":"D014409","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Treatment Outcome","uri":{"id":"D016896","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Antiviral Agents","uri":{"id":"D000998","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Immunosuppressive Agents","uri":{"id":"D007166","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hepacivirus","uri":{"id":"D016174","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Drug Monitoring","uri":{"id":"D016903","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hepatitis C, Chronic","uri":{"id":"D019698","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Animals","Antiviral Agents","Drug Monitoring","Hepacivirus","Hepatitis C, Chronic","Humans","Immunosuppressive Agents","Risk Factors","Treatment Outcome","Tumor Necrosis Factor-alpha"]},"pmid":"24307780","title":"Tumor necrosis factor-Î± inhibitors and chronic hepatitis C: a comprehensive literature review.","year":"2013"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"Kaposi sarcoma (KS) is a human herpesvirus-8-associated lymphoangioproliferative neoplasm. Both human and viral interleukin-6 (IL-6) proteins seem to drive much of the clinical manifestations of KS, which provides a new target for intervention by using IL-6-neutralizing antibodies. We describe the clinical course of a patient in whom tocilizumab, a monoclonal anti-IL-6 receptor antibody approved for rheumatoid arthritis (RA) treatment, was effective not only in inducing RA remission but was also safe for KS.","fulltextAvailable":false,"journal":"Clinical drug investigation","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Treatment Outcome","uri":{"id":"D016896","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Remission Induction","uri":{"id":"D012074","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis, Rheumatoid","uri":{"id":"D001172","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Remission Induction","uri":{"id":"D012074","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Sarcoma, Kaposi","uri":{"id":"D012514","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Antibodies","uri":{"id":"D000906","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis","uri":{"id":"D001168","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Drive","uri":{"id":"D004328","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasms","uri":{"id":"D009369","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Proteins","uri":{"id":"D011506","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Sarcoma","uri":{"id":"D012509","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Viruses","uri":{"id":"D014780","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Interleukin-6","uri":{"id":"D015850","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Adult","uri":{"id":"D000328","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Male","uri":{"id":"D008297","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Treatment Outcome","uri":{"id":"D016896","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Antibodies, Monoclonal, Humanized","uri":{"id":"D061067","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis, Rheumatoid","uri":{"id":"D001172","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Iatrogenic Disease","uri":{"id":"D007049","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Remission Induction","uri":{"id":"D012074","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Sarcoma, Kaposi","uri":{"id":"D012514","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Receptors, Interleukin-6","uri":{"id":"D019947","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Adult","Antibodies, Monoclonal, Humanized","Arthritis, Rheumatoid","Humans","Iatrogenic Disease","Male","Receptors, Interleukin-6","Remission Induction","Sarcoma, Kaposi","Treatment Outcome"]},"pmid":"24307431","title":"Tocilizumab monotherapy in a patient with rheumatoid arthritis and iatrogenic Kaposi sarcoma.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"We generalize a multistage procedure for parallel gatekeeping to what we refer to as k-out-of-n gatekeeping in which at least k out of n hypotheses ( 1 â©½ k â©½ n) in a gatekeeper family must be rejected in order to test the hypotheses in the following family. This gatekeeping restriction arises in certain types of clinical trials; for example, in rheumatoid arthritis trials, it is required that efficacy be shown on at least three of the four primary endpoints. We provide a unified theory of multistage procedures for arbitrary k, with kâ=â1 corresponding to parallel gatekeeping and kâ=ân to serial gatekeeping. The theory provides an insight into the construction of truncated separable multistage procedures using the closure method. Explicit formulae for calculating the adjusted p-values are given. The proposed procedure is simpler to apply for this particular problem using a stepwise algorithm than the mixture procedure and the graphical procedure with memory using entangled graphs.","fulltextAvailable":false,"journal":"Statistics in medicine","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis, Rheumatoid","uri":{"id":"D001172","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Algorithms","uri":{"id":"D000465","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis","uri":{"id":"D001168","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Methods","uri":{"id":"D008722","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Gatekeeping","uri":{"id":"D020793","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Algorithms","uri":{"id":"D000465","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anti-Inflammatory Agents","uri":{"id":"D000893","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Data Interpretation, Statistical","uri":{"id":"D003627","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis, Rheumatoid","uri":{"id":"D001172","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Clinical Trials as Topic","uri":{"id":"D002986","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Joints","uri":{"id":"D007596","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Algorithms","Anti-Inflammatory Agents","Arthritis, Rheumatoid","Clinical Trials as Topic","Data Interpretation, Statistical","Joints"]},"pmid":"24307257","title":"A general multistage procedure for k-out-of-n gatekeeping.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"Neurological symptoms occur in approximately 20% of patients with SjÃ¶gren's syndrome, and may be the presenting manifestations of the disease. Here, we review several neurological conditions that can occur in SjÃ¶gren's syndrome: sensory ganglionopathy, painful small fibre neuropathy, and transverse myelitis (independently or as part of neuromyelitis optica). We present the symptoms, signs, differential diagnoses, recommended diagnostic evaluation, and treatment of each of these, highlighting the features that should alert neurologists to consider SjÃ¶gren's syndrome.","fulltextAvailable":false,"journal":"Practical neurology","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Signs and Symptoms","uri":{"id":"D012816","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Diagnosis, Differential","uri":{"id":"D003937","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Myelitis, Transverse","uri":{"id":"D009188","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neurologic Manifestations","uri":{"id":"D009461","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neuromyelitis Optica","uri":{"id":"D009471","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Peripheral Nervous System Diseases","uri":{"id":"D010523","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Sjogren's Syndrome","uri":{"id":"D012859","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Diagnosis","uri":{"id":"D003933","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Evaluation Studies as Topic","uri":{"id":"D005069","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Syndrome","uri":{"id":"D013577","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Myelitis","uri":{"id":"D009187","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neurology","uri":{"id":"D009462","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Rheumatology","uri":{"id":"D012219","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Myelitis","uri":{"id":"D009187","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Peripheral Nervous System Diseases","uri":{"id":"D010523","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Sjogren's Syndrome","uri":{"id":"D012859","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Humans","Myelitis","Peripheral Nervous System Diseases","Sjogren's Syndrome"]},"pmid":"24307005","title":"The neurology of Sjogren's syndrome and the rheumatology of peripheral neuropathy and myelitis.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"The aim of this study was to determine whether the tumor necrosis factor-Î± (TNF-Î±) promoter -308 A/G polymorphism is associated with susceptibility to rheumatoid arthritis (RA) in populations with different ethnicities. MEDLINE and EMBASE databases and manual search were used to identify articles in which TNF-Î± polymorphism was determined in RA patients and controls. A meta-analysis was conducted on the associations between the TNF-Î± -308 A/G polymorphism and RA by using (1) allelic contrast and (2) dominant models. A total of 19 studies involving 2,584 RA patients and 3,254 controls were considered. The meta-analysis showed no association between the TNF-Î± -308 A allele and RA when all the subjects were considered [odds ratio (OR) = 1.129, 95 % CI 0.843-1.513, P = 0.416]. After stratification by ethnicity, the meta-analysis indicated that the A allele was significantly associated with RA in Latin Americans (OR = 1.620, 95 % CI 1.234-2.111, P = 3.6 Ã 10(-5)), but not in the European, Arab, or Asian populations. The meta-analysis of the AA/AG genotype showed the same pattern of results as with the A allele. No association was noted between the AA/AG genotype and RA when all the subjects were considered (OR = 1.114, 95 % CI 0.812-1.529, P = 0.503), but stratification by ethnicity revealed that the AA/AG genotype was significantly associated with RA in Latin Americans (OR = 1.650, 95 % CI 1.234-2.104, P = 0.001). This meta-analysis showed that the TNF-Î± -308 A/G polymorphism may represent a significant risk factor for RA in Latin Americans but not in the European, Arab, or Asian populations.","fulltextAvailable":false,"journal":"Rheumatology international","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis, Rheumatoid","uri":{"id":"D001172","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Risk Factors","uri":{"id":"D012307","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Odds Ratio","uri":{"id":"D016017","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Alleles","uri":{"id":"D000483","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis","uri":{"id":"D001168","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Genotype","uri":{"id":"D005838","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Necrosis","uri":{"id":"D009336","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasms","uri":{"id":"D009369","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Asian Continental Ancestry Group","uri":{"id":"D044466","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"MEDLINE","uri":{"id":"D016239","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arabs","uri":{"id":"D018912","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"24306269","title":"Association between TNF-Î± promoter -308 A/G polymorphism and rheumatoid arthritis: a meta-analysis.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"OBJECTIVE: Safe arthrodesis of the ankle as well as load carrying capacity free of pain. INDICATION: Painful arthritis of the ankle joint occurring idiopathic or posttraumatic, resulting from rheumatoid arthritis or neuromuscular diseases. Extensive bony defects in varus or valgus ankle deformities and after failed prosthesis. Complex hindfoot deformities in neurological disease, paralysis and instabilities. Joint destruction after infection. CONTRAINDICATIONS: Active osteitis, extensive skin ulcers in the approach area, periphery artery occlusive disease. SURGICAL TECHNIQUE: Posterolateral skin incision. Sparing cartilage resection. Penetrating sclerosis zones. Reorientating anatomic positioning of the talus thereby correcting axis deformities. Talarlock(Â®) plate positioning and tibiotalar arthrodesis. POSTOPERATIVE MANAGEMENT: Full weight bearing in an arthodesis boot for 6 weeks. After bone grafting partial weight bearing (20 kg) in an arthrodesis boot for 8 weeks. Full weight bearing after 10weeks. RESULTS: Ten patients were operated on using this procedure. The follow-up time was 1 year. There were no complications requiring further surgical procedures. Ankle fusion and a good clinical outcome could be achieved in all cases.","fulltextAvailable":false,"journal":"Operative OrthopÃ¤die und Traumatologie","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis, Rheumatoid","uri":{"id":"D001172","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Ankle Joint","uri":{"id":"D000843","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arterial Occlusive Diseases","uri":{"id":"D001157","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Conservation of Natural Resources","uri":{"id":"D003247","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neuromuscular Diseases","uri":{"id":"D009468","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Skin Ulcer","uri":{"id":"D012883","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Bone Transplantation","uri":{"id":"D016025","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Weight-Bearing","uri":{"id":"D016474","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Congenital Abnormalities","uri":{"id":"D000013","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Ankle","uri":{"id":"D000842","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arteries","uri":{"id":"D001158","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis","uri":{"id":"D001168","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Axis","uri":{"id":"D001368","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cartilage","uri":{"id":"D002356","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Methods","uri":{"id":"D008722","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Paralysis","uri":{"id":"D010243","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Sclerosis","uri":{"id":"D012598","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Talus","uri":{"id":"D013628","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Ulcer","uri":{"id":"D014456","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Lifting","uri":{"id":"D017770","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Penetrance","uri":{"id":"D019683","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prostheses and Implants","uri":{"id":"D019736","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Personal Autonomy","uri":{"id":"D026684","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Complicity","uri":{"id":"D028661","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthrodesis","uri":{"id":"D001174","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Osteitis","uri":{"id":"D010000","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"24306049","title":"[Ankle arthrodesis with an posterolateral approach using a polyaxial angle stable TalarlockÂ® plate].","year":"2013"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"Antitumor necrosis factor alpha agents are known to increase the risk for severe and atypical infections. Numerous atypical organisms have been reported previously, however, there is a paucity of reports of Salmonella as a complication of these therapies. We report a case of a 69-year-old female who developed Salmonella septic arthritis of the pubic symphysis while taking etanercept that resolved with cessation of etanercept and antibiotic treatment and we review the literature regarding this complication. Awareness of susceptibility to Gram-negative intracellular organisms and reactivation of dormant infections due to the mechanism of action of antitumor necrosis factor alpha medications is vital.","fulltextAvailable":false,"journal":"Military medicine","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis, Infectious","uri":{"id":"D001170","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pubic Symphysis","uri":{"id":"D011631","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anti-Bacterial Agents","uri":{"id":"D000900","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis","uri":{"id":"D001168","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Awareness","uri":{"id":"D001364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Female","uri":{"id":"D005260","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Literature","uri":{"id":"D008091","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Necrosis","uri":{"id":"D009336","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Salmonella","uri":{"id":"D012475","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Vitalism","uri":{"id":"D014799","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Complicity","uri":{"id":"D028661","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Research Report","uri":{"id":"D058028","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medicalization","uri":{"id":"D062528","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Aged","uri":{"id":"D000368","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Female","uri":{"id":"D005260","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis, Infectious","uri":{"id":"D001170","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis, Rheumatoid","uri":{"id":"D001172","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Immunoglobulin G","uri":{"id":"D007074","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Immunosuppressive Agents","uri":{"id":"D007166","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pubic Symphysis","uri":{"id":"D011631","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Salmonella Infections","uri":{"id":"D012480","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Receptors, Tumor Necrosis Factor","uri":{"id":"D018124","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Aged","Arthritis, Infectious","Arthritis, Rheumatoid","Female","Humans","Immunoglobulin G","Immunosuppressive Agents","Pubic Symphysis","Receptors, Tumor Necrosis Factor","Salmonella Infections"]},"pmid":"24306025","title":"Salmonella septic arthritis in a patient receiving etanercept: case report and review of the literature.","year":"2013"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"Chronic urticaria is defined as hives, typically occurring daily, for greater than 6 weeks duration. Chronic idiopathic urticaria, which has no discernable external cause, comprises the majority of cases of chronic urticaria. Over half of all cases of chronic idiopathic urticaria are thought to occur by an autoimmune mechanism, primarily autoantibodies against the high affinity immunoglobulin E (IgE) receptor (FcÎµRI). Chronic urticaria is hypothesized to occur because of a predilection in the patient to develop reactions to self. Supporting this hypothesis, a strong association has been found between chronic urticaria and additional autoimmune diseases, such as thyroid disease, rheumatoid arthritis, systemic lupus erythematosus, SjÃ¶gren's syndrome, celiac disease and type 1 diabetes, among others. Herein, we review the associations between chronic urticaria, thyroid disease, and other autoimmune disorders, as well as the implications that these correlations hold for therapeutic intervention in chronic urticaria.","fulltextAvailable":false,"journal":"Skin therapy letter","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Receptors, IgE","uri":{"id":"D017455","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis, Rheumatoid","uri":{"id":"D001172","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Autoimmune Diseases","uri":{"id":"D001327","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Celiac Disease","uri":{"id":"D002446","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Immunoglobulin E","uri":{"id":"D007073","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Lupus Erythematosus, Systemic","uri":{"id":"D008180","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Thyroid Diseases","uri":{"id":"D013959","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Receptors, IgE","uri":{"id":"D017455","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis","uri":{"id":"D001168","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Immunoglobulins","uri":{"id":"D007136","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Syndrome","uri":{"id":"D013577","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Therapeutics","uri":{"id":"D013812","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Thyroid Gland","uri":{"id":"D013961","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Thyroiditis","uri":{"id":"D013966","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Autoimmunity","uri":{"id":"D015551","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Autoantibodies","uri":{"id":"D001323","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Immunoglobulin E","uri":{"id":"D007073","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Urticaria","uri":{"id":"D014581","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"24305753","title":"Chronic urticaria and autoimmunity.","year":"2013 Nov-Dec"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"BACKGROUND: Approximately 10% of patients with rheumatoid arthritis (RA) have interstitial lung disease (ILD), and one-third have subclinical ILD on chest CT scan. In this study, we aimed to further characterize functional decrements in a spectrum of RA-associated ILD. METHODS: All subjects were enrolled in the Brigham and Women's Hospital Rheumatoid Arthritis Sequential Study (BRASS). The presence of interstitial lung abnormalities (ILAs) on clinically indicated chest CT scans was determined using a previously validated sequential reading method. Univariate and multivariate analyses were used to assess the association between degree of ILAs and physiologic, functional, and demographic variables of interest. RESULTS: Of 1,145 BRASS subjects, 91 subjects (8%) were included in this study. Twelve had radiologically severe ILAs, 34 had ILAs, and 38 had no ILAs on CT scan. Subjects with radiologically severe ILAs were older (P = .0037), had increased respiratory symptoms (cough, P = .027; dyspnea, P = .010), and more severe RA disease (rheumatoid factor, P = .018; total swollen joints, P = .046) compared with subjects with no ILAs. Participants also had a trend toward having an increased smoking history (P = .16) and having lower FVC % predicted (77% vs 94%, P = .097) and diffusion capacity of carbon monoxide % predicted (52% vs 77%, P = .068). Similar but attenuated increases in respiratory symptoms, functional decrements, and RA disease severity were observed in subjects with ILAs compared with those with no ILAs. CONCLUSIONS: We have shown that patients with RA have varying degrees of ILAs that are associated with a spectrum of functional and physiologic decrements. Our findings suggest that improved risk stratification and detection of ILAs will provide a therapeutic window that could improve RA-ILD outcomes.","fulltextAvailable":false,"journal":"Chest","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis, Rheumatoid","uri":{"id":"D001172","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Lung Diseases","uri":{"id":"D008171","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Multivariate Analysis","uri":{"id":"D015999","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Lung Diseases, Interstitial","uri":{"id":"D017563","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Carbon Monoxide","uri":{"id":"D002248","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Rheumatoid Factor","uri":{"id":"D012217","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis","uri":{"id":"D001168","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Demography","uri":{"id":"D003710","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Diffusion","uri":{"id":"D004058","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"History","uri":{"id":"D006664","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hospitalization","uri":{"id":"D006760","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hospitals","uri":{"id":"D006761","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Lung","uri":{"id":"D008168","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Reading","uri":{"id":"D011932","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Therapeutics","uri":{"id":"D013812","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Women","uri":{"id":"D014930","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Dyspnea","uri":{"id":"D004417","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Aged","uri":{"id":"D000368","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Female","uri":{"id":"D005260","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Follow-Up Studies","uri":{"id":"D005500","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Forced Expiratory Volume","uri":{"id":"D005541","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Lung","uri":{"id":"D008168","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Male","uri":{"id":"D008297","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Middle Aged","uri":{"id":"D008875","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prognosis","uri":{"id":"D011379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prospective Studies","uri":{"id":"D011446","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Severity of Illness Index","uri":{"id":"D012720","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Tomography, X-Ray Computed","uri":{"id":"D014057","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis, Rheumatoid","uri":{"id":"D001172","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Respiratory Function Tests","uri":{"id":"D012129","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Lung Diseases, Interstitial","uri":{"id":"D017563","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Aged","Arthritis, Rheumatoid","Female","Follow-Up Studies","Forced Expiratory Volume","Humans","Lung","Lung Diseases, Interstitial","Male","Middle Aged","Prognosis","Prospective Studies","Respiratory Function Tests","Severity of Illness Index","Tomography, X-Ray Computed"]},"pmid":"24305643","title":"Functional impact of a spectrum of interstitial lung abnormalities in rheumatoid arthritis.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"Leg ulcers are often complicated in patients with rheumatoid arthritis (RA), however, the etiology is multifactorial. We examined the cases of leg ulceration or gangrene in seven RA patients who were hospitalized over the past 3Â years. One patient was diagnosed as having pyoderma gangrenosum. Although vasculitis was suspected in three patients, no histological evidence was obtained from the skin specimens. In these patients, angiography revealed the stenosis or occlusion of digital arteries. In the remaining three patients, leg ulcers were considered to be due to venous insufficiency. Treatment should be chosen depending on the causes of leg ulcers.","fulltextAvailable":false,"journal":"The Journal of dermatology","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis, Rheumatoid","uri":{"id":"D001172","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Venous Insufficiency","uri":{"id":"D014689","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Leg Ulcer","uri":{"id":"D007871","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pyoderma Gangrenosum","uri":{"id":"D017511","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Angiography","uri":{"id":"D000792","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arteries","uri":{"id":"D001158","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis","uri":{"id":"D001168","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Constriction, Pathologic","uri":{"id":"D003251","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Diagnosis","uri":{"id":"D003933","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hospitalization","uri":{"id":"D006760","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hospitals","uri":{"id":"D006761","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Ulcer","uri":{"id":"D014456","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Complicity","uri":{"id":"D028661","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Gangrene","uri":{"id":"D005734","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pyoderma","uri":{"id":"D011711","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Vasculitis","uri":{"id":"D014657","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Aged","uri":{"id":"D000368","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Female","uri":{"id":"D005260","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Male","uri":{"id":"D008297","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Middle Aged","uri":{"id":"D008875","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Skin","uri":{"id":"D012867","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis, Rheumatoid","uri":{"id":"D001172","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Gangrene","uri":{"id":"D005734","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Leg Ulcer","uri":{"id":"D007871","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Aged","Arthritis, Rheumatoid","Female","Gangrene","Humans","Leg Ulcer","Male","Middle Aged","Skin"]},"pmid":"24304368","title":"Clinical analysis of leg ulcers and gangrene in rheumatoid arthritis.","year":"2013"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"Patients with rheumatic diseases, including rheumatoid arthritis and osteoarthritis, almost universally describe pain and stiffness as important contributors to reduced health-related quality of life. Of the treatment options available, NSAIDs are the most widely used agents for symptomatic treatment. NSAIDs are effective anti-inflammatory and analgesic drugs by virtue of their ability to inhibit biosynthesis of prostaglandins at the level of the cyclooxygenase enzyme. However, many of the adverse effects of NSAIDs are also related to inhibition of prostaglandin production, making their use problematic in some patient populations. For the clinician, understanding the biology of prostaglandin as it relates to gastrointestinal, renal, and cardiovascular physiology and the pharmacologic properties of specific NSAIDs is key to using these drugs safely. Of particular importance is the recognition of co-morbid conditions and concomitant drugs that may increase the risk of NSAIDs in particular patients. In patients with risk factors for NSAID toxicity, using the lowest dose of a drug with a short half-life only when it is needed is likely to be the safest treatment option. For those patients whose symptoms cannot be managed with intermittent treatment, using protective strategies is essential.","fulltextAvailable":false,"journal":"Arthritis research & therapy","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anti-Inflammatory Agents, Non-Steroidal","uri":{"id":"D000894","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis, Rheumatoid","uri":{"id":"D001172","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Quality of Life","uri":{"id":"D011788","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Risk Factors","uri":{"id":"D012307","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Analgesics","uri":{"id":"D000700","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cardiovascular Physiological Phenomena","uri":{"id":"D002320","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Rheumatic Diseases","uri":{"id":"D012216","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Analgesics","uri":{"id":"D000700","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anti-Inflammatory Agents","uri":{"id":"D000893","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis","uri":{"id":"D001168","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Biology","uri":{"id":"D001695","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmaceutical Preparations","uri":{"id":"D004364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Enzymes","uri":{"id":"D004798","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Physiology","uri":{"id":"D010827","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Universities","uri":{"id":"D014495","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Comorbidity","uri":{"id":"D015897","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Life","uri":{"id":"D019369","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anti-Inflammatory Agents, Non-Steroidal","uri":{"id":"D000894","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Half-Life","uri":{"id":"D006207","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Osteoarthritis","uri":{"id":"D010003","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prostaglandin-Endoperoxide Synthases","uri":{"id":"D011451","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prostaglandins","uri":{"id":"D011453","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Rheumatic Diseases","uri":{"id":"D012216","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Virtues","uri":{"id":"D028722","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cardiovascular Diseases","uri":{"id":"D002318","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Kidney Diseases","uri":{"id":"D007674","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Liver Diseases","uri":{"id":"D008107","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Risk Factors","uri":{"id":"D012307","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anti-Inflammatory Agents, Non-Steroidal","uri":{"id":"D000894","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis","uri":{"id":"D001168","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pain","uri":{"id":"D010146","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prostaglandins","uri":{"id":"D011453","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Biosynthetic Pathways","uri":{"id":"D053898","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Anti-Inflammatory Agents, Non-Steroidal","Arthritis","Biosynthetic Pathways","Cardiovascular Diseases","Humans","Kidney Diseases","Liver Diseases","Pain","Prostaglandins","Risk Factors"]},"pmid":"24267197","title":"Use of NSAIDs in treating patients with arthritis.","year":"2013"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"NSAIDs are anti-inflammatory, analgesic, and antipyretic agents, and they are typically used chronically to reduce pain, decrease stiffness, and improve function in patients with osteoarthritis, rheumatoid arthritis, and other forms of arthritis. Additionally, NSAIDs are also used for the more acute treatment of pain including headache, dysmenorrhea, and postoperative pain. However, NSAID use conveys potential significant adverse events that include gastrointestinal ulcers with consequential bleeding, perforation or obstruction, renal dysfunction and consequent renal failure, cardiovascular events, as well as the risk for death. Despite the many available forms of NSAIDs, including injectable as well as topical, oral dosing is the most common route, usually the one route consistently associated with chronic use and thus the one that carries the most risk. In the last several years, several topical NSAIDs including either diclofenac ibuprofen or salicylates for chronic pain have been approved in the United States while similar drugs have been available in Europe for years. One study of a diclofenac topical liquid included an oral diclofenac comparator, and demonstrated no difference in efficacy between the two therapies in treatment for the pain of osteoarthritis in the knee.","fulltextAvailable":false,"journal":"Arthritis research & therapy","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Osteoarthritis, Knee","uri":{"id":"D020370","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis, Rheumatoid","uri":{"id":"D001172","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pain, Postoperative","uri":{"id":"D010149","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"United States","uri":{"id":"D014481","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Renal Insufficiency","uri":{"id":"D051437","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Chronic Pain","uri":{"id":"D059350","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anti-Inflammatory Agents, Non-Steroidal","uri":{"id":"D000894","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Antipyretics","uri":{"id":"D058633","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Analgesics","uri":{"id":"D000700","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anti-Inflammatory Agents","uri":{"id":"D000893","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis","uri":{"id":"D001168","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmaceutical Preparations","uri":{"id":"D004364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Europe","uri":{"id":"D005060","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hemorrhage","uri":{"id":"D006470","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Ulcer","uri":{"id":"D014456","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anti-Inflammatory Agents, Non-Steroidal","uri":{"id":"D000894","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Diclofenac","uri":{"id":"D004008","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Dysmenorrhea","uri":{"id":"D004412","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Headache","uri":{"id":"D006261","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Ibuprofen","uri":{"id":"D007052","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Injections","uri":{"id":"D007267","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Osteoarthritis","uri":{"id":"D010003","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Salicylates","uri":{"id":"D012459","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Ethical Theory","uri":{"id":"D028663","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Antipyretics","uri":{"id":"D058633","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cardiovascular Diseases","uri":{"id":"D002318","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Gastrointestinal Diseases","uri":{"id":"D005767","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Kidney Diseases","uri":{"id":"D007674","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Liver Diseases","uri":{"id":"D008107","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Risk Factors","uri":{"id":"D012307","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anti-Inflammatory Agents, Non-Steroidal","uri":{"id":"D000894","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis, Rheumatoid","uri":{"id":"D001172","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Diclofenac","uri":{"id":"D004008","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Osteoarthritis","uri":{"id":"D010003","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthralgia","uri":{"id":"D018771","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Anti-Inflammatory Agents, Non-Steroidal","Arthralgia","Arthritis, Rheumatoid","Cardiovascular Diseases","Diclofenac","Gastrointestinal Diseases","Humans","Kidney Diseases","Liver Diseases","Osteoarthritis","Risk Factors"]},"pmid":"24267149","title":"Nonsteroidal anti-inflammatory drugs and their risk: a story still in development.","year":"2013"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"BACKGROUND: Amyloidosis is a systemic disease characterized by the extracellular deposition of amyloid fibrils in different organs and tissues. The thyroid gland may be affected by diffuse or nodular amyloid deposits, along with multiple myeloma (MM) (Amyloid Light-Chain Amyloidosis, AL amyloidosis) or chronic inflammatory diseases (Amyloid A Amyloidosis, AA amyloidosis), but thyroid gland involvement rarely appears as the first clinical manifestation in both conditions. The present study reports a case of primary thyroidal nodular amyloid goiter diagnosed by fine-needle cytology (FNC) in an elderly patient. CASE REPORT: A 66-year-old female patient presented with dysphagia and hoarseness; the patient suffered from rheumatoid arthritis but did not have kidney failure or altered thyroid function. Ultrasound examination (US) showed a 30 mm irregular, hypoechoic area in the left thyroid lobe. FNC showed abundant, dense and amorphous material similar to the one stained in purple at Diff-Quik stain and pinkish at the Papanicolaou. Spindle cells with thin, bland and bent nuclei were scattered in this material; few thyroid follicular cells were also present. An alcohol-fixed smear was stained with Congo red: the amyloid material appeared cherry red and it also showed apple-green birefringence when observed with a polarizing microscope. A differential diagnosis between different thyroid pathologies was considered and the cytological diagnosis of nodular amyloid goiter was pointed out. The patient underwent thyroid lobectomy and the subsequent histological examination confirmed the cytological diagnosis. CONCLUSIONS: FNC is a safe and effective procedure for the diagnosis of thyroid amyloidosis. Congo red-stained smears can be used to demonstrate the presence of amyloid material, showing the typical green birefringence under polarized light. An early and accurate cytological diagnosis may suggest an hematological screening and the appropriate treatment for the thyroid nodule.","fulltextAvailable":false,"journal":"BMC surgery","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Heterocyclic Compounds","uri":{"id":"D006571","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Amino Acids","uri":{"id":"D000596","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Colonic Neoplasms","uri":{"id":"D003110","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Developing Countries","uri":{"id":"D003906","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Colorectal Neoplasms","uri":{"id":"D015179","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Developed Countries","uri":{"id":"D019049","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hemeproteins","uri":{"id":"D006420","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Heterocyclic Compounds","uri":{"id":"D006571","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Intestinal Mucosa","uri":{"id":"D007413","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Intestine, Large","uri":{"id":"D007420","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Homeostasis","uri":{"id":"D006706","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Intestines","uri":{"id":"D007422","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Metabolism","uri":{"id":"D008660","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Mucous Membrane","uri":{"id":"D009092","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Proteins","uri":{"id":"D011506","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Incidence","uri":{"id":"D015994","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Amination","uri":{"id":"D000586","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Amines","uri":{"id":"D000588","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Heme","uri":{"id":"D006418","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Rectum","uri":{"id":"D012007","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Microbiota","uri":{"id":"D064307","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Diet","uri":{"id":"D004032","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Food Habits","uri":{"id":"D005510","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Meat","uri":{"id":"D008460","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Intestinal Mucosa","uri":{"id":"D007413","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Intestine, Large","uri":{"id":"D007420","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Colorectal Neoplasms","uri":{"id":"D015179","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Aged","Amyloid","Biopsy, Fine-Needle","Female","Goiter, Nodular","Humans"]},"pmid":"24267036","title":"Nodular goiter with amyloid deposition in an elderly patient: fine-needle cytology diagnosis and review of the literature.","year":"2013"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"Rituximab is recognized as a useful drug for the treatment of B-cell non-Hodgkin's lymphoma and its use has been extended to such diseases as idiopathic thrombocytopenic purpura, thrombotic thrombocytopenic purpura, chronic rheumatoid arthritis and ANCA-associated vasculitides. One serious complication associated with its use is the reactivation of hepatitis B virus and the search for methods to prevent this occurrence has resulted in the rapid accumulation of knowledge. In this review, we discuss case analyses from our department and other groups and outline the current knowledge on the topic and the remaining issues.","fulltextAvailable":false,"journal":"World journal of hepatology","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hepatitis Viruses","uri":{"id":"D006518","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Purpura, Schoenlein-Henoch","uri":{"id":"D011695","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Purpura, Thrombocytopenic","uri":{"id":"D011696","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Lymphoma, B-Cell","uri":{"id":"D016393","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis, Rheumatoid","uri":{"id":"D001172","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hepatitis B","uri":{"id":"D006509","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hepatitis B virus","uri":{"id":"D006515","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Lymphoma, Non-Hodgkin","uri":{"id":"D008228","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Purpura, Thrombocytopenic","uri":{"id":"D011696","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Purpura, Thrombotic Thrombocytopenic","uri":{"id":"D011697","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Purpura, Thrombocytopenic, Idiopathic","uri":{"id":"D016553","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis","uri":{"id":"D056648","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis","uri":{"id":"D001168","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"B-Lymphocytes","uri":{"id":"D001402","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmaceutical Preparations","uri":{"id":"D004364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hepatitis","uri":{"id":"D006505","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Lymphoma","uri":{"id":"D008223","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Purpura","uri":{"id":"D011693","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Viruses","uri":{"id":"D014780","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Knowledge","uri":{"id":"D019359","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Complicity","uri":{"id":"D028661","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Herpesvirus 1, Cercopithecine","uri":{"id":"D006568","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Vasculitis","uri":{"id":"D014657","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"24303089","title":"Hepatitis B virus reactivation with rituximab-containing regimen.","year":"2013"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"Synovial fibroblasts (SF) play a central role in the inflammatory and destructive process in rheumatoid arthritis (RA). High-mobility group box chromosomal protein 1 (HMGB1) or lipopolysaccharide (LPS) alone failed to induce significant changes in proliferation of cultured SF from RA patients, but premixed HMGB1 with LPS (HMGB1-LPS) significantly facilitated SF proliferation. HMGB1 alone failed to induce IL-6, MMP-3, and MMP-13 production in cultured SF but greatly enhanced LPS-induced expression of IL-6, MMP-3, and MMP-13 at both mRNA and protein levels. HMGB1-LPS synergistically upregulated TLR4 and receptor for advanced glycation endproducts (RAGE) expression on the surface of SF. Both blockers of TLR4 and RAGE significantly inhibited the synergistic effects of HMGB1-LPS on the production of IL-6 and MMPs, but blocking antibodies to TLR2 failed. HMGB1-LPS synergistically increased intracellular levels of phosphorylated p38 and phosphorylated I Îº B. Furthermore, both NF- Îº B inhibitor Bay11-7085 and p38 inhibitor SB203580 significantly suppressed the enhanced production of IL-6 and MMPs induced by HMGB1-LPS. In conclusion, HMGB1 acts in synergy with LPS to upregulate TLR4 and RAGE expression on the surface of SF in RA and then to augment IL-6, MMP-3, and MMP-13 production, which depends on p38 MAPK and NF-ÎºB activation.","fulltextAvailable":false,"journal":"Mediators of inflammation","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Toll-Like Receptor 4","uri":{"id":"D051197","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis, Rheumatoid","uri":{"id":"D001172","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Antibodies, Blocking","uri":{"id":"D019138","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"p38 Mitogen-Activated Protein Kinases","uri":{"id":"D048051","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Antibodies","uri":{"id":"D000906","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis","uri":{"id":"D001168","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Chromosomes","uri":{"id":"D002875","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Culture","uri":{"id":"D003469","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Fibroblasts","uri":{"id":"D005347","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Phosphorylation","uri":{"id":"D010766","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Proteins","uri":{"id":"D011506","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"RNA, Messenger","uri":{"id":"D012333","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Up-Regulation","uri":{"id":"D015854","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Boxing","uri":{"id":"D001914","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Lipopolysaccharides","uri":{"id":"D008070","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Interleukin-6","uri":{"id":"D015850","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Matrix Metalloproteinases","uri":{"id":"D020782","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"HMGB1 Protein","uri":{"id":"D024243","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Adult","uri":{"id":"D000328","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Aged","uri":{"id":"D000368","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Fibroblasts","uri":{"id":"D005347","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Gene Expression Regulation","uri":{"id":"D005786","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Middle Aged","uri":{"id":"D008875","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Phosphorylation","uri":{"id":"D010766","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"RNA, Messenger","uri":{"id":"D012333","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Signal Transduction","uri":{"id":"D015398","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Interleukin-6","uri":{"id":"D015850","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cell Proliferation","uri":{"id":"D049109","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis, Rheumatoid","uri":{"id":"D001172","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Imidazoles","uri":{"id":"D007093","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Lipopolysaccharides","uri":{"id":"D008070","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Nitriles","uri":{"id":"D009570","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pyridines","uri":{"id":"D011725","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Receptors, Immunologic","uri":{"id":"D011971","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Sulfones","uri":{"id":"D013450","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Synovial Membrane","uri":{"id":"D013583","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Matrix Metalloproteinase 3","uri":{"id":"D019278","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"HMGB1 Protein","uri":{"id":"D024243","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"p38 Mitogen-Activated Protein Kinases","uri":{"id":"D048051","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Toll-Like Receptor 4","uri":{"id":"D051197","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"NF-kappa B p50 Subunit","uri":{"id":"D052002","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Matrix Metalloproteinase 13","uri":{"id":"D053509","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Adult","Aged","Arthritis, Rheumatoid","Cell Proliferation","Fibroblasts","Gene Expression Regulation","HMGB1 Protein","Humans","Imidazoles","Interleukin-6","Lipopolysaccharides","Matrix Metalloproteinase 13","Matrix Metalloproteinase 3","Middle Aged","NF-kappa B p50 Subunit","Nitriles","Phosphorylation","Pyridines","RNA, Messenger","Receptors, Immunologic","Signal Transduction","Sulfones","Synovial Membrane","Toll-Like Receptor 4","p38 Mitogen-Activated Protein Kinases"]},"pmid":"24302816","title":"HMGB1 acts in synergy with lipopolysaccharide in activating rheumatoid synovial fibroblasts via p38 MAPK and NF-ÎºB signaling pathways.","year":"2013"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"OBJECTIVE: To analyze discordance between global estimates by patients (PATGL) and their physicians (DOCGL) according to demographic and self-report variables on a Multidimensional Health Assessment Questionnaire (MDHAQ) in patients with many rheumatic diseases seen in usual care. METHODS: Each patient completed an MDHAQ at each visit, which includes scores for physical function, pain, and PATGL, each found on the traditional Health Assessment Questionnaire (HAQ), and scores for sleep quality, anxiety, depression, self-report joint count, and fatigue, which are not found on the HAQ. A random visit of 980 patients with any rheumatic diagnosis was analyzed in 3 categories: PATGL=DOCGL (within 2 of 10 units), PATGL>DOCGL (by â¥2 of 10 units), and DOCGL>PATGL (by â¥2 of 10 units), using descriptive statistics and multinomial logistic regression models. RESULTS: Patients included 145 with rheumatoid arthritis, 57 with systemic lupus erythematosus, 173 with osteoarthritis, 348 with other inflammatory diseases, and 257 with other noninflammatory diseases. Overall, PATGL=DOCGL in 509 (52%), PATGL>DOCGL in 371 (38%), and DOCGL>PATGL in 100 (10%). PATGL>DOCGL was associated significantly with older age, female sex, low formal education, Hispanic ethnicity, not working, high MDHAQ physical function and pain scores, and high scores for fatigue, poor sleep, anxiety, depression, and self-report joint count, which are not available on the HAQ. Pain and fatigue were significant in a final multinomial logistic regression; the other variables may raise awareness of discordance to clinicians. CONCLUSION: Global estimates of patients indicated significantly poorer status than estimates of their physicians in 38% of 980 patients with rheumatic conditions, and were associated with demographic and MDHAQ scores, 5 of which are not available on the HAQ.","fulltextAvailable":false,"journal":"Arthritis care & research","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Logistic Models","uri":{"id":"D016015","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis, Rheumatoid","uri":{"id":"D001172","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Logistic Models","uri":{"id":"D016015","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Lupus Erythematosus, Systemic","uri":{"id":"D008180","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Rheumatic Diseases","uri":{"id":"D012216","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anxiety","uri":{"id":"D001007","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis","uri":{"id":"D001168","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Awareness","uri":{"id":"D001364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Demography","uri":{"id":"D003710","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Depression","uri":{"id":"D003863","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Diagnosis","uri":{"id":"D003933","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Education","uri":{"id":"D004493","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Fatigue","uri":{"id":"D005221","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Female","uri":{"id":"D005260","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hispanic Americans","uri":{"id":"D006630","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Organization and Administration","uri":{"id":"D009934","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Physicians","uri":{"id":"D010820","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Physics","uri":{"id":"D010825","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Questionnaires","uri":{"id":"D011795","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Work","uri":{"id":"D014937","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Internationality","uri":{"id":"D038622","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Osteoarthritis","uri":{"id":"D010003","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Rheumatic Diseases","uri":{"id":"D012216","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Adult","uri":{"id":"D000328","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Aged","uri":{"id":"D000368","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Female","uri":{"id":"D005260","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Male","uri":{"id":"D008297","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Middle Aged","uri":{"id":"D008875","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Physicians","uri":{"id":"D010820","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Questionnaires","uri":{"id":"D011795","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Retrospective Studies","uri":{"id":"D012189","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Rheumatic Diseases","uri":{"id":"D012216","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Severity of Illness Index","uri":{"id":"D012720","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patient Care","uri":{"id":"D005791","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Health Status Indicators","uri":{"id":"D006305","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patient Participation","uri":{"id":"D010358","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Adult","Aged","Female","Health Status Indicators","Humans","Male","Middle Aged","Patient Care","Patient Participation","Physicians","Questionnaires","Retrospective Studies","Rheumatic Diseases","Severity of Illness Index"]},"pmid":"24302706","title":"Discordance of global estimates by patients and their physicians in usual care of many rheumatic diseases: association with 5 scores on a Multidimensional Health Assessment Questionnaire (MDHAQ) that are not found on the Health Assessment Questionnaire (HAQ).","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"OBJECTIVE: During the past decades, a more cautious approach with respect to prescribing medication and physical exercise progressed toward evidence-based guidelines regarding the management of rheumatoid arthritis (RA). Currently, physical activity and other means to improve well-being and functioning are encouraged, and the disease is targeted earlier with more intensive and aggressive pharmacologic treatment. The current study examined whether psychological distress and physical disability in patients with RA reduced over the last 2 decades and whether this is explained by a reduction of disease activity. METHODS: From 1990-2011, consecutive patients with RA (n = 1,151, age range 17-86 years, 68% female, 62% rheumatoid factor positive) were monitored at diagnosis and after 3-5 years of treatment (followup). Depressed mood, anxiety, and physical disability were predicted in multiple linear regression analyses by year of assessment, disease activity, and patient demographics. RESULTS: Over the decades, depressed mood (P = 0.01), anxiety (P = 0.001), and physical disability (P = 0.02) reduced at diagnosis and within-treatment improvement of anxiety (P = 0.04) and physical disability (P < 0.001) increased. Percentages of patients with depressed mood, anxiety, and physical disability at followup changed from 25%, 23%, and 53%, respectively, 2 decades ago to 14%, 12%, and 31%, respectively, currently. After taking account of reduction in disease activity, the decrease in physical disability remained significant (P < 0.001). CONCLUSION: Over the last 2 decades, psychological distress and physical disability decreased. This favorable trend might partly be due to reduced disease activity. The results indicate that patients with RA have a better opportunity to live a valued life currently than 20 years ago.","fulltextAvailable":false,"journal":"Arthritis care & research","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Value of Life","uri":{"id":"D026712","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis, Rheumatoid","uri":{"id":"D001172","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Motor Activity","uri":{"id":"D009043","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Regression Analysis","uri":{"id":"D012044","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Disabled Persons","uri":{"id":"D006233","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Rheumatoid Factor","uri":{"id":"D012217","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Exercise","uri":{"id":"D015444","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Linear Models","uri":{"id":"D016014","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anxiety","uri":{"id":"D001007","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis","uri":{"id":"D001168","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Demography","uri":{"id":"D003710","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Diagnosis","uri":{"id":"D003933","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Female","uri":{"id":"D005260","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Physics","uri":{"id":"D010825","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Exercise","uri":{"id":"D015444","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Living Wills","uri":{"id":"D016224","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Life","uri":{"id":"D019369","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medicalization","uri":{"id":"D062528","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Adolescent","uri":{"id":"D000293","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Adult","uri":{"id":"D000328","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Aged","uri":{"id":"D000368","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Aged, 80 and over","uri":{"id":"D000369","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Disability Evaluation","uri":{"id":"D004185","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Female","uri":{"id":"D005260","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Follow-Up Studies","uri":{"id":"D005500","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Male","uri":{"id":"D008297","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Middle Aged","uri":{"id":"D008875","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prospective Studies","uri":{"id":"D011446","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Stress, Psychological","uri":{"id":"D013315","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Disease Progression","uri":{"id":"D018450","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Young Adult","uri":{"id":"D055815","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis, Rheumatoid","uri":{"id":"D001172","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Adolescent","Adult","Aged","Aged, 80 and over","Arthritis, Rheumatoid","Disability Evaluation","Disease Progression","Female","Follow-Up Studies","Humans","Male","Middle Aged","Prospective Studies","Stress, Psychological","Young Adult"]},"pmid":"24302705","title":"Change of psychological distress and physical disability in patients with rheumatoid arthritis over the last two decades.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"AIM: We investigated whether there was a significant increase in thyroid autoimmunity in patients with Familial Mediterranean fever (FMF). PATIENTS AND METHODS: In total, 220 patients, consisting of 42 with FMF, 75 with rheumatoid arthritis (RA), and 103 healthy controls, were enrolled. Serum thyroid-stimulating hormone (TSH), free triiodothyronine (fT3), free thyroxine (fT4), and thyroid autoantibodies (anti-thyroid peroxidase and anti-thyroglobulin) were measured in all participants. RESULTS: After adjustment for age, gender, and smoking status, statistically significant differences between serum levels of anti-thyroglobulin antibody, anti-thyroid peroxidase antibody, and fT3 were found between the groups (all p < 0.001). Serum TSH level did not differ between the groups (p > 0.05). The frequency of autoimmune thyroiditis in FMF group is higher than control group. However, this difference did not reached the level of statistical significance (p > 0.05). CONCLUSIONS: Although statistically not significant, thyroid autoimmunity was observed more frequently in patients with FMF than in healthy controls. Thyroid autoantibodies were significantly higher in patients with FMF. Studies with greater number of patients are required for evaluating the frequency of the autoimmune thyroiditis in patients with FMF.","fulltextAvailable":false,"journal":"European review for medical and pharmacological sciences","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis, Rheumatoid","uri":{"id":"D001172","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Control Groups","uri":{"id":"D035061","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Familial Mediterranean Fever","uri":{"id":"D010505","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Thyroiditis, Autoimmune","uri":{"id":"D013967","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Thyrotropin","uri":{"id":"D013972","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Antibodies","uri":{"id":"D000906","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis","uri":{"id":"D001168","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Evaluation Studies as Topic","uri":{"id":"D005069","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hormones","uri":{"id":"D006728","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Thyroid Gland","uri":{"id":"D013961","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Thyroiditis","uri":{"id":"D013966","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Autoimmunity","uri":{"id":"D015551","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Personal Autonomy","uri":{"id":"D026684","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Serum","uri":{"id":"D044967","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Autoantibodies","uri":{"id":"D001323","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Peroxidase","uri":{"id":"D009195","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Peroxidases","uri":{"id":"D010544","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Thyroxine","uri":{"id":"D013974","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Triiodothyronine","uri":{"id":"D014284","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Adult","uri":{"id":"D000328","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Female","uri":{"id":"D005260","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Male","uri":{"id":"D008297","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Thyrotropin","uri":{"id":"D013972","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Autoimmunity","uri":{"id":"D015551","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cytokines","uri":{"id":"D016207","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"C-Reactive Protein","uri":{"id":"D002097","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Familial Mediterranean Fever","uri":{"id":"D010505","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Thyroid Gland","uri":{"id":"D013961","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Thyroid Hormones","uri":{"id":"D013963","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Thyroiditis, Autoimmune","uri":{"id":"D013967","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Adult","Autoimmunity","C-Reactive Protein","Cytokines","Familial Mediterranean Fever","Female","Humans","Male","Thyroid Gland","Thyroid Hormones","Thyroiditis, Autoimmune","Thyrotropin"]},"pmid":"24302182","title":"Thyroid autoimmunity in patients with Familial Mediterranean Fever: preliminary results.","year":"2013"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"Literature and experimental data relevant to the decision to allow a waiver of in vivo bioequivalence (BE) testing for the approval of immediate release (IR) solid oral dosage forms containing piroxicam in the free acid form are reviewed. Piroxicam solubility and permeability, its therapeutic use and therapeutic index, pharmacokinetic properties, data related to the possibility of excipient interactions and reported BE/bioavailability (BA), and corresponding dissolution data are taken into consideration. The available data suggest that according to the current biopharmaceutics classification system (BCS) and all current guidances, piroxicam would be assigned to BCS Class II. The extent of piroxicam absorption seems not to depend on manufacturing conditions or excipients, so the risk of bioinequivalence in terms of area under the curve (AUC) is very low, but the rate of absorption (i.e., BE in terms of Cmax ) can be affected by the formulation. Current in vitro dissolution methods may not always reflect differences in terms of Cmax for BCS Class II weak acids; however, minor differences in absorption rate of piroxicam would not subject the patient to unacceptable risks: as piroxicam products may be taken before or after meals, the rate of absorption cannot be considered crucial to drug action. Therefore, a biowaiver for IR piroxicam solid oral dosage form is considered feasible, provided that (a) the test product contains only excipients, which are also present in IR solid oral drug products containing piroxicam, which have been approved in ICH or associated countries, for instance, those presented in Table 3 of this paper; (b) both the test and comparator drug products dissolve 85% in 30 min or less at pH 1.2, 4.5, and 6.8; and (c) the test product and comparator show dissolution profile similarity in pH 1.2, 4.5, and 6.8. When not all of these conditions can be fulfilled, BE of the products should be established in vivo.","fulltextAvailable":false,"journal":"Journal of pharmaceutical sciences","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Piroxicam","uri":{"id":"D010894","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Animals","uri":{"id":"D000818","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Chemistry, Pharmaceutical","uri":{"id":"D002626","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Stereoisomerism","uri":{"id":"D013237","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Tissue Distribution","uri":{"id":"D014018","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Rats","uri":{"id":"D051381","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anti-Inflammatory Agents, Non-Steroidal","uri":{"id":"D000894","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis, Rheumatoid","uri":{"id":"D001172","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Biological Availability","uri":{"id":"D001682","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Biopharmaceutics","uri":{"id":"D001702","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Excipients","uri":{"id":"D005079","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Half-Life","uri":{"id":"D006207","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Intestinal Absorption","uri":{"id":"D007408","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Piroxicam","uri":{"id":"D010894","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Solubility","uri":{"id":"D012995","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Therapeutic Equivalency","uri":{"id":"D013810","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Food-Drug Interactions","uri":{"id":"D018565","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Caco-2 Cells","uri":{"id":"D018938","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Animals","Anti-Inflammatory Agents, Non-Steroidal","Arthritis, Rheumatoid","Biological Availability","Biopharmaceutics","Caco-2 Cells","Chemistry, Pharmaceutical","Excipients","Food-Drug Interactions","Half-Life","Humans","Intestinal Absorption","Piroxicam","Rats","Solubility","Stereoisomerism","Therapeutic Equivalency","Tissue Distribution"]},"pmid":"24301077","title":"Biowaiver monographs for immediate release solid oral dosage forms: piroxicam.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"There are a number of reasons that lead to inadequate salivation or complete cessation of salivation. Among others, one of the main can be systemic diseases like SjÃ¶gren's syndrome, and the use of medication and radiation therapy. When affected by Xerostomia, oral mucosa requires constant moisturizing. Medicaments stimulating saliva secretion and moisturizers for oral mucosa alleviate symptoms in most of the cases. LABORATORIOS KIN S.A. is a Spanish company offering a mouth moisturizing products' line, among others, KIN HIDRAT toothpaste and KIN HIDRAT spray with a formulation close to natural saliva.","fulltextAvailable":false,"journal":"StomatologiiÍ¡a","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Mouth Mucosa","uri":{"id":"D009061","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Mucous Membrane","uri":{"id":"D009092","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Radiation","uri":{"id":"D011827","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Saliva","uri":{"id":"D012463","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Syndrome","uri":{"id":"D013577","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Nature","uri":{"id":"D019368","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medicalization","uri":{"id":"D062528","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Salivation","uri":{"id":"D012472","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Toothpastes","uri":{"id":"D014100","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Xerostomia","uri":{"id":"D014987","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Radiotherapy","uri":{"id":"D011878","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Saliva","uri":{"id":"D012463","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Salivation","uri":{"id":"D012472","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Sjogren's Syndrome","uri":{"id":"D012859","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Toothpastes","uri":{"id":"D014100","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Xerostomia","uri":{"id":"D014987","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Oral Sprays","uri":{"id":"D058993","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Humans","Oral Sprays","Radiotherapy","Saliva","Salivation","Sjogren's Syndrome","Toothpastes","Xerostomia"]},"pmid":"24300700","title":"[Xerostomia and means that facilitate its symptoms].","year":"2013"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"OBJECTIVE: To explore the significance and evaluate the early structural erosion through the expressions of Th17 cells in peripheral blood of patients with rheumatoid arthritis (RA) in clinical remission. METHODS: A total of 41 active RA patients without structural erosion were selected. Intracelluar flow cytometric detection of Th17 cells in peripheral blood was performed. And the supernatant level of interleukin (IL)-17A was determined simultaneously in RA patients and control groups at baseline and endpoint of 24-month therapy. The correlations were analyzed between Th17 cells and RA disease activity index DAS28. They were classified into radiographic progression (P, n = 10) and radiographic non-progression groups (NP, n = 26) by the Sharp/van der Heijde score (SHS) at the endpoint. The differences of Th17 cells and IL-17A levels were analyzed between P (SHS > 0.5) and NP groups (SHS â¤ 0.5). RESULTS: The expression of Th17 cells in active RA patients was significantly higher than that of controls [(1.63 Â± 0.45)% vs (0.91 Â± 0.26)%, P < 0.01]. And the results of IL-17A level were similar [1510 Â± 280) vs (320 Â± 31) ng/L, P < 0.05]. The expression of Th17 cells was positively correlated with DAS28 score (r = 0.87, P < 0.01). Thirty-six RA patients were followed up at the endpoint and all of them stayed in clinical remission (DAS28 < 2.6). The peripheral blood expressions of Th17 cells of P group were significantly higher than those of NP group . At the same time, no differences of IL-17A levels existed between two groups. CONCLUSION: Structural erosion still progresses in some RA patients despite an apparent clinic remission. And a high-level peripheral expression of Th17 hints at structural erosion.","fulltextAvailable":false,"journal":"Zhonghua yi xue za zhi","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Interleukin-17","uri":{"id":"D020381","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis, Rheumatoid","uri":{"id":"D001172","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Control Groups","uri":{"id":"D035061","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Th17 Cells","uri":{"id":"D058504","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Abstracting and Indexing as Topic","uri":{"id":"D000043","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis","uri":{"id":"D001168","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Evaluation Studies as Topic","uri":{"id":"D005069","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Interleukins","uri":{"id":"D007378","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Interleukin-17","uri":{"id":"D020381","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Adult","uri":{"id":"D000328","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Female","uri":{"id":"D005260","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Flow Cytometry","uri":{"id":"D005434","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Male","uri":{"id":"D008297","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Middle Aged","uri":{"id":"D008875","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Case-Control Studies","uri":{"id":"D016022","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Disease Progression","uri":{"id":"D018450","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis, Rheumatoid","uri":{"id":"D001172","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Interleukin-17","uri":{"id":"D020381","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Th17 Cells","uri":{"id":"D058504","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Adult","Arthritis, Rheumatoid","Case-Control Studies","Disease Progression","Female","Flow Cytometry","Humans","Interleukin-17","Male","Middle Aged","Th17 Cells"]},"pmid":"24300151","title":"[Detection significance of Th17 cells in peripheral blood of patients with rheumatoid arthritis in clinical remission].","year":"2013"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"OBJECTIVE: To explore the risk factors of deep vein thrombosis (DVT) in lower extremities. METHODS: Retrospective data analyses were performed for a total of 1264 DVT patients at our department from January 2010 to December 2012. RESULTS: Among them, 984 cases (77.85%) were over 40 years old, no overt cause was found for 642 cases (50.79%), 142 cases (11.23%) had a clear history of trauma before onset (without surgery). Among 316 recurrent postoperative cases, there were the surgical histories of orthopedics (n = 142, 11.23%), gynecology (n = 90, 7.12%), general practice (n = 42, 3.32%), vascular (n = 23, 1.82%), urological (n = 12, 0.94%) and others (n = 7, 0.55%). Ten cases (0.79%) occurred after suffering bedridden chronic diseases. And 20 cases (1.58%) were caused by conditions during pregnancy or postpartum period.had Malignant tumors were found in 25 (1.98%) patients. After long-term uses of hormones, 10 patients (0.79%) of rheumatoid arthritis had a recurrence.Owing to varicose veins, 27 patients (2.14%) recurred. Eight patients (0.63%) had a history of drug abuse, 2 cases (0.16%) suffered depression and 62 cases (4.9%) were recurrent. CONCLUSION: There are many causative factors of DVT so that prevention is of great importance. We should pay more attention to the prevention and treatment of high-risk DVT patients.","fulltextAvailable":false,"journal":"Zhonghua yi xue za zhi","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Street Drugs","uri":{"id":"D013287","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis, Rheumatoid","uri":{"id":"D001172","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Chronic Disease","uri":{"id":"D002908","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Risk Factors","uri":{"id":"D012307","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Statistics as Topic","uri":{"id":"D013223","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Substance-Related Disorders","uri":{"id":"D019966","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Venous Thrombosis","uri":{"id":"D020246","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Lower Extremity","uri":{"id":"D035002","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Varicose Veins","uri":{"id":"D014648","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Drug Users","uri":{"id":"D055030","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"General Practice","uri":{"id":"D058006","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis","uri":{"id":"D001168","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Depression","uri":{"id":"D003863","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmaceutical Preparations","uri":{"id":"D004364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Extremities","uri":{"id":"D005121","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"History","uri":{"id":"D006664","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hormones","uri":{"id":"D006728","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasms","uri":{"id":"D009369","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Orthopedics","uri":{"id":"D009985","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pregnancy","uri":{"id":"D011247","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Recurrence","uri":{"id":"D012008","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Stress, Psychological","uri":{"id":"D013315","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"General Surgery","uri":{"id":"D013502","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Thrombosis","uri":{"id":"D013927","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Postpartum Period","uri":{"id":"D049590","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Gynecology","uri":{"id":"D006176","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Adolescent","uri":{"id":"D000293","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Adult","uri":{"id":"D000328","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Aged","uri":{"id":"D000368","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Aged, 80 and over","uri":{"id":"D000369","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Child","uri":{"id":"D002648","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Female","uri":{"id":"D005260","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Male","uri":{"id":"D008297","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Middle Aged","uri":{"id":"D008875","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Retrospective Studies","uri":{"id":"D012189","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Risk Factors","uri":{"id":"D012307","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Young Adult","uri":{"id":"D055815","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Venous Thrombosis","uri":{"id":"D020246","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Lower Extremity","uri":{"id":"D035002","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Adolescent","Adult","Aged","Aged, 80 and over","Child","Female","Humans","Lower Extremity","Male","Middle Aged","Retrospective Studies","Risk Factors","Venous Thrombosis","Young Adult"]},"pmid":"24300145","title":"[Analyses of risk factors for deep vein thrombosis in lower extremities].","year":"2013"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"BACKGROUND: Rheumatoid arthritis (RA), as a common systemic inflammatory autoimmune disease, affects approximately 1 in 100 individuals. Effective treatment for RA is not yet available because current research does not have a clear understanding of the etiology and pathogenesis of RA. Xinfeng Capsule, a patent Chinese herbal medicine, has been used in the treatment of RA in recent years. Despite its reported clinical efficacy, there are no large-sample, multicenter, randomized trials that support the use of Xinfeng Capsule for RA. Therefore, we designed a randomized, double-blind, multicenter, placebo-controlled trial to assess the efficacy and safety of Xinfeng Capsule in the treatment of RA. METHODS AND DESIGN: This is a 12-week, randomized, placebo-controlled, double-blind, multicenter trial on the treatment of RA. The participants will be randomly assigned to the experimental group and the control group at a ratio of 1:1. Participants in the experimental group will receive Xinfeng Capsule and a pharmaceutical placebo (imitation leflunomide). The control group will receive leflunomide and an herbal placebo (imitation Xinfeng Capsule). The American College of Rheumatology (ACR) Criteria for RA will be used to measure the efficacy of the Xinfeng Capsule. The primary outcome measure will be the percentage of study participants who achieve an ACR 20% response rate (ACR20), which will be measured every 4 weeks after randomization. Secondary outcomes will include the ACR50 and ACR70 responses, the side effects of the medications, the Disease Activity Score 28, RA biomarkers, quality of life, and X-rays of the hands and wrists. The first four of the secondary outcomes will be measured every 4 weeks and the others will be measured at baseline and after 12 weeks of treatment. DISCUSSION: The result of this trial will help to evaluate whether Xinfeng Capsule is effective and safe in the treatment of RA. TRIAL REGISTRATION: This trial has been registered in ClinicalTrials.gov. The identifier is NCT01774877.","fulltextAvailable":false,"journal":"Journal of integrative medicine","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Multicenter Studies as Topic","uri":{"id":"D015337","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis, Rheumatoid","uri":{"id":"D001172","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Quality of Life","uri":{"id":"D011788","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Treatment Outcome","uri":{"id":"D016896","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Outcome Assessment (Health Care)","uri":{"id":"D017063","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Control Groups","uri":{"id":"D035061","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Autoimmune Diseases","uri":{"id":"D001327","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Multicenter Studies as Topic","uri":{"id":"D015337","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Herbal Medicine","uri":{"id":"D029001","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis","uri":{"id":"D001168","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Evaluation Studies as Topic","uri":{"id":"D005069","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medicine","uri":{"id":"D008511","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Random Allocation","uri":{"id":"D011897","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Safety","uri":{"id":"D012449","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Wrist","uri":{"id":"D014953","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"X-Rays","uri":{"id":"D014965","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Biological Markers","uri":{"id":"D015415","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Autoimmunity","uri":{"id":"D015551","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Life","uri":{"id":"D019369","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Herbal Medicine","uri":{"id":"D029001","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Asian Continental Ancestry Group","uri":{"id":"D044466","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Research Report","uri":{"id":"D058028","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medicalization","uri":{"id":"D062528","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Rheumatology","uri":{"id":"D012219","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Adolescent","uri":{"id":"D000293","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Adult","uri":{"id":"D000328","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Aged","uri":{"id":"D000368","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Double-Blind Method","uri":{"id":"D004311","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Drugs, Chinese Herbal","uri":{"id":"D004365","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Middle Aged","uri":{"id":"D008875","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis, Rheumatoid","uri":{"id":"D001172","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Capsules","uri":{"id":"D002214","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Clinical Protocols","uri":{"id":"D002985","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Quality Control","uri":{"id":"D011786","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Sample Size","uri":{"id":"D018401","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Adolescent","Adult","Aged","Arthritis, Rheumatoid","Capsules","Clinical Protocols","Double-Blind Method","Drugs, Chinese Herbal","Humans","Middle Aged","Quality Control","Sample Size"]},"pmid":"24299607","title":"Chinese herbal medicine Xinfeng Capsule in treatment of rheumatoid arthritis: study protocol of a multicenter randomized controlled trial.","year":"2013"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"INTRODUCTION: Targeting the CD20 antigen has been a successful therapeutic intervention in the treatment of rheumatoid arthritis (RA). However, in some patients with an inadequate response to anti-CD20 therapy, a persistence of CD20- plasmablasts is noted. The strong expression of CD319 on CD20- plasmablast and plasma cell populations in RA synovium led to the investigation of the potential of CD319 as a therapeutic target. METHODS: PDL241, a novel humanized IgG1 monoclonal antibody (mAb) to CD319, was generated and examined for its ability to inhibit immunoglobulin production from plasmablasts and plasma cells generated from peripheral blood mononuclear cells (PBMC) in the presence and absence of RA synovial fibroblasts (RA-SF). The in vivo activity of PDL241 was determined in a human PBMC transfer into NOD scid IL-2 gamma chain knockout (NSG) mouse model. Finally, the ability of PDL241 to ameliorate experimental arthritis was evaluated in a collagen-induced arthritis (CIA) model in rhesus monkeys. RESULTS: PDL241 bound to plasmablasts and plasma cells but not naÃ¯ve B cells. Consistent with the binding profile, PDL241 inhibited the production of IgM from in vitro PBMC cultures by the depletion of CD319+ plasmablasts and plasma cells but not B cells. The activity of PDL241 was dependent on an intact Fc portion of the IgG1 and mediated predominantly by natural killer cells. Inhibition of IgM production was also observed in the human PBMC transfer to NSG mouse model. Treatment of rhesus monkeys in a CIA model with PDL241 led to a significant inhibition of anti-collagen IgG and IgM antibodies. A beneficial effect on joint related parameters, including bone remodeling, histopathology, and joint swelling was also observed. CONCLUSIONS: The activity of PDL241 in both in vitro and in vivo models highlights the potential of CD319 as a therapeutic target in RA.","fulltextAvailable":false,"journal":"Arthritis research & therapy","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Mice, Knockout","uri":{"id":"D018345","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Blood Cells","uri":{"id":"D001773","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Antibodies, Monoclonal, Humanized","uri":{"id":"D061067","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis, Rheumatoid","uri":{"id":"D001172","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Killer Cells, Natural","uri":{"id":"D007694","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Antibodies, Monoclonal","uri":{"id":"D000911","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis, Experimental","uri":{"id":"D001169","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Macaca mulatta","uri":{"id":"D008253","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Plasma Cells","uri":{"id":"D010950","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Bone Remodeling","uri":{"id":"D016723","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Antigens, CD20","uri":{"id":"D018951","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Haplorhini","uri":{"id":"D000882","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Antibodies","uri":{"id":"D000906","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Antigens","uri":{"id":"D000941","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis","uri":{"id":"D001168","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"B-Lymphocytes","uri":{"id":"D001402","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Culture","uri":{"id":"D003469","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Evaluation Studies as Topic","uri":{"id":"D005069","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Fibroblasts","uri":{"id":"D005347","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Immunoglobulin G","uri":{"id":"D007074","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Immunoglobulins","uri":{"id":"D007136","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Therapeutics","uri":{"id":"D013812","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Nature","uri":{"id":"D019368","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Mice","uri":{"id":"D051379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Immunoglobulin M","uri":{"id":"D007075","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Interleukin-2","uri":{"id":"D007376","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Synovial Membrane","uri":{"id":"D013583","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Animals","uri":{"id":"D000818","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Flow Cytometry","uri":{"id":"D005434","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Immunohistochemistry","uri":{"id":"D007150","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Mice, SCID","uri":{"id":"D016513","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Mice, Inbred NOD","uri":{"id":"D016688","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Mice, Knockout","uri":{"id":"D018345","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Mice","uri":{"id":"D051379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Antibodies, Monoclonal, Humanized","uri":{"id":"D061067","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Antibody Formation","uri":{"id":"D000917","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis, Rheumatoid","uri":{"id":"D001172","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Immunoglobulins","uri":{"id":"D007136","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Macaca mulatta","uri":{"id":"D008253","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Plasma Cells","uri":{"id":"D010950","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Receptors, Immunologic","uri":{"id":"D011971","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Synovial Membrane","uri":{"id":"D013583","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Heterografts","uri":{"id":"D064593","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Animals","Antibodies, Monoclonal, Humanized","Antibody Formation","Arthritis, Rheumatoid","Flow Cytometry","Heterografts","Humans","Immunoglobulins","Immunohistochemistry","Macaca mulatta","Mice","Mice, Inbred NOD","Mice, Knockout","Mice, SCID","Plasma Cells","Receptors, Immunologic","Synovial Membrane"]},"pmid":"24299175","title":"PDL241, a novel humanized monoclonal antibody, reveals CD319 as a therapeutic target for rheumatoid arthritis.","year":"2013"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"AIM: To determine whether there is a relationship between periodontal disease and rheumatoid arthritis. METHODS: A total of 1520 (852 - periodontal group; 668 - general group) individuals of 30-70 years age group and residents of Baddi industrial estate in Himachal Pradesh, India, were assessed for the prevalence of rheumatoid arthritis and Periodontal Disease (PD). The prevalence and severity of periodontitis were determined by recording the Community Periodontal Index (CPI) with loss of attachment, based on WHO guidelines (1997). The criteria considered for diagnosis of rheumatoid arthritis were as those given by American Rheumatism Association -1988. Frequency distributions for bivariate analysis and logistic regression for multivariate analysis were used for assessment of statistical association between variables. RESULTS: In patients referred for periodontal treatment, the prevalence of rheumatoid arthritis was 4.4%. Females (3.2%) and subjects aged above 50 years (3.5%) showed a significantly higher prevalence in comparison to their counterparts (p<0.001). The odds of rheumatoid arthritis in females were nearly three times (OR=2.813) higher than those in males, which was also statistically significant (p<0.05). CONCLUSION: The findings provide evidence of a relationship, suggesting that individuals with moderate to severe periodontal disease are at higher risk of suffering from rheumatoid arthritis and vice versa.","fulltextAvailable":false,"journal":"Journal of clinical and diagnostic research : JCDR","meshAnnotations":{"@type":"java.util.ArrayList"},"meshHeading":null,"pmid":"24298523","title":"Rheumatoid Arthritis among Periodontitis Patients in Baddi Industrial Estate of Himachal Pradesh, India: A Cross Sectional Study.","year":"2013"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"The post-translational conversion of peptidylarginine to peptidylcitrulline, a process also known as citrullination, is catalyzed by the enzyme family of peptidylarginine deiminases (PADs) and has been demonstrated to be involved in many physiological processes, including the regulation of gene expression. In addition, citrullination has been shown to be associated with several diseases, such as cancer, multiple sclerosis, rheumatoid arthritis, and Alzheimer's disease. To get more insight into the role of PAD enzymes and citrullination in both health and disease, experimental strategies to study PAD activity and to characterize citrullinated proteins in complex biological samples are crucial. Here, we describe the chemical, proteomic and antibody-based procedures that are currently available and discuss their applicability for the analysis of complex samples. The methods that have been developed can be used to provide more insight in the substrate specificity of PAD enzymes. Because the evidence that PADs play a pathophysiological role in the diseases mentioned above is increasing, they become attractive targets for therapeutic interventions. More knowledge of PAD specificity and the availability of reliable, high-throughput assays for PAD activity will facilitate the development of highly specific PAD inhibitors.","fulltextAvailable":false,"journal":"Molecular & cellular proteomics : MCP","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Gene Expression Regulation","uri":{"id":"D005786","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Genes, Regulator","uri":{"id":"D005809","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Alzheimer Disease","uri":{"id":"D000544","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis, Rheumatoid","uri":{"id":"D001172","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Multiple Sclerosis","uri":{"id":"D009103","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Gene Expression","uri":{"id":"D015870","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Physiological Processes","uri":{"id":"D055705","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Gene Expression Regulation","uri":{"id":"D005786","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Substrate Specificity","uri":{"id":"D013379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis","uri":{"id":"D001168","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Enzymes","uri":{"id":"D004798","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Genes","uri":{"id":"D005796","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Methods","uri":{"id":"D008722","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Proteins","uri":{"id":"D011506","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Sclerosis","uri":{"id":"D012598","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Sensitivity and Specificity","uri":{"id":"D012680","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Therapeutics","uri":{"id":"D013812","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Knowledge","uri":{"id":"D019359","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Proteome","uri":{"id":"D020543","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Proteomics","uri":{"id":"D040901","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Citrulline","uri":{"id":"D002956","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Animals","uri":{"id":"D000818","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Immunohistochemistry","uri":{"id":"D007150","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Proteomics","uri":{"id":"D040901","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Citrulline","uri":{"id":"D002956","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Colorimetry","uri":{"id":"D003124","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hydrolases","uri":{"id":"D006867","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Protein Processing, Post-Translational","uri":{"id":"D011499","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Enzyme Assays","uri":{"id":"D057075","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Animals","Citrulline","Colorimetry","Enzyme Assays","Humans","Hydrolases","Immunohistochemistry","Protein Processing, Post-Translational","Proteomics"]},"pmid":"24298040","title":"Methods for the detection of peptidylarginine deiminase (PAD) activity and protein citrullination.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"OBJECTIVE: To compare the performance of published classification/diagnostic criteria for polymyalgia rheumatica (PMR), including the new 2012 European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) criteria, in a single-centre study. METHODS: We studied all consecutive patients with new-onset PMR seen in our centre over 6 years, whose diagnosis was confirmed during a prospective 12-month follow-up period. Subjects were classified by each of the seven different criteria. Sensitivity and specificity were compared. Control population consisted of all consecutive patients aged â¥50 years seen in a 4-year period in our early arthritis clinic who had a 12-month confirmation of a diagnosis of rheumatoid arthritis (RA) or other inflammatory articular diseases. RESULTS: Data were collected from 136 cases and 149 controls, including 94 patients with RA. The most sensitive criteria were the new 2012 EULAR/ACR classification criteria (92.6%). Adding ultrasound (US) specificity increased from 81.5% to 91.3% in total cases and from 79.7% to 89.9% in RA. Bird criteria had a sensitivity of 89.2% but the lowest specificity (40.2% in total cases and 72.5% in RA). Jones and Nobunaga criteria were the most specific criteria (96.7% and 97.8% in total cases and 98.6% and 99.5% in RA) but the less sensitive (63.1% and 58.2%) ones. Overall, discriminatory ability, as reflected by the area under the receiver operating characteristic curve, was better for the 2012 US EULAR/ACR criteria (0.920 in total cases and 0.910 in RA). CONCLUSIONS: The new EULAR/ACR criteria in new-onset PMR patients perform best in discriminating PMR from RA and other inflammatory articular diseases. Ultrasound further increases the specificity of the criteria.","fulltextAvailable":false,"journal":"Annals of the rheumatic diseases","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis, Rheumatoid","uri":{"id":"D001172","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"ROC Curve","uri":{"id":"D012372","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Sensitivity and Specificity","uri":{"id":"D012680","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Polymyalgia Rheumatica","uri":{"id":"D011111","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Population Control","uri":{"id":"D011155","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis","uri":{"id":"D001168","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Classification","uri":{"id":"D002965","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Diagnosis","uri":{"id":"D003933","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Discrimination (Psychology)","uri":{"id":"D004192","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Publishing","uri":{"id":"D011643","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Sensitivity and Specificity","uri":{"id":"D012680","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Rheumatic Diseases","uri":{"id":"D012216","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Rheumatology","uri":{"id":"D012219","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Aged","uri":{"id":"D000368","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Aged, 80 and over","uri":{"id":"D000369","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Autoantibodies","uri":{"id":"D001323","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Female","uri":{"id":"D005260","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Male","uri":{"id":"D008297","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Middle Aged","uri":{"id":"D008875","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Rheumatology","uri":{"id":"D012219","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"ROC Curve","uri":{"id":"D012372","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Sensitivity and Specificity","uri":{"id":"D012680","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Case-Control Studies","uri":{"id":"D016022","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis, Rheumatoid","uri":{"id":"D001172","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Blood Sedimentation","uri":{"id":"D001799","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"C-Reactive Protein","uri":{"id":"D002097","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Diagnosis, Differential","uri":{"id":"D003937","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hip Joint","uri":{"id":"D006621","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Peptides, Cyclic","uri":{"id":"D010456","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Polymyalgia Rheumatica","uri":{"id":"D011111","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Rheumatoid Factor","uri":{"id":"D012217","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Shoulder Joint","uri":{"id":"D012785","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Area Under Curve","uri":{"id":"D019540","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Aged","Aged, 80 and over","Area Under Curve","Arthritis, Rheumatoid","Autoantibodies","Blood Sedimentation","C-Reactive Protein","Case-Control Studies","Diagnosis, Differential","Female","Hip Joint","Humans","Male","Middle Aged","Peptides, Cyclic","Polymyalgia Rheumatica","ROC Curve","Rheumatoid Factor","Rheumatology","Sensitivity and Specificity","Shoulder Joint"]},"pmid":"24297384","title":"Performance of the new 2012 EULAR/ACR classification criteria for polymyalgia rheumatica: comparison with the previous criteria in a single-centre study.","year":"2014"}